<SEC-DOCUMENT>0001213900-18-012974.txt : 20180925
<SEC-HEADER>0001213900-18-012974.hdr.sgml : 20180925
<ACCEPTANCE-DATETIME>20180925161235
ACCESSION NUMBER:		0001213900-18-012974
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20180925
DATE AS OF CHANGE:		20180925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227243
		FILM NUMBER:		181085817

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>fs12018a1_aytubioscience.htm
<DESCRIPTION>AMENDMENT NO. 1 TO REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"> <B>As filed with the Securities and Exchange Commission on September
25, 2018</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration No.&nbsp;333-227243</B> </P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 1</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>TO</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>47-0883144</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>373 Inverness Parkway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 206</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Englewood, Colorado 80112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(720) 437-6580</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code and telephone
number, including area code, of registrant&rsquo;s principal executive offices) &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joshua R. Disbrow </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>373 Inverness Parkway, Suite 206</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Englewood, Colorado 80112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (720) 437-6580</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Copies to: </I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Nolan S. Taylor </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Anthony W. Epps </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Michael R. Newton </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Dorsey &amp; Whitney LLP </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> 111 South Main St., Suite 2100 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Salt Lake City, Utah 84111 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> (801) 933-7360 </P></TD>
    <TD STYLE="width: 10%; padding-right: -0.5in; padding-left: 5.4pt; font-size: 10pt"></TD>
    <TD STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Michael Nertney </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Charles Phillips </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Ellenoff Grossman &amp; Schole
        LLP </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> 1345 Avenue of the Americas,
        11<SUP>th</SUP> Floor </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> New York, NY 10105 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> (212) 370-1300 </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.35pt"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Approximate date of
commencement of proposed sale to the public: As soon as practicable after the effective date of the registration statement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this form is a
post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller
reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
    filer&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-accelerated
        filer&nbsp;&nbsp;&#9744;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&nbsp;&nbsp;&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Do not check if a smaller reporting
    company)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp;&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> Title of Each Class of Securities
    to be Registe<FONT STYLE="font-size: 10pt">red</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Proposed</B><BR>
                                         <B>Maximum</B><BR> <B>Aggregate</B><BR> <B>Offering</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 10pt"><B>Price<SUP>(1)</SUP></B></FONT> </P></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amount
    of</B></FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration Fee<SUP>(5)</SUP></B></FONT></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock, par value $0.0001 per share<SUP>(2)</SUP></FONT></FONT> </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> <FONT STYLE="font-size: 10pt">3,850,000</FONT> </P>


</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">479.33</FONT> </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    to purchase Common Stock<SUP>(3)</SUP></FONT></FONT> </TD><TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock issuable upon exercise of warrants<SUP>(2)</SUP></FONT></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">12,650,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">1,574.93</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Series C Preferred Stock, par value
    $0.0001 per share</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">8,800,000</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">1,095.60</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock issuable upon conversion of the Series C Preferred Stock<SUP>(2) (3)</SUP></FONT></FONT> </TD><TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: right"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Representative&rsquo;s
    warrant to purchase shares of Common Stock<SUP>(3) (4)</SUP></FONT></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt"></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt"></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock issuable upon exercise of representative&rsquo;s warrant to purchase common stock</FONT></FONT> </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><P STYLE="margin: 0"> <FONT STYLE="font-size: 10pt">379,500</FONT> </P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><P STYLE="margin: 0"> <FONT STYLE="font-size: 10pt">47.25</FONT> </P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">Total</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-size: 10pt">25,679,500</FONT> </TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-size: 10pt">$</FONT> </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> 3,197.10 </P>


</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended. Includes the price of additional shares of common stock and/or warrants to purchase shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fee pursuant to Rule 457(i) under the Securities Act of 1933,
        as amended.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 10pt">(4) </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">Represents warrants to purchase a number of shares of common
    stock equal to 3% of the number of shares of Common Stock (including the shares of Common Stock issuable upon conversion of
    the Series C Preferred Stock) being offered at an exercise price equal to 125% of the public offering price per share of Common
    Stock and Warrant.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> (5) </TD>
    <TD STYLE="text-align: justify"> $996.00 was paid previously. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: red"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
relating to these securities filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to
sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT> </TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-size: 10pt; color: red"><B>SUBJECT
    TO COMPLETION</B></FONT> </TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt; color: red"><B>DATED:&nbsp;SEPTEMBER
    25, 2018</B></FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aytu BioScience, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>839,695 Shares of Common Stock,</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>4,198,473 Warrants to Purchase Shares
of Common Stock and</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>3,358,778 Shares of Series C Convertible
Preferred Stock</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-size: 4pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(and Shares of Common Stock Underlying
Shares of Series C Convertible Preferred Stock and Warrants)</B> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> We are offering
839,695 shares of common stock, par value $0.0001 per share (the &ldquo;common stock&rdquo;) and warrants to purchase 839,695
shares of our common stock at an assumed combined public offering purchase price of $2.62 per fixed combination of one share of
common stock and one warrant to purchase one share of common stock (and the shares issuable from time to time upon exercise of
the warrants). The shares and warrants will be separately issued, but the shares and warrants will be issued and sold to purchasers
in the ratio of one to one. Each warrant will have an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;per share, will be exercisable
upon issuance and will expire five years from the date of issuance. The warrants will be issued in book-entry form pursuant to
a warrant agency agreement between us and VStock Transfer, LLC, as warrant agent. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> We are also offering
to those purchasers whose purchase of common stock in this offering would result in the purchaser, together with its affiliates
and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
common stock following the consummation of this offering, the opportunity to purchase, if they so choose, in lieu of the shares
of common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%), up to 3,358,778
shares of Series C Convertible Preferred Stock, par value $0.0001 per share (the &ldquo;Series C Preferred Stock&rdquo;), convertible
into one share of common stock and warrants to purchase 3,358,778 shares of our common stock at an assumed public offering price
of $2.62 per share of Series C Preferred Stock and warrant (and the shares issuable from time to time upon exercise of the warrants
and conversion of the Series C Preferred Stock). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-size: 4pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> The underwriters
have the option to purchase additional shares of common stock and/or warrants to purchase shares of common stock solely to cover
over-allotments, if any, at the price to the public less the underwriting discounts and commissions. The over-allotment option
may be used to purchase shares of common stock, or warrants, or any combination thereof, as determined by the underwriters, but
such purchases cannot exceed an aggregate of 15% of the number of shares of common stock (including the number of shares of common
stock issuable upon conversion of shares of Series C Preferred Stock) and warrants sold in the primary offering. The over-allotment
option is exercisable for 45 days from the date of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-size: 4pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> Our common
stock is listed on the NASDAQ Capital Market under the symbol &ldquo;AYTU.&rdquo; On September 24, 2018, the last reported sale
price of our common stock on the NASDAQ Capital Market was $2.62. </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves
a high degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo;
beginning on page 8 of this prospectus, and under similar headings in any amendments or supplements to this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Per&nbsp;Share of Common
    Stock and Warrant </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Per&nbsp;Share of Series
    C Preferred Stock and Warrant </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"> Public offering price(1) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt"> Underwriting discount(2)(3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"> Proceeds, before expenses, to AYTU Bioscience, Inc. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    public offering price and underwriting discount corresponds to (i)&nbsp;a public offering price per share of common stock
    of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    (ii)&nbsp;a public offering price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    and (iii)&nbsp;a public offering price per share of Series C Preferred Stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
    </FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have also agreed to reimburse Ladenburg Thalmann for certain expenses. See &ldquo;Underwriting&rdquo; for additional information. </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted a 45-day day option to the underwriters to purchase additional shares of common stock and/or warrants to purchase shares of common stock (up to 15% of the number of shares of common stock (including the number of shares of common stock issuable upon conversion of shares of Series C Preferred Stock) and warrants sold in the primary offering) solely to cover over-allotments, if any. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters expect to deliver the
securities to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Sole Book-Running Manager</I> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Ladenburg
Thalmann</B></FONT><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Co-Manager</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Northland Capital Markets</B> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 4pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_006.jpg" ALT="" STYLE="height: 1054; width: 800"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="toc"></A>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt; width: 92%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_001"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_002"><FONT STYLE="font-size: 10pt">The Offering</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_003"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_004"><FONT STYLE="font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_006"><FONT STYLE="font-size: 10pt">Market for Common Stock</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_007"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_008"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_009"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_010"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_011"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_012"><FONT STYLE="font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_013"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_014"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_015"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> You should rely only on the information
contained in this prospectus or in any related free writing prospectus filed by us with the Securities and Exchange Commission,
or the SEC. We have not, and the underwriters and their affiliates have not, authorized anyone to provide you with any information
or to make any representation not contained in this prospectus. We do not, and the underwriters and their affiliates do not, take
any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you.
This prospectus is not an offer to sell or an offer to buy securities in any jurisdiction where offers and sales are not permitted.
The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any
sale of securities. You should also read and consider the information in the documents to which we have referred you under the
caption &ldquo;Where You Can Find More Information&rdquo; in the prospectus.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Neither we nor the underwriters have
done anything that would permit a public offering of the securities or possession or distribution of this prospectus in any jurisdiction
where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession
of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and
the distribution of this prospectus outside of the United States. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to read carefully this prospectus,
as supplemented and amended, before deciding whether to invest in any of the common stock being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the context indicates otherwise,
as used in this prospectus, the terms &ldquo;Aytu,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo;
and &ldquo;our business&rdquo; refer to Aytu BioScience, Inc. and its subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We own or have rights to various U.S. federal
trademark registrations and applications, and unregistered trademarks and service marks, including Fiera, Natesto, ZolpiMist, ProstaScint,
MiOXSYS, RedoxSYS, Luoxis, Vyrix and Nuelle. All other trade names, trademarks and service marks appearing in this prospectus are
the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating.
Accordingly, such terms, when first mentioned in this prospectus, appear with the trade name, trademark or service mark notice
and then throughout the remainder of this prospectus without trade name, trademark or service mark notices for convenience only
and should not be construed as being used in a descriptive or generic sense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><B><A NAME="aa_001"></A>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><I>This summary highlights certain
information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain
all of the information that you should consider before investing in shares of our securities and it is qualified in its entirety
by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus and the documents
incorporated by reference including the information referred to under the heading &ldquo;Risk Factors&rdquo; and the financial
statements and related notes in this prospectus and the documents incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">We are a commercial-stage specialty
pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. We have multiple
approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across
a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales
force and an international distribution network with sales in 29 countries. We are currently concentrating on hypogonadism, male
infertility and, recently, insomnia and plan to expand into other indications for which we believe there are significant medical
needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">We acquired exclusive U.S. rights
to Natesto<SUP>&reg;</SUP> (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use
nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016. Natesto is approved by the U.S.
Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone
replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes
in a $1.8 billion market accounting for over 6.8 million prescriptions annually. Importantly, as Natesto is delivered via the nasal
mucosa and not the skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning
associated with all other topically applied TRTs, including the market leader AndroGel<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">Outside the U.S. we market MiOXSYS<SUP>&reg;</SUP>,
a novel in vitro diagnostic system that is currently CE marked (which generally enables it to be sold within the European Economic
Area), Health Canada cleared, and Australian TGA and Mexican COFEPRAS-approved, and for which we intend to initiate a clinical
study to enable FDA clearance in the U.S. &nbsp;Our MiOXSYS system is a novel, point-of-care semen analysis system with the potential
to become a standard of care in the diagnosis and management of male infertility. Male infertility is a prevalent and underserved
condition and oxidative stress (the core biological component measured by the MiOXSYS system) is widely implicated in its pathophysiology.
MiOXSYS was developed from our previously developed oxidation-reduction potential research platform known as RedoxSYS<SUP>&reg;</SUP>.
We are advancing MiOXSYS toward FDA clearance as an aid in the assessment of male infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">In June 2018 we acquired an exclusive
U.S. license to ZolpiMist&trade;. ZolpiMist is an FDA-approved prescription product that is indicated for the short-term treatment
of insomnia, and is the only oral spray formulation of zolpidem tartrate - the most widely prescribed prescription sleep aid in
the U.S. ZolpiMist is commercially available and competes in the non-benzodiazepine prescription sleep aid category, a $1.8 billion
prescription drug category with over 43 million prescriptions written annually. Thirty million prescriptions of zolpidem tartrate
(Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;, and generic forms of immediate-release, controlled
release, and orally dissolving tablet formulations) are written each year in the U.S., representing almost 70% of the non-benzodiazepine
sleep aid category. Approximately 2.5 million prescriptions are written for novel formulations of zolpidem tartrate products (controlled
release and sublingual tablets). We intend to integrate ZolpiMist into our sales force&rsquo;s promotional efforts as an adjunct
product to Natesto as there is substantial overlap of physician prescribers of both testosterone and prescription sleep aids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">In the future we will look to
acquire additional commercial-stage or near-market products, including existing products we believe can offer distinct commercial
advantages. Our management team&rsquo;s prior experience has involved identifying both clinical-stage and commercial-stage assets
that can be launched or re-launched to increase value, with a focused commercial infrastructure specializing in novel, niche products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">Our management team has extensive
experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized,
and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect
that we will build a substantial portfolio of complementary urology products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Natesto&reg; (testosterone) nasal gel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">Natesto is a patented, FDA-approved
testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the U.S.
Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small,
portable, Transportation Security Administration, or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly
to the patient&rsquo;s skin as other topically applied TRTs. Rather, Natesto is delivered directly into the nasal mucosa via a
proprietary nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&rsquo;s
female partner or children &mdash; as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery
directly onto the skin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">We launched Natesto in the U.S.
in late summer 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment solution for men with active,
busy lifestyles who suffer from hypogonadism. Natesto is also positioned for men who have previously been prescribed a TRT, including
Androgel, and want a product with a different clinical profile available in a convenient, easy-to-use, effective therapeutic option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of Natesto (testosterone) nasal gel&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unique delivery of Natesto also enables
simple, discreet use by a single application into each nostril three times daily and may improve compliance over topical forms
that are applied to large sections of the arms, shoulders, and other large areas of the man&rsquo;s upper torso. It also offers
a more discreet method of TRT administration compared to films and patches (such as Androderm&reg;) and doesn&rsquo;t involve the
pain, potential for site injection infections, and the administration inconvenience of the implantable and/or injectable TRTs such
as Testopel&reg; (pellets), Aveed&reg; (injectable testosterone undecanoate) or testosterone cypionate injections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A concern associated with the use of the
currently marketed testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact with
the man&rsquo;s application site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate
contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This
condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms.
Natesto, as it is nasally administered, does not present this potential complication of &lsquo;transference&rsquo; and thus does
not have a black box warning as is associated with the topically applied testosterone supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto is a nasally-administered androgen
indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism,
bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter&rsquo;s syndrome, chemotherapy, or toxic damage
from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating
hormone [FSH] and luteinizing hormone [LH]) above the normal range.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Hypogonadotropic hypogonadism (congenital or acquired):
gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma,
or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ZolpiMist&trade; (zolpidem tartrate oral spray)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ZolpiMist is an FDA-approved prescription
product that is indicated for the short-term treatment of insomnia, and is the only oral spray formulation of zolpidem tartrate
- the most widely prescribed prescription sleep aid in the U.S. ZolpiMist is commercially available and competes in the non-benzodiazepine
prescription sleep aid category, a $1.8 billion prescription drug category with over 43 million prescriptions written annually.
Thirty million prescriptions of zolpidem tartrate (Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;,
and generic forms of immediate-release, controlled release, and orally dissolving tablet formulations) are written each year in
the U.S., representing almost 70% of the non-benzodiazepine sleep aid category. Approximately 2.5 million prescriptions are written
for novel formulations of zolpidem tartrate products (controlled release and sublingual tablets).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ZolpiMist (5 mg per dose and available
in both a 30-dose and 60-dose canister) was approved for marketing by the FDA in December of 2008 and was shown to be bioequivalent
to Ambien&reg; 5 mg and 10 mg tablets. ZolpiMist is indicated for the short-term treatment of insomnia characterized by difficulties
with sleep initiation and is contraindicated in patients with a known hypersensitivity to zolpidem tartrate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of ZolpiMist in its Child-Resistant Container</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to ZolpiMist&rsquo;s unique oral spray
delivery and the resulting rapid absorption through the oral mucosa, ZolpiMist has several clinical advantages over oral tablet
formulations, most notably a rapid onset of action that quickly induces sleep. Additionally, and also due to the product&rsquo;s
oral spray formulation, ZolpiMist does not require swallowing and may therefore be easier and more convenient to take than tablets
for patients who have difficulty swallowing or have an aversion to taking tablets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MiOXSYS&reg; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">MiOXSYS
is the Company&rsquo;s diagnostic system that consists of a desktop analyzer and disposable sensors.&nbsp; The system performs
a rapid test to determine the health of semen as a unique approach to assessing male reproductive health.&nbsp; The key measurement
made by the MiOXSYS system is static oxidation-reduction potential (&ldquo;sORP&rdquo;).&nbsp; The&nbsp; FDA has concluded that
the MiOXSYS System is an innovative product, and acknowledged that the use of sORP technology as an aid in assessing semen quality
is a unique and progressive method, demonstrates forward thinking, and has the potential to improve the accuracy and speed of
identifying a population of men for whom timely access to assisted reproductive techniques would be beneficial.</FONT> </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> MiOXSYS is CE marked, has been cleared
by Health Canada, and has been approved by the Australian TGA and Mexican COFEPRAS.&nbsp; The Company is pursuing FDA clearance.&nbsp;
In connection with Aytu&rsquo;s plan for FDA clearance, the Company sponsors research projects in key US research labs including
the Cleveland Clinic, Tulane University and other laboratories around the world.&nbsp; Further, management believes that there
are no marketed predicate devices with the same proposed intended uses as the MiOXSYS System. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of the MiOXSYS Analyzer&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><IMG SRC="img_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; color: Red"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The MiOXSYS Disposable Sensors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MiOXSYS disposable sensors, via standard
biological specimen collection techniques, receive 20 &ndash; 40 microliters of a specimen from which the ORP clinical analysis
is performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead
configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated with
the sensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of the MiOXSYS Disposable Sensors&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><IMG SRC="img_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><B>Our Strategy&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the near-term, we expect to create value
for shareholders by implementing a focused, four-pronged strategy. Our primary focus is on growing sales of Natesto in the U.S.
and relaunching ZolpiMist through our sales force, expanding the MiOXSYS business both inside and outside the U.S., advancing MiOXSYS
toward FDA clearance, and continuing to build a product pipeline through efficient business development. Upon achieving growth
of our current, revenue-generating products, we intend to build a complementary portfolio of aligned assets that can be efficiently
commercialized through our specialty sales force and, when appropriate, aligned distribution partners outside the U.S. In just
over three years since our formation through the merger, we have acquired or in-licensed four FDA-approved, marketed assets (and
have since divested one asset &ndash; Primsol&reg; Solution and have discontinued another, ProstaScint&reg;), launched a U.S.-based
specialty sales force, advanced our lead diagnostic asset MiOXSYS to CE marking, Health Canada clearance, Australian TGA approval,
and Mexican COFEPRAS clearance, engaged in asset purchase and licensing discussions for products aligned to our strategy, launched
Natesto in the U.S. through our own sales force, licensed ZolpiMist in the U.S. and Canada, and are now preparing for ZolpiMist&rsquo;s
re-launch through our sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as Rosewind Corporation
on August 9, 2002 in the State of Colorado.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vyrix Pharmaceuticals, Inc., or Vyrix,
was incorporated under the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc.
(NYSE American: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out
of the sexual dysfunction therapeutics business, including the late-stage men&rsquo;s health product candidates, Zertane and Zertane-ED,
from Ampio, that carve-out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws
of the State of Delaware on January 24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger.
Luoxis was initially focused on developing and advancing the RedoxSYS System. The MiOXSYS System was developed following the completed
development of the RedoxSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2015, Rosewind formed Rosewind
Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger, and on
April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis,
and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with
Rosewind as the surviving corporation (herein referred to as the Merger). Concurrent with the closing of the Merger, Rosewind abandoned
its pre-merger business plans, and we now solely pursue the specialty healthcare market, focusing on urological related conditions,
including the business of Vyrix and Luoxis. When we discuss our business in this prospectus, we include the pre-Merger business
of Luoxis and Vyrix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2015, we (i) reincorporated
as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu
BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder received one share of common stock
for each 12.174 shares outstanding. At our annual meeting of stockholders held on May 24, 2016, our stockholders approved (1) an
amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock from 300.0 million to 100.0
million, which amendment was effective on June 1, 2016, and (2) an amendment to our Certificate of Incorporation to affect a reverse
stock split at a ratio of 1-for-12 which became effective on June 30, 2016. At our special meeting of stockholders held on July
26, 2017, our stockholders approved an amendment to our Certificate of Incorporation to affect a reverse stock split at a ratio
of 1-for-20 which became effective on August 25, 2017. In addition, at our annual meeting of stockholders held on June 27, 2018,
our stockholders approved an amendment to our Certificate of Incorporation to affect a reverse stock split at a ratio of up to
1-for-20, which reverse stock split became effective at a ratio of 1-for-20 on August 10, 2018. All share and per share amounts
in this prospectus have been adjusted to reflect the effect of these four reverse stock splits (hereafter referred to collectively
as the &ldquo;Reverse Stock Splits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, and our phone number is (720) 437-6580. Our corporate website address
is http://www.aytubio.com. The information contained on, connected to or that can be accessed via our website is not part of this
prospectus. We have included our website address in this prospectus as an inactive textual reference only and not as an active
hyperlink.&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><B><A NAME="aa_002"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%; padding-right: 6.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aytu
    BioScience, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Securities
    offered</FONT></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><P STYLE="margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">839,695
                                         shares of our common stock, warrants to purchase up to 4,198,473 shares of our common
                                         stock, and 3,358,778 shares of our Series&nbsp;C Preferred Stock.</FONT> </P>




    <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Assumed
    public offering price per share of common stock and warrant</FONT></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$2.62</FONT></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Assumed
    public offering price per share of Series C Preferred Stock and warrant</FONT></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$2.62</FONT></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Over-allotment
    option</FONT></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
    underwriters have the option to purchase up to&nbsp;629,771 additional shares of common stock, and/or warrants to purchase
    shares of common stock solely to cover over-allotments, if any, at the price to the public less the underwriting discounts
    and commissions. The over-allotment option may be used to purchase shares of common stock, or warrants, or any combination
    thereof, as determined by the underwriters, but such purchases cannot exceed an aggregate of 15% of the number of shares of
    common stock (including the number of shares of common stock issuable upon conversion of shares of Series C Preferred Stock)
    and warrants sold in the primary offering. The over-allotment option is exercisable for 45 days from the date of this prospectus.</FONT></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    warrants will be exercisable beginning on the date of issuance and expire on the five (5)&nbsp;year anniversary of the date
    of issuance at an initial exercise price per share equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, subject
    to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications,
    reorganizations or similar events affecting our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.7pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
        share of Series C Preferred Stock is convertible at any time at the holder&rsquo;s option into one share of common stock.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
        the foregoing, we shall not effect any conversion of Series C Preferred Stock, with certain exceptions, to the extent
        that, after giving effect to an attempted conversion, the holder of shares of Series C Preferred Stock (together with
        such holder&rsquo;s affiliates, and any persons acting as a group together with such holder or any of such holder&rsquo;s
        affiliates) would beneficially own a number of shares of our common stock in excess of 4.99% (or, at the election of the
        purchaser prior to the date of issuance, 9.99%) of the shares of our common stock then outstanding after giving effect
        to such conversion. For additional information, see &ldquo;Description of Capital Stock &mdash; Series C Preferred Stock&rdquo;
        for a discussion of the terms of the Series C Preferred.</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock outstanding before this offering</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%; padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,801,411 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock
    to be outstanding immediately after this offering</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,999,884 shares,
    or 6,629,654 shares if the underwriters exercise in full their option to purchase additional shares of common stock (on an
    as-converted to common stock basis with respect to any shares of Series C Preferred Stock sold). The outstanding share data does not take into account the exercise of warrants issued in this offering.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> Series C Preferred Stock to be outstanding immediately after this offering </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0"> 3,358,778 shares (assuming no conversion of Series C Preferred
                                    Stock) </P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that
    the net proceeds to us from this offering will be approximately $9.9 million, based on an assumed offering price of $2.62
    for each share of common stock and warrant and $2.62 for each share of Series C Preferred Stock and warrant, after deducting
    the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds
    from this offering for general corporate purposes, including working capital. See &ldquo;Use of Proceeds&rdquo; for additional
    information.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This investment involves a high degree of risk. You should read the description of risks set forth under &ldquo;Risk Factors&rdquo; beginning on page 8 of this prospectus and the documents incorporated by reference herein for a discussion of factors to consider before deciding to purchase our securities.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ Capital Market trading symbol of common stock</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;AYTU&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No listing of Series C Preferred Stock or warrants</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no established public trading market for the warrants or Series C Preferred Stock, and we do not expect an active trading market to develop. We do not intend to list the warrants or the Series C Preferred Stock on any securities exchange or other trading market. Without an active trading market, the liquidity of the warrants and the Series C Preferred Stock will be limited.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered
    Securities</FONT> </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    prospectus also relates to the offering of the shares issuable upon conversion of the Series C Preferred Stock and upon exercise
    of the warrants.</FONT> </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all
information in this prospectus assumes no exercise by the underwriters of their option to purchase additional shares of common
stock and/or warrants to cover over-allotments, if any, and excludes as of August 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,798 shares of our common stock issuable upon exercise
of outstanding stock options under our 2015 Stock Option and Incentive Plan at a weighted average exercise price of $325.97 per
share;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,882,661 shares of our common stock issuable upon exercise
of outstanding warrants with a weighted average exercise price of $25.94 per share; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> &#9679; </TD><TD STYLE="text-align: justify"> shares
                                         of common stock underlying the warrants and Series C Preferred Stock offered hereby. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities includes
a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific
factors discussed below, together with all of the other information contained in this prospectus and the documents incorporated
by reference, including the risks identified under &ldquo;Item 1A. Risk Factors&rdquo; in our Annual Report on Form 10-K for the
fiscal year ended June 30, 2018. Our business, financial condition, results of operations and prospects could be materially and
adversely affected by these risks.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Financial Condition
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a limited operating history, have incurred losses,
and can give no assurance of profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a commercial-stage healthcare company
with a limited operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did
not have a focus on profitability. As a result, we have not generated substantial revenue to date and are not profitable and have
incurred losses in each year since our inception. Our net loss for the years ended June 30, 2018 and 2017 was $10.2 million and
$22.5million, respectively. We have not demonstrated the ability to be a profit-generating enterprise to date. Even though we expect
to have revenue growth in the next several fiscal years, it is uncertain that the revenue growth will be significant enough to
offset our expenses and generate a profit in the future. Our ability to generate significant revenue is uncertain, and we may never
achieve profitability. We have a very limited operating history on which investors can evaluate our potential for future success.
Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered
by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">uncertain market acceptance of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of sufficient capital;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">U.S. regulatory approval of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign regulatory approval of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated problems, delays, and expense relating to product development and implementation;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of sufficient intellectual property;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the ability to attract and retain qualified employees;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">competition; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">technological changes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our limited operating history,
and the increasingly competitive nature of the markets in which we compete, our historical financial data, is of limited value
in anticipating future operating expenses. Our planned expense levels will be based in part on our expectations concerning future
operations, which is difficult to forecast accurately based on our limited operating history and the recentness of the acquisition
of our products Natesto, ZolpiMist, and MiOXSYS. We may be unable to adjust spending in a timely manner to compensate for any unexpected
budgetary shortfall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not received any substantial revenues
from the commercialization of our current products to date and might not receive significant revenues from the commercialization
of our current products or our product candidates in the near term. Even though Natesto and ZolpiMist are each an approved drug
that we are marketing, we only acquired Natesto in April 2016 and ZolpiMist in June 2018. In addition, we only launched our MiOXSYS
device in early fiscal 2017. As a result, we have limited experience on which to base the revenue we could expect to receive from
sales of these products. To obtain revenues from our products and product candidates, we must succeed, either alone or with others,
in a range of challenging activities, including expanding markets for our existing products and completing clinical trials of our
product candidates, obtaining positive results from those clinical trials, achieving marketing approval for those product candidates,
manufacturing, marketing and selling our existing products and those products for which we, or our collaborators, may obtain marketing
approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government
payors. We, and our collaborators, if any, may never succeed in these activities and, even if we do, or one of our collaborators
does, we may never generate revenues that are sufficient enough for us to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need to raise additional funding,
which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay,
limit or terminate our product expansion and development efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are expending resources to expand the
market for Natesto, ZolpiMist, and MiOXSYS, none of which might be as successful as we anticipate or at all and all of which might
take longer and be more expensive to market than we anticipate. We also are currently advancing our MiOXSYS device through clinical
development. Developing product candidates is expensive, lengthy and risky, and we expect to incur research and development expenses
in connection with our ongoing clinical development activities with the MiOXSYS System. As of June 30, 2018, our cash, cash equivalents
and restricted cash totaling $7.1 million, available to fund our operations offset by an aggregate $2.3 million in accounts payable
and other and accrued liabilities. In November 2016, we conducted a public offering of our common stock and warrants from which
we received gross proceeds of approximately $8.6 million. We closed on a private placement of common stock, Series A preferred
stock and warrants in August 2017 from which we received gross proceeds of approximately $11.8 million. We also closed on an underwritten
public offering of our common stock, warrants, and Series B preferred stock in March 2018 from which we received gross proceeds
of approximately $12.9 million. Our operating plan may change as a result of many factors currently unknown to us, and we may need
to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party
funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a
combination of these approaches. In any event, we will require additional capital to continue the expansion of marketing efforts
for Natesto and ZolpiMist and to obtain regulatory approval for, and to commercialize, our current product candidate, the MiOXSYS
System. Raising funds in the current economic environment, as well our lack of operating history, may present additional challenges.
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any additional fundraising efforts may
divert our management from their day-to-day activities, which may adversely affect our ability to expand any existing product or
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the
rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute
all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability
to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or
product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business,
operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to obtain funding on a
timely basis, we may be unable to expand the market for Natesto, ZolpiMist, or MiOXSYS and/or be required to significantly curtail,
delay or discontinue one or more of our research or development programs for the MiOXSYS system, or any future product candidate
or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect
our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain the capital necessary
to fund our operations, we will be unable to successfully expand the commercialization of Natesto and ZolpiMist and to develop,
obtain regulatory approval of, and commercialize, our current product candidate, the MiOXSYS System.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expansion of marketing and commercialization
activities for our existing products and the development of pharmaceutical products, medical diagnostics and medical devices is
capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements
will depend on, and could increase significantly as a result of, many factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs, progress and timing of our efforts to expand the marketing of Natesto and ZolpiMist;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">progress in, and the costs of, our pre-clinical studies
and clinical trials and other research and development programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs of securing manufacturing arrangements for commercial production;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the scope, prioritization and number of our research and development programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the achievement of milestones or occurrence of other developments that trigger payments under any
collaboration agreements we obtain;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs of establishing, expanding or contracting for sales and marketing capabilities for any
existing products and if we obtain regulatory clearances to market our current product candidate, the MiOXSYS system;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial
costs under future collaboration agreements, if any; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual
property rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If funds are not available, we may be required
to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our technologies, research or development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur increased costs associated
with, and our management will need to devote substantial time and effort to, compliance with public company reporting and other
requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we incur significant
legal, accounting and other expenses. In addition, the rules and regulations of the SEC and any national securities exchange to
which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our
corporate governance practices, with which we will need to comply. Further, we will continue to be required to, among other things,
file annual, quarterly and current reports with respect to our business and operating results. Based on currently available information
and assumptions, we estimate that we will incur up to approximately $500,000 in expenses on an annual basis as a direct result
of the requirements of being a publicly traded company. Our management and other personnel will need to devote substantial time
to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts
and initiatives to comply with those requirements could be expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain
proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management
conducted an assessment of the effectiveness of our internal controls over financial reporting for the year ended June 30, 2018
and concluded that such control was effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if in the future we were to conclude
that our internal control over financial reporting were not effective, we cannot be certain as to the timing of completion of our
evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available
by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in
time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will
not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section
404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could
require us to restate our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to conclude that we have
effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us, when
required, with an attestation report on the effectiveness of internal control over financial reporting as required by Section 404
of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be
subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404
of the Sarbanes-Oxley Act, we may not be able to maintain listing on the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Product Development,
Regulatory Approval and Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natesto, ZolpiMist, and MiOXSYS may
prove to be difficult to effectively commercialize as planned.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various commercial, regulatory, and manufacturing
factors may impact our ability to maintain or grow revenues from sales of Natesto, MiOXSYS, ProstaScint and Fiera. Specifically,
we may encounter difficulty by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our inability to adequately market and increase sales of
any of these products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our inability to secure continuing prescribing of any of
these products by current or previous users of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our inability to effectively transfer and scale manufacturing
as needed to maintain an adequate commercial supply of these products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">reimbursement and medical policy changes that may adversely
affect the pricing, profitability or commercial appeal of Natesto, ZolpiMist, or MiOXSYS; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our inability to effectively identify and align with commercial
partners outside the U.S., or the inability of those selected partners to gain the required regulatory, reimbursement, and other
approvals needed to enable commercial success of MiOXSYS.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited experience selling
our current products as they were acquired from other companies or were recently approved for sale. As a result, we may be unable
to successfully commercialize our products and product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite our management&rsquo;s extensive
experience in launching and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution experience
with our current products. Our ability to achieve profitability depends on attracting and retaining customers for our current products,
and building brand loyalty for Natesto, ZolpiMist, and MiOXSYS. To successfully perform sales, marketing, distribution and customer
support functions, we will face a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to attract and retain skilled support team,
marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance for
our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability of our sales and marketing team to identify
and penetrate the potential customer base; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the difficulty of establishing brand recognition and loyalty
for our products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may seek to enlist one
or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world. If we
do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners, or
we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those
of any third-party sales and distribution partners, are not successful, our currently approved products may not achieve increased
market acceptance and our product candidates may not gain market acceptance, which would materially impact our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that we will
be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to develop our current
or any future product candidates. Our product candidates will require substantial additional clinical development, testing, and
regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are,
and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation
by numerous government authorities in the U.S. and in other countries where we intend to test and, if approved, market any product
candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through
pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This
process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial
resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory
approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund
our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed
or commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not permitted to market a product
in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries
until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and
uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not be able to demonstrate that a product candidate is safe and effective to the satisfaction
of the FDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results of our clinical trials may not meet the level of statistical or clinical significance
required by the FDA for marketing approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may require that we conduct additional clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not approve the formulation, labeling or specifications of any product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may
take actions outside of our control that materially adversely impact our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate
that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients
or the public in general;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical
trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not accept data generated at our clinical trial sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties
scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application
or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations
on approved labeling or distribution and use restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
of approval or post-approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not approve the manufacturing processes or facilities of third-party manufacturers
with which we contract; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may change its approval policies or adopt new regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These same risks apply to applicable foreign
regulatory agencies from which we may seek approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these factors, many of which are
beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate.
Moreover, because a substantial portion of our business is or may be dependent upon our product candidates, any such setback in
our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to successfully acquire
new products, we may lose market position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquiring new products is an important
factor in our planned sales growth, including products that already have been developed and found market acceptance. If we fail
to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue
source to help pay for our development activities as well as possible acquisitions. This failure would delay implementation of
our business plan, which could have a negative adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not secure collaborations
with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products
and generate meaningful revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may enter into collaborations with third
parties to conduct clinical testing, as well as to commercialize and manufacture our products and product candidates. If we are
able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements
will depend on our collaborators&rsquo; abilities to successfully perform the functions assigned to them in these arrangements.
Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety,
obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety
are demonstrated. Further, the economic environment at any given time may result in potential collaborators electing to reduce
their external spending, which may prevent us from developing our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we succeed in securing collaborators,
the collaborators may fail to develop or effectively commercialize our products or product candidates. Collaborations involving
our product candidates pose a number of risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may not have sufficient resources or may decide not to devote the necessary resources
due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may believe our intellectual property is not valid or is unenforceable or the product
candidate infringes on the intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may dispute their responsibility to conduct development and commercialization activities
pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may decide to pursue a competitive product developed outside of the collaboration
arrangement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory
approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may delay the development or commercialization of our product candidates in favor
of developing or commercializing their own or another party&rsquo;s product candidate; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may decide to terminate or not to renew the collaboration for these or other reasons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, collaboration agreements may
not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example, our
former collaborator that licensed our former product candidate, Zertane conducted clinical trials which we believe demonstrated
efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated
the collaboration agreement. The Merger also created a potential conflict with a principal customer of the acquired company, which
sells a product to treat premature ejaculation in certain European markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaboration agreements are generally
terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product
candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&rsquo;s
objectives and meet our expectations, we may be unable to advance our products or product candidates and may not generate meaningful
revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We or our strategic partners may
choose not to continue an existing product or choose not to develop a product candidate at any time during development, which would
reduce or eliminate our potential return on investment for that product.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time and for any reason, we or our
strategic partners may decide to discontinue the development or commercialization of a product or product candidate. If we terminate
a program in which we have invested significant resources, we will reduce the return, or not receive any return, on our investment
and we will have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic
partners terminates a program, we will not receive any future milestone payments or royalties relating to that program under our
agreement with that party. As an example, we discontinued the development of Zertane in June 2016, sold Primsol in March 2017,
and abandoned Fiera and ProstaScint in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our pre-commercial product candidates
are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for
which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and
efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development and commercialization of these product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical testing and clinical trials
are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical
studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical
testing and clinical development necessary to commercialize a drug, and delays or failure can occur at any stage. Interim results
of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does
not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be
certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval
of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An
unfavorable outcome in one or more trials would be a major set-back for that product candidate and for us. Due to our limited financial
resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more
product development programs, which could have a material adverse effect on our business, prospects and financial condition and
on the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with clinical testing and
trials, we face a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic,
or has unacceptable side effects;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">patients may die or suffer other adverse effects for reasons that may or may not be related to
the product candidate being tested;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results may not confirm the positive results of earlier testing or trials; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results may not meet the level of statistical significance required by the FDA or other regulatory
agencies to establish the safety and efficacy of the product candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not successfully complete pre-clinical
and clinical development, we will be unable to market and sell products derived from our product candidates and generate revenues.
Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials
that may be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs in development in the
U.S. and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization,
and only a small number achieve widespread physician and consumer acceptance following regulatory approval. If our clinical trials
are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive
regulatory approval of any of these product candidates and our business, prospects and financial condition will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays, suspensions and terminations
in any clinical trial we undertake could result in increased costs to us and delay or prevent our ability to generate revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive,
time-consuming, and difficult to design, implement and complete. Should we undertake the development of a pharmaceutical product
candidate, we would expect the necessary clinical trials to take up to 24 months to complete, but the completion of trials for
any product candidates may be delayed for a variety of reasons, including delays in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical
trial;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">validating test methods to support quality testing of the drug substance and drug product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining sufficient quantities of the drug substance or device parts;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">manufacturing sufficient quantities of a product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining approval of an IND from the FDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical
trial site;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">determining dosing and clinical design and making related adjustments; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">patient enrollment, which is a function of many factors, including the size of the patient population,
the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the
relevant disease and the eligibility criteria for the clinical trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commencement and completion of clinical
trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of effectiveness of product candidates during clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>adverse events, safety issues or side effects relating
to the product candidates or their formulation or design;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to raise additional capital in sufficient amounts to continue clinical trials or development
programs, which are very expensive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve
resources;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to enter into collaborations relating to the development and commercialization of
our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability or the inability of our collaborators to manufacture or obtain from third parties
materials sufficient for use in pre-clinical studies and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines,
including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect to clinical
trial results;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure of our collaborators to advance our product candidates through clinical development;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">delays in patient enrollment, variability in the number and types of patients available for clinical
trials, and lower-than anticipated retention rates for patients in clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">difficulty in patient monitoring and data collection due to failure of patients to maintain contact
after treatment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical
trials, such as a pandemic, terrorist activities or war, or a natural disaster; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">varying interpretations of our data, and regulatory commitments and requirements by the FDA and
similar foreign regulatory agencies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these factors may also ultimately
lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical trial, the
commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may encounter delays or
product candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in
FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals, such approvals
may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">diminishment of any competitive advantages that such product candidates may have or attain.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, if we fail to comply with
applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">diminishment of any competitive advantages that such product candidates may have or attain;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">delays or termination in clinical trials or commercialization;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements
to approved applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product recalls or seizures;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">suspension of manufacturing;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawals of previously approved marketing applications; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">fines, civil penalties, and criminal prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The medical device regulatory clearance
or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals
could prevent us from broadly commercializing the MiOXSYS System for clinical use.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MiOXSYS System is subject to 510k de
novo clearance by the FDA prior to its marketing for commercial use in the U.S., and to regulatory approvals beyond CE marking
required by certain foreign governmental entities prior to its marketing outside the U.S. In addition, any changes or modifications
to a device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or
would constitute a major change in its intended use, may require the submission of a new application for 510k de novo clearance,
pre-market approval, or foreign regulatory approvals. The 510k de novo clearance and pre-market approval processes, as well as
the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve
months from submission to obtain 510k de novo clearance, and from one to three years from submission to obtain pre-market approval;
however, it may take longer, and 510k de novo clearance or pre-market approval may never be obtained. We have limited experience
in filing FDA applications for 510k de novo clearance and pre-market approval. In addition, we are required to continue to comply
with applicable FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that
we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material
delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The approval process for pharmaceutical
and medical device products outside the U.S. varies among countries and may limit our ability to develop, manufacture and sell
our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates
from being marketed abroad.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market and sell our products
in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply
with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing.
We may conduct clinical trials for, and seek regulatory approval to market, our product candidates in countries other than the
U.S. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may
decide to first seek regulatory approvals of a product candidate in countries other than the U.S., or we may simultaneously seek
regulatory approvals in the U.S. and other countries. If we or our collaborators seek marketing approval for a product candidate
outside the U.S., we will be subject to the regulatory requirements of health authorities in each country in which we seek approval.
With respect to marketing authorizations in Europe, we will be required to submit a European Marketing Authorisation Application,
or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product
for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the
time required to obtain approval may differ from that required to obtain FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining regulatory approvals from health
authorities in countries outside the U.S. is likely to subject us to all of the risks associated with obtaining FDA approval described
above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and
approval by foreign health authorities does not ensure marketing approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we, or our collaborators,
obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit
how we or they market our products, which could materially impair our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we receive regulatory approval
for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive
disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can
market a product or the patient population that may utilize the product, or may be required to carry a warning in its labeling
and on its packaging. Products with black box warnings are subject to more restrictive advertising regulations than products without
such warnings. These restrictions could make it more difficult to market any product candidate effectively. Accordingly, assuming
we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect
to continue to expend time, money and effort in all areas of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any of our products and product
candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions
or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply
with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of our approved products and product
candidates for which we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post approval
studies and measures, labeling, advertising and promotional activities for such products, among other things, are or will be subject
to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of
safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing,
quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution
of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject
to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the FDA
requirement to implement a REMS to ensure that the benefits of a drug outweigh its risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may also impose requirements for
costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other
agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products
to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions
of the approved labeling. The FDA imposes stringent restrictions on manufacturers&rsquo; communications regarding off-label use
and if we, or our collaborators, do not market any of our product candidates for which we, or they, receive marketing approval
for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation
of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs
may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer
protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not achieve our projected
development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates
may be delayed, and our business will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sometimes estimate for planning purposes
the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones
may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission
of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some
of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs,
receipt of marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside
of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones
to vary considerably from our estimates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our available capital resources or capital constraints we experience;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the rate of progress, costs and results of our clinical trials and research and development activities,
including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll
patients who meet clinical trial eligibility criteria;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other actions, decisions or rules issued by regulators;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture
of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the efforts of our collaborators with respect to the commercialization of our products; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the securing of, costs related to, and timing issues associated with, product manufacturing as
well as sales and marketing activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to achieve announced milestones
in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business, prospects
and results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on third parties to conduct
our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully
commercializing product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely, and will rely in the future,
on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to
perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials
conducted in reliance on third parties may be delayed, suspended, or terminated if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the third parties do not successfully carry out their contractual duties or fail to meet regulatory
obligations or expected deadlines;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we replace a third party; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the quality or accuracy of the data obtained by third parties is compromised due to their failure
to adhere to clinical protocols, regulatory requirements, or for other reasons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third party performance failures may increase
our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product
candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such
alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if collaborators with which
we contract in the future successfully complete clinical trials of our product candidates, those product candidates may not be
commercialized successfully for other reasons.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we contract with collaborators
that successfully complete clinical trials for one or more of our product candidates, those candidates may not be commercialized
for other reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to receive regulatory clearances required to market them as drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being subject to proprietary rights held by others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being difficult or expensive to manufacture on a commercial scale;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">having adverse side effects that make their use less desirable; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failing to compete effectively with products or treatments commercialized by competitors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any third-party manufacturers we
engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays
in, our product commercialization as a result of these regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing processes and facilities
of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer will
be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design,
testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces
the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional
compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements,
or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers
we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">administrative or judicially imposed sanctions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctions or the imposition of civil penalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">recall or seizure of the product in question;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal or suspension of marketing clearances or approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">clinical holds;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">warning letters;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal to permit the export of the product in question; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these actions, in combination or
alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a product defect or regulatory
violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary
recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have
similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger
health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims,
and harm our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face substantial competition from
companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving
approval for, or commercializing products before or more successfully than us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete with companies that design,
manufacture and market already-existing and new urology and sexual wellbeing products. We anticipate that we will face increased
competition in the future as new companies enter the market with new technologies and/or our competitors improve their current
products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical.
Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial
intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more
substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing
capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may
not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">expand the market for our approved products, especially Natesto, MiOXSYS and Fiera;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">successfully commercialize our product candidates alone or with commercial partners;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">discover and develop product candidates that are superior to other products in the market;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtain required regulatory approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">attract and retain qualified personnel; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtain patent and/or other proprietary protection for our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Established pharmaceutical companies devote
significant financial resources to discovering, developing or licensing novel compounds that could make our products and product
candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us.
Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto competes in a large, growing market.
The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions,
and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are
also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For ZolpiMist, we compete with companies
that design, manufacture and market treatments for insomnia, some of which have a large market share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the MiOXSYS System, we compete with
companies that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging systems and
radio-imaging agents for cancer detection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will face increased
competition in the future as new companies enter the market with new technologies and our competitors improve their current products.
One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of
our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual
property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial
experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution
channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to
become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any new product we develop or commercialize
that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or
safety in order to address price competition and be commercially successful. If we are not able to compete effectively against
our current and future competitors, our business will not grow and our financial condition and operations will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Government restrictions on pricing
and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate
revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuing efforts of the government,
insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care
may adversely affect one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our or our collaborators&rsquo; ability to set a price
we believe is fair for our approved products;</TD>
</TR></TABLE>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our ability to generate revenue from our approved products
and achieve profitability; and</TD>
</TR></TABLE>






<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the availability of capital.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2010 enactments of the Patient Protection
and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act,
significantly impacted the provision of, and payment for, health care in the U.S. Various provisions of these laws are designed
to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits,
prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support
for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to
reform healthcare and government insurance programs, along with the trend toward managed healthcare in the U.S., could influence
the purchase of medicines and medical devices and reduce demand and prices for our products and product candidates, if approved.
This could harm our or our collaborators&rsquo; ability to market any approved products and generate revenues. As we expect to
receive significant revenues from reimbursement of our Natesto and ProstaScint products by commercial third-party payors and government
payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform
could significantly reduce potential revenues from the sale of any of our products and product candidates approved in the future,
and could cause an increase in our compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets,
the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable.
We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which
may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in some foreign countries,
the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing
pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict
the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt
a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. A member
state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be
no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched
in the European Union do not follow price structures of the U.S. and generally tend to have significantly lower prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our financial results will depend
on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success depends on the acceptance
by our target customers, third-party payors and the medical community that our products and product candidates are reliable, safe
and cost-effective. Many factors may affect the market acceptance and commercial success of our products and product candidates,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to convince our potential customers of the advantages and economic value our products
and product candidates over existing technologies and products;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the relative convenience and ease of our products and product
candidates over existing technologies and products;</TD>
</TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the introduction of new technologies and competing products that may make our products and product
candidates less attractive for our target customers;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our success in training medical personnel on the proper use of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the willingness of third-party payors to reimburse our target customers that adopt our products
and product candidates;</TD></TR>                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the acceptance in the medical community of our products and product candidates;</TD></TR>                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the extent and success of our marketing and sales efforts; and</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">general economic conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If third-party payors do not reimburse
our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at
a profit, our ability to sell those products and our results of operations will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While Natesto and ZolpiMist are already
FDA-approved and generating revenues in the U.S., they may not receive, or continue to receive, physician or hospital acceptance,
or they may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product candidates is
approved and reaches the market, the product may not achieve physician or hospital acceptance, or it may not obtain adequate reimbursement
from third party payors. In the future, we might possibly sell other product candidates to target customers substantially all of
whom receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare,
Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions
by particular third-party payors depend upon a number of factors, including each third-party payor&rsquo;s determination that use
of a product is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a covered benefit under its health plan;</TD></TR>                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">appropriate and medically necessary for the specific indication;</TD></TR>                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">cost effective; and</TD></TR>                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">neither experimental nor investigational.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors may deny reimbursement
for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods,
as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse
for procedures and devices deemed to be experimental.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining coverage and reimbursement approval
for a product from each government or third-party payor is a time consuming and costly process that could require us to provide
supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party
payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition,
eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that
allows our potential customers to make a profit or even cover their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors are increasingly attempting
to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels
of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors
may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively
impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our
products, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Manufacturing risks and inefficiencies
may adversely affect our ability to produce our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to engage third parties to manufacture
components of the MiOXSYS and RedoxSYS systems. We have an agreement for supplies of Natesto with Acerus, from whom we license
Natesto. We have an agreement with a third-party manufacturer for our ZolpiMist product as well. For any future product, we expect
to use third-party manufacturers because we do not have our own manufacturing capabilities. In determining the required quantities
of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current
market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing our
current products, there could be significant differences between our estimates and the actual amounts of product we require. If
we do not effectively maintain our supply agreements for Natesto and Fiera, we will face difficulty finding replacement suppliers,
which could harm sales of those products. If we do not secure collaborations with manufacturing and development partners to enable
production to scale of the MiOXSYS System, we may not be successful in selling or in commercializing the MiOXSYS System in the
event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future products, we may not be
successful in establishing or continuing the commercialization of our products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reliance on third-party manufacturers entails
risks to which we would not be subject if we manufactured these components ourselves, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reliance on third parties for regulatory compliance and quality assurance;</TD></TR>                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible breaches of manufacturing agreements by the third parties because of factors beyond our
control;</TD></TR>                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible regulatory violations or manufacturing problems experienced by our suppliers; and</TD></TR>                                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible termination or non-renewal of agreements by third parties, based on their own business
priorities, at times that are costly or inconvenient for us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if we are unable to secure the
needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition
our third party manufacturing. We may not be able to meet the demand for our products if one or more of any third-party manufacturers
is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers
for any of our products or product candidates in a timely manner and on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any third-party manufacturers we
engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays
in, our product commercialization as a result of these regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing processes and facilities
of third-party manufacturers we engage for our current and any future FDA-approved products are required to comply with the federal
Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality
assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced
inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause
delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown
problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take
satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">administrative or judicially imposed sanctions;</TD></TR>                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctions or the imposition of civil penalties;</TD></TR>                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">recall or seizure of the product in question;</TD></TR>                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution;</TD></TR>                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</TD></TR>                                                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal or suspension of marketing clearances or approvals;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">clinical holds;</TD></TR>                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">warning letters;</TD></TR>                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal to permit the export of the product in question; and</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these actions, in combination or
alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a product defect or regulatory
violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary
recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have
similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger
health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims,
and harm our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future growth depends, in part,
on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future profitability will depend, in
part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to primarily rely
on collaboration with third parties. If we commercialize our products or product candidates in foreign markets, we would be subject
to additional risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to directly control commercial activities because we are relying on third parties;</TD></TR>                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal
requirements;</TD></TR>                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</TD></TR>                                                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">import or export licensing requirements;</TD></TR>                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer accounts receivable collection times;</TD></TR>                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer lead times for shipping;</TD></TR>                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">language barriers for technical training;</TD></TR>                                                                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reduced protection of intellectual property rights in some foreign countries, and related prevalence
of generic alternatives to our products;</TD></TR>                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign currency exchange rate fluctuations;</TD></TR>                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our customers&rsquo; ability to obtain reimbursement for our products in foreign markets; and</TD></TR>                                                                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the interpretation of contractual provisions governed by foreign laws in the event of a contract
dispute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign sales of our products or product
candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade
restrictions and changes in tariffs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to various regulations
pertaining to the marketing of our approved products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state
laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other
remuneration for the purchase of our products, including inducements to potential patients to request our products and services.
Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions
with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute.
The Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing
remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging
for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs.
Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states
have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare
items or services reimbursed by any third party payer, not only the Medicare and Medicaid programs, and do not contain identical
safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely
impact the marketing of our existing products or delay introduction of our product candidates, which may have a material adverse
effect on our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our products and product candidates
may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Undesirable side effects caused by our
product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if a product candidate receives
marketing approval and we or others identify undesirable side effects caused by the product after the approval, or if drug abuse
is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could
result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">regulatory authorities may withdraw or limit their approval of the product;</TD></TR>                                                                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">regulatory authorities may require the addition of labeling statements, such as a &ldquo;Black
Box warning&rdquo; or a contraindication;</TD></TR>                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may be required to change the way the product is distributed or administered, conduct additional
clinical trials or change the labeling of the product;</TD></TR>                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may decide to remove the product from the marketplace;</TD></TR>                                                                                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we could be sued and held liable for injury caused to individuals exposed to or taking the product;
and</TD></TR>             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these events could prevent us from
achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing
an affected product or product candidates and significantly impact our ability to successfully commercialize or maintain sales
of our product or product candidates and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natesto and ZolpiMist contain, and
future other product candidates may contain, controlled substances, the manufacture, use, sale, importation, exportation, prescribing
and distribution of which are subject to regulation by the DEA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto and ZolpiMist, which are both approved
by the FDA, are regulated by the DEA as Schedule III controlled substances. Before any commercialization of any product candidate
that contains a controlled substance, the DEA will need to determine the controlled substance schedule, taking into account the
recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially
diminish any regulatory exclusivity periods for which we may be eligible. Natesto and ZolpiMist are, and our other product candidates
may, if approved, be regulated as &ldquo;controlled substances&rdquo; as defined in the Controlled Substances Act of 1970, or CSA,
and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution,
importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to
us, to our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates
the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials
used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of
states and foreign countries also independently regulate these drugs as controlled substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA regulates controlled substances
as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not
be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto is regulated by the DEA as a Schedule
III controlled substance, and ZolpiMist as a Schedule IV controlled substance. Consequently, the manufacturing, shipping, storing,
selling and using of the products are subject to a high degree of regulation. Also, distribution, prescribing and dispensing of
these drugs are highly regulated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual registration is required for any
facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to
the particular location, activity and controlled substance schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of their restrictive nature, these
laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply
with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution
activities, consent decrees, criminal and civil penalties and state actions, among other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If testosterone replacement therapies
are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected and our
business could be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent publications have suggested potential
health risks associated with testosterone replacement therapy, such as increased cardiovascular disease risk, including increased
risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development
of clinical prostate disease, including prostate cancer, and the suppression of sperm production. Prompted by these events, the
FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further. The FDA has also asked health
care professionals and patients to report side effects involving prescription testosterone products to the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the T-class Advisory Committee meeting
held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom
testosterone replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined
as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with testosterone replacement therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the meeting, the Advisory Committee
voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study
or controlled clinical trial) to further assess the potential cardiovascular risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is possible that the FDA&rsquo;s evaluation
of this topic and further studies on the effects of testosterone replacement therapies could demonstrate the risk of major adverse
cardiovascular events or other health risks or could impose requirements that impact the marketing and sale of Natesto, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">mandate that certain warnings or precautions be included in our product labeling;</TD></TR>                                                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">require that our product carry a &ldquo;black box warning&rdquo;; and</TD></TR>                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limit use of Natesto to certain populations, such as men without specified conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Demonstrated testosterone replacement therapy
safety risks, as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement,
could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>FDA action regarding testosterone
replacement therapies could add to the cost of producing and marketing Natesto.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA is requiring post-marketing safety
studies for all testosterone replacement therapies approved in the U.S. to assess long-term cardiovascular events related to testosterone
use. Depending on the total cost and structure of the FDA&rsquo;s proposed safety studies there may be a substantial cost associated
with conducting these studies. Pursuant to our license agreement with Acerus Pharmaceuticals, Acerus is obligated to reimburse
us for the entire cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able to reimburse
us for the cost of any required safety studies, we may be forced to incur this cost, which could have a material adverse impact
on our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our approved products may not be
accepted by physicians, patients, or the medical community in general.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if the medical community accepts a
product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we or any collaborator
is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable
to any existing medicines or treatments. We cannot predict the degree of market acceptance of any of our approved products, which
will depend on a number of factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the efficacy and safety of the product;</TD></TR>                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the approved labeling for the product and any required warnings;</TD></TR>                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the advantages and disadvantages of the product compared
to alternative treatments;</TD>
</TR>     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our and any collaborator&rsquo;s ability to educate the medical community about the safety and
effectiveness of the product;</TD></TR>                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the reimbursement policies of government and third-party payors pertaining to the product; and</TD></TR>                                                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the market price of our product relative to competing treatments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may use hazardous chemicals and
biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be
time consuming and costly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development processes
may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk
of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination
that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and
our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of
these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health
and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development
efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and
penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain
compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any
changes in the way existing and future laws and regulations are interpreted and enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intellectual Property Risks Related to
Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on our relationships
and license agreements, and we rely on the patent rights granted to us pursuant to the license agreements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A number of our patent rights for are derived
from our license agreements with third parties. Pursuant to these license agreements, we have licensed rights to various patents
and patent applications within and outside of the United States. We may lose our rights to these patents and patent applications
if we breach our obligations under such license agreements, including, without limitation, our financial obligations to the licensors.
If we violate or fail to perform any term or covenant of the license agreements, the licensors may terminate the license agreements
upon satisfaction of applicable notice requirements and expiration of any applicable cure periods. Additionally, any termination
of license agreements, whether by us or the licensors will not relieve us of our obligation to pay any license fees owing at the
time of such termination. If we fail to retain our rights under these license agreements, we will not be able to commercialize
certain products subject to patent or patent application, and our business, results of operations, financial condition and prospects
would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of our products
depends, in large part, on our ability to use patents licensed to us by third parties in order to exclude others from competing
with our products. The patent position of emerging pharmaceutical companies like us can be highly uncertain and involve complex
legal and technical issues. Until our licensed patents are interpreted by a court, either because we have sought to enforce them
against a competitor or because a competitor has preemptively challenged them, we will not know the breadth of protection that
they will afford us. Our patents may not contain claims sufficiently broad to prevent others from practicing our technologies or
marketing competing products. Third parties may intentionally attempt to design around our patents or design around our patents
so as to compete with us without infringing our patents. Moreover, the issuance of a patent is not conclusive as to its validity
or enforceability, and so our patents may be invalidated or rendered unenforceable if challenged by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to compete may decline
if we do not adequately protect our proprietary rights or if we are barred by the patent rights of others.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends on obtaining
and maintaining proprietary rights to our products and product candidates as well as successfully defending these rights against
third-party challenges. We will only be able to protect our products and product candidates from unauthorized use by third parties
to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent
protection for our products and product candidates is uncertain due to a number of factors, including that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not have been the first to make the inventions covered by pending patent applications or
issued patents;</TD></TR>                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not have been the first to file patent applications for our products and product candidates;</TD></TR>                                                                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may independently develop identical, similar or alternative products, compositions or devices
and uses thereof;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our disclosures in patent applications may not be sufficient to meet the statutory requirements
for patentability;</TD></TR>                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any or all of our pending patent applications may not result in issued patents;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not seek or obtain patent protection in countries that may eventually provide us a significant
business opportunity;</TD></TR>                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any patents issued to us may not provide a basis for commercially viable products, may not provide
any competitive advantages, or may be successfully challenged by third parties;</TD></TR>                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our compositions, devices and methods may not be patentable;</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may design around our patent claims to produce competitive products which fall outside of
the scope of our patents; or</TD></TR>                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may identify prior art or other bases which could invalidate our patents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we have or obtain patents covering
our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of
others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical
to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices,
personal care products and devices and some of these relate to our products and product candidates. These could materially affect
our ability to sell our products and develop our product candidates. Because patent applications can take many years to issue,
there may be currently pending applications unknown to us that may later result in issued patents that our products and product
candidates may infringe. These patent applications may have priority over patent applications filed by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining a patent portfolio
entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees,
various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications,
as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may
or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure
to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of
a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose
to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position
could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal actions to enforce our patent rights
can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful
and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to
pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to
the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual
property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pharmaceutical and medical device
patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could
negatively impact our patent position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
and medical device companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth
of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine and are often
affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The
standards of the U.S. Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently,
the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented.
U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination
proceedings, post-grant review and/or inter partes review in the USPTO. Foreign patents may be subject to opposition or comparable
proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent
application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such
interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights
under any issued patents may not provide us with sufficient protection against competitive products or processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changes in or different interpretations
of patent laws in the U.S. and foreign countries may permit others to use our discoveries or to develop and commercialize our technology
and products and product candidates without providing any compensation to us or may limit the number of patents or claims we can
obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries
may lack adequate rules and procedures for defending our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to obtain and maintain patent
protection and trade secret protection of our products and product candidates, we could lose our competitive advantage and competition
we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments in patent law could
have a negative impact on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the U.S. Supreme Court,
other federal courts, the U.S. Congress or the USPTO may change the standards of patentability and any such changes could have
a negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Leahy-Smith America Invents
Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law.
These changes include a transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system, changes
the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These
changes may favor larger and more established companies that have greater resources to devote to patent application filing and
prosecution. The USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act, and
many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions,
became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability
to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents
Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries
and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to patent protection, because
we operate in the highly technical field of discovery and development of therapies and medical devices, we rely in part on trade
secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect.
We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside
scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the
other party keep confidential and not disclose to third parties all confidential information developed by the party or made known
to the party by us during the course of the party&rsquo;s relationship with us. These agreements also generally provide that inventions
conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may
not be honored and may not effectively assign intellectual property rights to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to contractual measures, we
try to protect the confidential nature of our proprietary information using physical and technological security measures. Such
measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized
access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant
from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not
provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the
U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could
prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed
or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to enforce our
intellectual property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The laws of some foreign countries do not
protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems
in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially
those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of
our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries
have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit
the enforceability of patents against third parties, including government agencies or government contractors. In these countries,
patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is
an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.
Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes
in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain adequate protection
for our technology and the enforcement of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may assert ownership
or commercial rights to inventions we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties may in the future make claims
challenging the inventorship or ownership of our intellectual property. We have or expect to have written agreements with collaborators
that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must
negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made by our collaborators
that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly
the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient
ownership and commercial rights to the inventions that result from our use of a third-party collaborator&rsquo;s materials where
required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&rsquo;s
samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims
by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property
to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership
disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial
value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be
precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome
could have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may assert that our
employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We might employ individuals who were previously
employed at universities or other biopharmaceutical or medical device companies, including our competitors or potential competitors.
Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their
work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or
otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer
or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A dispute concerning the infringement
or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable
outcome could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant litigation in the
pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not currently
subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed
to future litigation by third parties based on claims that our products or product candidates infringe the intellectual property
rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay
significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions or
devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the
scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly
employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals
may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we
become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of
whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling
in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal
action against us or our collaborators could lead to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&rsquo;s
patent rights;</TD></TR>                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctive or other equitable relief that may effectively block our ability to further develop,
commercialize, and sell products; or</TD></TR>                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we or our collaborators having to enter into license arrangements that may not be available on
commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business,
prospects and financial condition. As a result, we could be prevented from commercializing our products and product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Organization, Structure
and Operation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We intend to acquire, through asset
purchases or in-licensing, businesses or products, or form strategic alliances, in the future, and we may not realize the intended
benefits of such acquisitions or alliances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to acquire, through asset purchases
or in-licensing, additional businesses or products, form strategic alliances and/or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses or assets with promising markets or technologies,
we may not be able to realize the benefit of acquiring such businesses or assets if we are unable to successfully integrate them
with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing
any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits
or enhancing our business. We cannot assure you that, following any such acquisition or alliance, we will achieve the expected
synergies to justify the transaction. These risks apply to our acquisition of Natesto in April 2016 and ZolpiMist in June 2018.
As an example, we acquired Primsol in October 2015, but sold it in March 2017. Depending on the success or lack thereof of any
of our existing or future acquired products and product candidates, we might seek to out-license, sell or otherwise dispose of
any of those products or product candidates, which could adversely impact our operations if the dispositions triggers a loss, accounting
charge or other negative impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>In fiscal 2018, the great majority
of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially
and adversely affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following
customers contributed greater than&nbsp;10%&nbsp;of the Company's gross revenue during the year ended June 30, 2018 and 2017, respectively.
As of June 30, 2018, three customers accounted for 86% of gross revenue. The revenue from these customers as a percentage of gross
revenue was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Customer A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">32</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The loss of one or more of the Company's
significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are also subject
to credit risk from our accounts receivable related to our product sales. As of June 30, 2018, three customers accounted for 81%
of gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Customer C</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to develop and expand
our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2018, we had 52 full-time
employees, and in connection with being a public company, we expect to continue to increase our number of employees and the scope
of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also,
our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial
amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage
the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure,
give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects,
such as the planned expanded commercialization of our approved products and the development of our product candidates. If our management
is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability
to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial
performance and our ability to expand the market for our approved products and develop our product candidates, if approved, and
compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on key personnel and attracting
qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends to a significant degree
upon the technical and management skills of our directors, officers and key personnel. Any of our directors could resign from our
board at any time and for any reason. Although our executive officers Joshua Disbrow, Jarrett Disbrow and David Green have employment
agreements, the existence of an employment agreement does not guarantee the retention of the executive officer for any period of
time, and each agreement obligates us to pay the officer lump sum severance of two years of salary if we terminate him without
cause, as defined in the agreement, which could hurt our liquidity. The loss of the services of any of these individuals would
likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified
management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our
officers or key personnel. The loss of any of our directors or key executives, or the failure to attract, integrate, motivate,
and retain additional key personnel could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete for such personnel, including
directors, against numerous companies, including larger, more established companies with significantly greater financial resources
than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure
to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product liability and other lawsuits
could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk that we may be sued on product
liability claims is inherent in the development and commercialization of pharmaceutical, medical device and personal care products
and devices. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration
of a patient&rsquo;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of
product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups
seeking to represent a class. These lawsuits may divert our management from pursuing our business strategy and may be costly to
defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to
limit or forgo further commercialization of the affected products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to legal or administrative
proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business,
financial condition and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we maintain general liability,
clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition,
inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product
or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products
and product candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could
also harm our reputation, which may adversely affect our collaborators&rsquo; ability to commercialize our products successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our internal computer systems, or
those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption
of our product development programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the implementation of security
measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from
computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we
do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to
occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our product candidates which
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or
applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information,
we could incur liabilities and the further development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to use our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2018, we had federal net
operating loss carryforwards of approximately $59.3 million. The available net operating losses, if not utilized to offset taxable
income in future periods, will begin to expire in 2031 and will completely expire in 2037. Under the Internal Revenue Code of 1986,
as amended (the &ldquo;Code&rdquo;) and the regulations promulgated thereunder, including, without limitation, the consolidated
income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards and
other tax attributes (such as research tax credits) to offset our income. Because Ampio&rsquo;s equity ownership interest in our
company fell to below 80% in January 2016, we were deconsolidated from Ampio&rsquo;s consolidated federal income tax group. As
a result, certain of our net operating loss carryforwards may not be available to us and we may not be able to use them to offset
our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible that certain other tax attributes and
benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our company and Ampio do not have
a tax sharing agreement that could mitigate the loss of net operating losses and other tax attributes resulting from the deconsolidation
or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint and several liability
of group members. In addition to the deconsolidation risk, an &ldquo;ownership change&rdquo; (generally a 50% change (by value)
in equity ownership over a three-year period) under Section 382 of the Code could limit our ability to offset, post-change, our
U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable
income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses.
We believe that the August 2017 financing created over a 50% change in our equity ownership so our current tax loss carryforward
will be limited in the future. Either the deconsolidation or the ownership change scenario could result in increased future tax
liability to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Several stockholders potentially
own a significant percentage of our stock and could be able to exert significant control over matters subject to stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our August 2017 and March 2018 offerings,
some entities who invested in our common and preferred stock and warrant financing owned common and/or preferred stock and warrants
that potentially would enable them to beneficially own in excess of 4.99% or 9.99% of our common stock. The preferred stock and
warrants held by these investors contain a provision that prohibits the conversion or exercise of the preferred stock or warrants
should the holder beneficially own in excess of 4.99% or 9.99%, as elected by the investor, after giving effect to such conversion
or exercise. However, the significant ownership potential of these investors, and the significant investment that they have made
in our company, could give these stockholders the ability to influence us through their ownership positions, even if they are prohibited
from converting or exercising their preferred stock or warrants to acquire more than 4.99% or 9.99% of our common stock at any
time. Further, this significant ownership potential may prevent or discourage unsolicited acquisition proposals or offers for our
common stock that you may feel are in your best interest as one of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restrictions under our August 2017
Securities Purchase Agreement may limit our ability to raise funds and operate our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Each investor in the August 2017 offering
has the right to participate for 24 months in any issuance by us of any common stock or common stock equivalents for cash consideration
or indebtedness or a combination thereof (a &ldquo;Subsequent Financing&rdquo;), up to an amount of the Subsequent Financing equal
to 35% of the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing. This offering
is considered a Subsequent Financing and, therefore, the investors in the August 2017 offering are entitled to participate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In addition, the August 2017 Securities
Purchase Agreement contains the covenant described below that may restrict our ability to finance future operations or capital
needs or to engage in other business activities. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until such time as
no investor in the August 2017 offering holds any of the warrants, we are prohibited from effecting or entering into an agreement
to affect any issuance by us of our common stock or common stock equivalents involving a Variable Rate Transaction, as defined
in the Securities Purchase Agreement. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which we (i) issue any debt
or equity securities that are convertible into common stock either (A) at a conversion price, exercise price or exchange rate or
other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of our common stock at any
time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of
specified or contingent events directly or indirectly related to our business or the market for our common stock or (ii) enter
into any transaction under, any agreement, including, but not limited to, an equity line of credit, an &ldquo;at-the-market&rdquo;
offering or similar agreement, whereby we may issue securities at a future determined price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The restrictions and covenants in the August
2017 Securities Purchase Agreement, as well as any future financing agreements that we may enter into, may restrict our ability
to finance our operations, engage in business activities or expand or fully pursue our business strategies. Our ability to comply
with these covenants may be affected by events beyond our control and we may not be able to meet those covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Securities Markets and
Investment in our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to meet the continued
listing requirements of the NASDAQ Capital Market could result in a delisting of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to satisfy the continued listing
requirements of the NASDAQ Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement,
the exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our
common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting,
we anticipate that we would take actions to restore our compliance with applicable exchange requirements, such as stabilize our
market price, improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&rsquo;s minimum
bid price requirement, or prevent future non-compliance with such exchange&rsquo;s listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2018, we received a letter
from NASDAQ indicating that the Company has failed to comply with the minimum bid price requirement of NASDAQ Listing Rule 5550(a)(2).
NASDAQ Listing Rule 5550(a)(2) requires that companies listed on the NASDAQ Capital Market maintain a minimum closing bid price
of at least $1.00 per share. However, on August 10, 2018, we effected a 1-for-20 reverse stock split, which has brought us back
into compliance with NASDAQ Listing Rule 5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our
equity securities or rights to purchase our equity securities, including pursuant to equity incentive plans, would result in additional
dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we raise additional capital
by issuing equity securities, our stockholders may experience substantial dilution. We may, as we have in the past, sell common
stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors
may be further diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new
investors could gain rights superior to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our 2015 Stock Plan, our Board
of Directors is currently authorized to award up to a total of 3.0 million shares of common stock or options to purchase shares
of common stock to our officers, directors, employees and non-employee consultants. As of June 30, 2018, options to purchase 1,798
shares of common stock issued under our 2015 Stock Plan at a weighted average exercise price of $325.97 per share were outstanding.
In addition, at June 30, 2018, there were outstanding warrants to purchase an aggregate of 1,882,661 shares of our common stock
at a weighted average exercise price of $25.94. Stockholders will experience dilution in the event that additional shares of common
stock are issued under our 2015 Stock Plan, or options issued under our 2015 Stock Plan are exercised, or any warrants are exercised
for shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our share price is volatile and may
be influenced by numerous factors, some of which are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price of our common stock is
likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond
our control. In addition to the factors discussed in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus and
the documents incorporated by reference herein, these factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the products or product candidates we acquire for commercialization;</TD></TR>                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the products and product candidates we seek to pursue, and our ability to obtain rights to develop,
commercialize and market those product candidates;</TD></TR>                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an
existing clinical trial;</TD></TR>                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated adverse results or delays in our clinical trials;</TD></TR>                                                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our failure to expand the market for our currently approved products or commercialize our product
candidates, if approved;</TD></TR>                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated serious safety concerns related to the use of any of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overall performance of the equity markets and other factors that may be unrelated to our operating
performance or the operating performance of our competitors, including changes in market valuations of similar companies;</TD></TR>                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</TD></TR>                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">introduction of new products offered by us or our competitors;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments
by us or our competitors;</TD></TR>                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain an adequate rate of growth and manage such growth;</TD></TR>                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">issuances of debt or equity securities;</TD></TR>                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">sales of our common stock by us or our stockholders in the future, or the perception that such
sales could occur;</TD></TR>                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">trading volume of our common stock;</TD></TR>                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</TD></TR>                                                                                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">general political and economic conditions;</TD></TR>                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">effects of natural or man-made catastrophic events;</TD></TR>                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other events or factors, many of which are beyond our control;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adverse regulatory decisions;</TD></TR>                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">additions or departures of key scientific or management personnel;</TD></TR>                                                                                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">changes in laws or regulations applicable to our product candidates, including without limitation
clinical trial requirements for approvals;</TD></TR>                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">disputes or other developments relating to patents and other proprietary rights and our ability
to obtain patent protection for our product candidates;</TD></TR>                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our dependence on third parties, including CROs and scientific and medical advisors;</TD></TR>                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to meet or exceed any financial guidance or expectations regarding development milestones
that we may provide to the public;</TD></TR>                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated variations in quarterly operating results; and</TD></TR>                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to meet or exceed the estimates and projections of the investment community.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the stock market in general,
and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad
market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
The realization of any of the above risks or any of a broad range of other risks, including those described in these &ldquo;Risk
Factors,&rdquo; could have a dramatic and material adverse impact on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts
do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume
could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any trading market for our common stock
that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our
business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities
or industry analysts commence coverage of our company, the trading price for our stock could be negatively affected. If securities
or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable
research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company
or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading
volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We effected a reverse stock split
at a ratio of 1-for-20 on August 10, 2018, which may not achieve one or more of our objectives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have effected four reverse stock splits
since June 8, 2015, each of which has impacted the trading liquidity of the shares of our common stock. There can be no assurance
that the market price per share of our common stock after a reverse stock split will remain unchanged or increase in proportion
to the reduction in the number of shares of our common stock outstanding before the reverse stock split. The market price of our
shares may fluctuate and potentially decline after a reverse stock split. Accordingly, the total market capitalization of our common
stock after a reverse stock split may be lower than the total market capitalization before the reverse stock split. Moreover, the
market price of our common stock following a reverse stock split may not exceed or remain higher than the market price prior to
the reverse stock split.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, there can be no assurance
that a reverse stock split will result in a per-share market price that will attract institutional investors or investment funds
or that such share price will satisfy investing guidelines of institutional investors or investment funds. As a result, the trading
liquidity of our common stock may not necessarily improve. Further, if a reverse stock split is effected and the market price of
our common stock declines, the percentage decline may be greater than would occur in the absence of a reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our
common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result in
dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We could need significant additional capital
in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted
by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders, and new investors
could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future sales of our
common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock
to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the
exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Some provisions of our charter documents
and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of
our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions in our Certificate of Incorporation
and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party
to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the authorization of 50.0 million shares of &ldquo;blank check&rdquo; preferred stock, the rights,
preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion
from time to time and without stockholder approval;</TD></TR>                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limiting the removal of directors by the stockholders;</TD></TR>                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">allowing for the creation of a staggered board of directors;</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD></TR>                                                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">establishing advance notice requirements for nominations for election to the board of directors
or for proposing matters that can be acted upon at stockholder meetings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace
members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject
to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of
a broad range of business combinations with an interested stockholder for a period of three years following the date on which the
stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This provision could
have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired
by or beneficial to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any provision of our Certificate of Incorporation
or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit
the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially
beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The elimination of personal liability
against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers
and employees may result in substantial expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and our
Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary
duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation and our Bylaws
provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the Delaware law
and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit or proceeding
prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost
of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and
resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or
officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay cash dividends
on our capital stock in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any dividends
on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends
in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate
laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors.
Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is a limited trading market
for our common stock, which could make it difficult to liquidate an investment in our common stock, in a timely manner.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is currently traded on
the NASDAQ Capital Market. Because there is a limited public market for our common stock, investors may not be able to liquidate
their investment whenever desired. We cannot assure that there will be an active trading market for our common stock and the lack
of an active public trading market could mean that investors may be exposed to increased risk. In addition, if we failed to meet
the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities
to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from
recommending or selling our common stock, which may further affect its liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of the Series C Preferred
Stock and the warrants could impede our ability to enter into certain transactions or obtain additional financing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series C Preferred Stock
and the warrants require us, upon the consummation of any &ldquo;fundamental transaction&rdquo; (as defined in the securities),
to, among other obligations, cause any successor entity resulting from the fundamental transaction to assume all of our obligations
under the Series C Preferred Stock and the warrants and the associated transaction documents. In addition, holders of Series C
Preferred Stock and warrants are entitled to participate in any fundamental transaction on an as-converted or as-exercised basis,
which could result in the holders of our common stock receiving a lesser portion of the consideration from a fundamental transaction.
The terms of the Series C Preferred Stock and the warrants could also impede our ability to enter into certain transactions or
obtain additional financing in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution as a result of this offering and may experience additional dilution in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> You will incur immediate and substantial
dilution as a result of this offering. After giving effect to the sale by us of shares offered in this offering at an assumed
public offering price of $2.62 per share, and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us, investors in this offering can expect an immediate dilution of approximately $0.63 per share. See &ldquo;Dilution&rdquo;
below for a more detailed discussion of the dilution you will incur if you purchase our common stock in the offering. In addition,
the conversion of shares of Series C Preferred Stock and exercise of the warrants will result in the issuance of additional shares
of common stock that will result in significant dilution to holders of our common stock. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Management will have broad discretion
as to the use of the proceeds from this offering and may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
in the application of the net proceeds from this offering and could spend the proceeds in ways that may not improve our results
of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse
effect on our business and cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Series C Preferred Stock and
warrants will not be listed on any securities exchange and as such there will not be a public market for such securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for the Series C Preferred Stock or warrants, and we do not expect a market to develop. In addition, we do not intend to
apply for listing of the Series C Preferred Stock or warrants on any securities exchange or trading system. Without an active market,
the liquidity of the Series C Preferred Stock and warrants will be limited, and investors may be unable to liquidate their investments
in the Series C Preferred Stock and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The offering price will be set by
our Board of Directors and does not necessarily indicate the actual or market value of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors will approve the
offering price and other terms of this offering after considering, among other things: the number of shares authorized in our certificate
of incorporation; the current market price of our common stock; trading prices of our common stock over time; the volatility of
our common stock; our current financial condition and the prospects for our future cash flows; the availability of and likely cost
of capital of other potential sources of capital; and market and economic conditions at the time of the offering. The offering
price is not intended to bear any relationship to the book value of our assets or our past operations, cash flows, losses, financial
condition, net worth or any other established criteria used to value securities. The offering price may not be indicative of the
fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants may not have any value.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants will be exercisable for five
years from the closing date at an initial exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
In the event that the price of a share of our common stock does not exceed the exercise price of the warrants during the period
when the warrants are exercisable, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants are subject to an issuer
call. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, after the closing date, (i)&nbsp;the
volume weighted average price for each of 30 consecutive trading days (the &ldquo;Measurement Period&rdquo;), which Measurement
Period commences on the closing date, exceeds 250% of the exercise price (subject to adjustment for forward and reverse stock splits,
recapitalizations, stock dividends and the like after the initial exercise date), (ii) the average daily volume for such Measurement
Period exceeds $600,000 per trading day and, (iii)&nbsp;the warrant holder is not in possession of any material non-public information
which was provided by the Company, then the Company may, within one trading day of the end of such Measurement Period, call for
cancellation of all or any portion of the warrants for which an exercise notice has not yet been delivered for consideration equal
to $0.001 per warrant share. The Company&rsquo;s right to call the warrants shall be exercised ratably among the holders based
on the then outstanding warrants. You may be unable to reinvest your proceeds from the call in an investment with a return that
is as high as the return on the warrants would have been if they had not been called.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A warrant does not entitle the holder
to any rights as common stockholders until the holder exercises the warrant for shares of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until you acquire shares of our common
stock upon exercise of your warrants, the warrants will not provide you any rights as a common stockholder. Upon exercise of your
warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs
on or after the exercise date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy
and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally
written in the future tense and/or are preceded by words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations
on such terms or comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including without limitation the risks described in &ldquo;Risk Factors&rdquo;
in this prospectus and the documents incorporated by reference herein. These risks are not exhaustive. Moreover, we operate in
a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management
to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You
should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected
in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements, except as may be
required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We estimate that the net proceeds from
the sale of securities in this offering will be approximately $9.9&nbsp;million, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we
estimate that our net proceeds will be approximately $11.4 million, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. We will not receive any additional proceeds from any future conversions of the
Series&nbsp;C Preferred Stock. We will only receive additional proceeds from the exercise of the warrants issuable in connection
with this offering if the warrants are exercised and the holders of such warrants pay the exercise price in cash upon such exercise
and do not utilize the cashless exercise provision of the warrants. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from
this offering for general corporate purposes, including working capital to support ongoing and new commercial activities primarily
related to Natesto and ZolpiMist and to complete clinical studies around our MiOXSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This expected use of the net proceeds from
this offering represents our intentions based upon our current plans and business conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_006"></A>MARKET FOR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has been listed on the
NASDAQ Capital Market under the symbol &ldquo;AYTU&rdquo; since October 20, 2017. Prior to October 20, 2017, our common stock was
quoted on the OTCQX and prior to that, on the OTCQB. The following table sets forth the range of high and low bid prices for our
common stock on the OTCQX or OTCQB, or high and low sales prices on the NASDAQ Capital Market, as applicable, for the periods shown.
The quotations for the OTCQX or OTCQB represent inter-dealer prices without retail markup, markdown or commission, and may not
necessarily represent actual transactions. All share prices give effect to our 1-for-20 reverse stock splits completed in each
of August 2017 and August 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">First Quarter (ended September 30, 2016)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,204.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Second Quarter (ended December 31, 2016)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,556.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">408.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Third Quarter (ended March 31, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">504.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">296.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Fourth Quarter (ended June 30, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">364.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">204.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">First Quarter (ended September 30, 2017)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">240.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">66.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Second Quarter (ended December 31, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">136.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Third Quarter (ended March 31, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">85.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Fourth Quarter (ended June 30, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Fiscal Year ended June 30, 2019 </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> High </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Low </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"> First Quarter (through September 24, 2018) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 7.80 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 2.49 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of August 31, 2018, there were 496 holders of record of our
common stock. <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not paid any cash dividends on
our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our
operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined by the
Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements and other
factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the dividend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we would not be able to pay our debts as they become due in the usual course of business; or</TD></TR>                                                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our total assets would be less than the sum of our total liabilities plus the amount that would
be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth above, there are no
restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely to limit materially
the future payment of dividends on common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors has the right to
authorize the issuance of preferred stock, without further stockholder approval, the holders of which may have preferences over
the holders of our common stock as to payment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_008"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> If you purchase shares in this offering,
your interest will be diluted to the extent of the difference between the public offering price per share of common stock and
warrant and the net tangible book value per share of our common stock after this offering. Our net tangible book value as of June
30, 2018 was $2.1 million, or $1.15 per share of common stock (based upon 1,794,762 outstanding shares of common stock). &ldquo;Net
tangible book value&rdquo; is total assets minus the sum of liabilities and intangible assets. &ldquo;Net tangible book value
per share&rdquo; is net tangible book value divided by the total number of shares of common stock outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> After giving effect to the sale by
us in this offering of the securities in this offering at an assumed public offering price of $2.62&nbsp;per share of common stock
and warrant (the closing price of our common stock as quoted on the NASDAQ Capital Market on September 24, 2018), and assuming
all shares of Series C Preferred Stock were converted to common stock, and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses that we will pay, our net tangible book value as of June 30, 2018 would have been
approximately $11.9 million, or $1.99 per share of common stock. This amount represents an immediate increase in net tangible
book value of $0.84 per share to existing stockholders and an immediate dilution of $0.63 per share to purchasers in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following
table illustrates the dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left"> Assumed public offering price per share
    of common stock and warrant </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 2.62 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Net tangible book value per share as of June 30, 2018 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.15 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Increase in net tangible book value per share attributable
    to this offering </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 0.84 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Pro forma net tangible book value per share after
    this offering </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.99 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Dilution per share to new investors </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 0.63 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering
price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
above table is based on 1,794,762 shares of common stock outstanding as of June 30, 2018, and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of options to purchase an aggregate of 1,798 shares of common stock with
                                         a weighted average exercise price of $325.97, issued and outstanding under our 2015 Stock
                                         Plan and outstanding and exercisable on June 30, 2018;</FONT></TD></TR>                                                                                                                <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of warrants to purchase 1,882,661 shares of common stock with a weighted
                                         average exercise price of $25.94 per share outstanding on June 30, 2018; and</FONT></TD></TR>                                                                                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise by the underwriters of their over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> If the underwriters exercise in full
their over-allotment option, our net tangible book value per share after giving effect to this offering would be approximately
$13.5 million, or $2.03 per share, which amount represents an immediate increase in net tangible book value of $0.88 per share
to existing stockholders and a dilution to new investors of $0.59 per share. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we issue any additional shares in connection with outstanding options or warrants, there will be additional dilution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_009"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2018 on:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         actual basis; and</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma basis to give effect to the sale by us in this offering of the securities offered hereby, at the assumed public
    offering price of $2.62 per share of common stock and warrant, which is the last reported sale price of our common stock on
    the Nasdaq Capital Market on September 24, 2018, after deducting underwriting discounts and commissions and estimated offering
    expenses payable by us, and assuming all shares of Series C Preferred Stock were converted to common stock.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
pro forma information set forth in the table below is illustrative only and will be adjusted based on the actual public offering
price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this table in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations,&rdquo; our audited financial statements for the fiscal years ended June 30, 2018 and 2017, and the related notes
thereto, included by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify"> &nbsp; </TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of
    June 30, 2018 </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify"> &nbsp; </TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: justify; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Cash,
    cash equivalents and restricted cash </TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 7,112,527 </TD><TD STYLE="width: 1%; padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 17,003,594 </TD><TD STYLE="width: 1%; padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Long-term
    contingent consideration </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 4,146,829 </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 4,146,829 </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 10pt"> Stockholders&rsquo; equity: </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 20pt"> Preferred Stock, par value $0.0001;
    50,000,000 shares authorized; 0 shares of Series A issued and outstanding; 0 shares of Series B issued and outstanding; 0
    shares of Series C issued and outstanding </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 0 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 0 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 20pt"> Common Stock, par value $0.0001;
    100,000,000 shares authorized; 1,794,762 shares issued and outstanding, actual;&nbsp;4,198,473 shares issued and outstanding
    pro forma </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 179 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 599 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; text-indent: -10pt; padding-left: 10pt"> Additional paid-in capital </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 92,681,918 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 102,572,565 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"> Accumulated
    deficit </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> (79,257,592 </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> ) </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> (79,257,592 </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> Total stockholders&rsquo;
    equity </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 13,424,505 </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> 23,315,572 </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
number of shares to be outstanding immediately after giving effect to this offering as shown above is based on 1,794,762 shares
outstanding as of June 30, 2018 and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of options to purchase an aggregate of 1,798 shares of common stock with
                                         a weighted average exercise price of $325.97, issued under our 2015 Stock Plan and outstanding
                                         on June 30, 2018;</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of warrants to purchase 1,882,661 shares of common stock with a weighted
                                         average exercise price of $25.94 per share outstanding on June 30, 2018; and</FONT></TD></TR>                                                                                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise by the underwriters of their over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_010"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred
stock, $0.0001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, a total of 1,801,411 shares of our common stock were issued and outstanding, no shares of our Series A Preferred
Stock were issued and outstanding, and no shares of our Series B Preferred Stock were issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
holders of common stock are entitled to one vote per share. Our Certificate of Incorporation does not expressly prohibit cumulative
voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board
of Directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are
entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive,
subscription, redemption or conversion rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights
of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Securities to be Issued in this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are offering 839,695 shares of common
stock and warrants to purchase 839,695&nbsp;shares of our common stock at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
together with the shares of common stock underlying such warrants, at an assumed public offering price of $2.62 per share of common
stock and warrant. The shares of common stock and warrants are immediately separable and will be issued separately in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are also offering to those purchasers
whose purchase of common stock in this offering would result in the purchaser, together with its affiliates and certain related
parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following
the consummation of this offering, the opportunity to purchase, in lieu of the number of shares of common stock that would result
in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%), 3,358,778 shares of Series C Preferred Stock, par
value $0.0001 per share, convertible into one share of common stock and warrants to purchase 3,358,778 shares of our common stock
at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
together with the shares of common stock underlying such shares of Series C Preferred Stock and warrants, at an assumed public
offering price of $2.62. The shares of Series C Preferred Stock and the warrants are immediately separable and will be issued
separately in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Series
C Preferred Stock</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General</I>.
In connection with this offering, our board of directors will designate shares of our preferred stock as Series C Preferred Stock.
The preferences and rights of the Series C Preferred Stock will be as set forth in a Certificate of Designation (the &ldquo;<U>Series
C Certificate of Designation</U>&rdquo;) filed as an exhibit to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Conversion</I>.
Each share of Series C Preferred Stock will be initially convertible at any time at the holder&rsquo;s option into one share of
common stock, which conversion ratio will be subject to adjustment for stock splits, stock dividends, distributions, subdivisions
and combinations. Notwithstanding the foregoing, the Series C Certificate of Designation will further provide that we shall not
effect any conversion of the Series C Preferred Stock, with certain exceptions, to the extent that, after giving effect to an
attempted conversion, the holder of Series C Preferred Stock (together with such holder&rsquo;s affiliates, and any persons acting
as a group together with such holder or any of such holder&rsquo;s affiliates) would beneficially own a number of shares of Common
Stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our common
stock then outstanding after giving effect to such exercise (the &ldquo;<U>Series C Preferred Stock Beneficial Ownership Limitation</U>&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <I>Fundamental Transaction</I>. In
the event we consummate a merger or consolidation with or into another person or other reorganization event in which our common
stock is converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or
otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares
of common stock, then following such event, the holders of the Series C Preferred Stock will be entitled to receive upon conversion
of such Series C Preferred Stock the same kind and amount of securities, cash or property which the holders would have received
had they converted their Series C Preferred Stock immediately prior to such fundamental transaction. Any successor to us or surviving
entity shall assume the obligations under the Series C Preferred Stock. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Liquidation
Preference</I>. In the event of a liquidation, the holders of Series C Preferred Stock will be entitled to participate on an as-converted-to-common-stock
basis with holders of the common stock in any distribution of assets of the Company to the holders of the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <I>Voting Rights</I>. With certain
exceptions, as described in the Series C Certificate of Designation, the Series C Preferred Stock will have no voting rights.
However, as long as any shares of Series C Preferred Stock remain outstanding, the Series C Certificate of Designation will provide
that we shall not, without the affirmative vote of holders of a majority of the then-outstanding shares of Series C Preferred
Stock: (a) alter or change adversely the powers, preferences or rights given to the Series C Preferred Stock or alter or amend
the Series C Certificate of Designation, (b) amend the Company&rsquo;s certificate of incorporation or other charter documents
in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized shares of Series C Preferred
Stock or (d) effect a stock split or reverse stock split of the Series C Preferred Stock or any like event. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dividends</I>.
The Series C Certificate of Designation will provide, among other things, that we shall not pay any dividends on shares of common
stock (other than dividends in the form of common stock) unless and until such time as we pay dividends on each share of Series
C Preferred Stock on an as-converted basis. Other than as set forth in the previous sentence, the Series C Certificate of Designation
will provide that no other dividends shall be paid on shares of Series C Preferred Stock and that we shall pay no dividends (other
than dividends in the form of common stock) on shares of common stock unless we simultaneously comply with the previous sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Repurchase
Restrictions</I>. The Series C Certificate of Designation will not provide for any restriction on the repurchase of Series C Preferred
Stock by us while there is any arrearage in the payment of dividends on the Series C Preferred Stock. There will be no sinking
fund provisions applicable to the Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Redemption.
</I>We will not be obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock
will not otherwise be entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exchange Listing.</I> We do not intend
to apply for listing of the Series C Preferred Stock on any securities exchange or other trading system.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General</I>.
The material terms and provisions of the warrants being offered pursuant to this prospectus are summarized below. This summary
of some provisions of the warrants is not complete. For the complete terms of the warrants, you should refer to the form of warrant
filed as an exhibit to the registration statement of which this prospectus is a part. Pursuant to a warrant agency agreement between
us and VStock Transfer, LLC, as warrant agent, the warrants will be issued in book-entry form and shall initially be represented
only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company,
or DTC, and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC, or as otherwise directed by DTC.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <I>Exercise of Warrants</I>. Each warrant
is exercisable for one share of our common stock, with an exercise price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share at any time for up to five (5)&nbsp;years after the date of the closing of this offering. The warrants issued in this
offering will be governed by the terms of a global warrant held in book-entry form. The holder of a warrant will not be deemed
a holder of our underlying common stock until the warrant is exercised. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to certain limitations as described below the warrants are immediately exercisable upon issuance on the closing date and expire
on the five (5)&nbsp;year anniversary of the closing date. Subject to limited exceptions, a holder of warrants will not have the
right to exercise any portion of its warrants if the holder (together with such holder&rsquo;s affiliates, and any persons acting
as a group together with such holder or any of such holder&rsquo;s affiliates) would beneficially own a number of shares of common
stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our common
stock then outstanding after giving effect to such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event
of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events
affecting our common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such
warrant holders are utilizing the cashless exercise provision of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the holder&rsquo;s exercise of a warrant,
we will issue the shares of common stock issuable upon exercise of the warrant within two trading days following our receipt of
a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the extent permitted via the
&ldquo;cashless&rdquo; exercise provision). Prior to the exercise of any warrants to purchase common stock, holders of the warrants
will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as
set forth therein.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
holders may exercise warrants only if the issuance of the shares of common stock upon exercise of the warrants is covered by an
effective registration statement, or an exemption from registration is available under the Securities Act and the securities laws
of the state in which the holder resides. We intend to use commercially reasonable efforts to have the registration statement,
of which this prospectus forms a part, effective when the warrants are exercised. The warrant holders must pay the exercise price
in cash upon exercise of the warrants unless there is not an effective registration statement or, if required, there is not an
effective state law registration or exemption covering the issuance of the shares underlying the warrants (in which case, the
warrants may only be exercised via a &ldquo;cashless&rdquo; exercise provision).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Fundamental
Transaction</I>. In the event we consummate a merger or consolidation with or into another person or other reorganization event
in which our common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign,
transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of
our outstanding shares of common stock, then following such event, the holders of the warrants will be entitled to receive upon
exercise of such warrants the same kind and amount of securities, cash or property which the holders would have received had they
exercised their warrants immediately prior to such fundamental transaction. Any successor to us or surviving entity shall assume
the obligations under the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Notwithstanding the foregoing, in the
event of a fundamental transaction (other than certain fundamental transactions where the Company remains the surviving company)
as described above, the holder may, subject to certain conditions, require the Company or a successor entity to purchase the warrant
from the holder by paying to the holder an amount in cash equal to the Black-Scholes value of the remaining unexercised portion
of the warrant on the effective date of such change of control; provided, however, that, if the change of control is not within
the Company's control, including not approved by the Company's board of directors, the holder will only be entitled to receive
from the Company or any successor entity, as of the date of consummation of such change of control, the same type or form of consideration
(and in the same proportion), at the Black-Scholes value of the unexercised portion of the warrant, that is being offered and
paid to the holders of our common stock in connection with the change of control, whether that consideration is in the form of
cash, stock or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative
forms of consideration in connection with the change of control. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Call Feature</I>. The warrants are callable
by us in certain circumstances. Subject to certain exceptions, in the event that the warrants are outstanding, if, after the closing
date, (i)&nbsp;the volume weighted average price of our common stock for 30 consecutive trading days (the &ldquo;Measurement Period&rdquo;),
which Measurement Period commences on the closing date, exceeds 250% of the exercise price (subject to adjustment for forward and
reverse stock splits, recapitalizations, stock dividends and similar transactions after the initial exercise date), (ii) the average
daily trading volume for such Measurement Period exceeds $600,000 per trading day and (iii)&nbsp;the warrant holder is not in possession
of any information that constitutes or might constitute, material non-public information which was provided by the Company, and
subject to the Beneficial Ownership Limitation, then we may, within one trading day of the end of such Measurement Period, upon
notice (a &ldquo;<U>Call Notice</U>&rdquo;), call for cancellation of all or any portion of the warrants for which a notice of
exercise has not yet been delivered (a &ldquo;<U>Call</U>&rdquo;) for consideration equal to $0.001 per warrant share. Any portion
of a warrant subject to such Call Notice for which a notice of exercise shall not have been received by the Call Date (as hereinafter
defined) will be canceled at 6:30 p.m. (New York City time) on the tenth trading day after the date the Call Notice is sent by
the Company (such date and time, the &ldquo;Call Date&rdquo;). Our right to call the warrants shall be exercised ratably among
the holders based on the then outstanding warrants</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Exchange
Listing</I>. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Representative Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Upon completion of this offering, will
issue Ladenburg Thalmann &amp; Co. Inc. (the &ldquo;Representative&rdquo;) a warrant to purchase a number of shares of common
stock equal to 3% of the number of shares of common stock and preferred stock sold in this offering. The terms of the Representative&rsquo;s
warrant are identical to the terms of the warrants in this offering, except that the exercise price will be 125% of the public
offering price of the common stock and warrants, and the Representative&rsquo;s warrant and any shares issued upon exercise of
the Representative&rsquo;s warrant shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any
hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities
by any person for a period of 180 days immediately following the effectiveness date of this prospectus. </P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Certificate of Incorporation provides our Board of Directors with the authority to divide the preferred stock into series and
to fix and determine the rights and preferences of the shares of any series of preferred stock established to the full extent
permitted by the laws of the State of Delaware and the Certificate of Incorporation. We previously designated 10,000 shares as
Series A Preferred Stock. No shares of Series A Preferred Stock are outstanding as of August 31, 2018. We also previously designated
3,216 shares as Series B Preferred Stock. No shares of Series B Preferred Stock are outstanding as of August 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, we had outstanding warrants to purchase an aggregate of 1,882,661 shares of our common stock, consisting of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 35 shares of our common stock that were issued in February 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $3,120.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 22 shares of our common stock that were issued in February 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $300.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 58 shares of our common stock that were issued in May 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $1,920.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,361 shares of our common stock that were issued in the public offering
                                         of common stock and warrants we completed on May 6, 2016. These warrants are exercisable
                                         for five years from issuance and have an exercise price equal to $2,400.00;</FONT></TD></TR>                                                                                                                                     <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 767 shares of our common stock that were issued upon the closing of our public
                                         offering on May 5, 2016. These warrants are exercisable for five years from issuance
                                         and have an exercise price equal to $2,400.00;</FONT></TD></TR>                                                                                                        <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to 279 shares of common stock issued to the underwriters of our public offering. These
                                         warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise
                                         price equal to $300.00;</FONT></TD></TR>                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         with a release to purchase 221 shares of common stock issued to the Luoxis stockholders.
                                         These warrants expire on July 7, 2021 and have an exercise price equal to $1,600.00;</FONT></TD></TR>                                                                                                                                              <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 10,548 shares of our common stock that were issued upon the closing of our
                                         public offering on November 2, 2016. These warrants are exercisable for five years from
                                         issuance and have an exercise price equal to $744.00;</FONT></TD></TR>                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,009 shares of common stock issued to the underwriters of our November public
                                         offering. These warrants are exercisable beginning October 27, 2016 until October 27,
                                         2021 and have an exercise price equal to $300.00;</FONT></TD></TR>                                                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 221,006 shares of our common stock that were issued in the public offering
                                         of common stock, preferred stock and warrants we completed on August 15, 2017. These
                                         warrants are exercisable for five years from issuance and have an exercise price equal
                                         to $72.00;</FONT></TD></TR>                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 19,749 shares of our common stock that were issued in August 2017 to the
                                         placement agents in our public offering of common stock, preferred stock and warrants
                                         we completed on August 15, 2017. These placement agents&rsquo; warrants have a term of
                                         five years from August 25, 2017, and have an exercise price of $72.00, and provide for
                                         cashless exercise;</FONT></TD></TR>                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,527,606 shares of our common stock that were issued in the public offering
                                         of common stock, preferred stock and warrants we completed on March 6, 2018. These warrants
                                         are exercisable for five years from issuance and have an exercise price equal to $10.80;
                                         and</FONT></TD></TR>                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 100,000 shares of our common stock were issued in on March 23, 2018. These
                                         warrants are exercisable for five years from issuance and have an exercise price equal
                                         to $10.80.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 1, 2015, our stockholders approved the 2015 Stock Option and Incentive Plan, which provides for the award of stock options,
stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common stock.
The shares of common stock underlying any awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without
any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the
shares of common stock available for issuance under the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, we had outstanding options to purchase an aggregate of 1,798 shares of our common stock at a weighted average
exercise price of $325.97 per share. Of these, an aggregate of 1,527 are exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
271 options that are unvested, will vest per the following schedule: 100 options on November 11, 2018, 18 options on November
11, 2019, an aggregate of three options on August 7, 2019, 150 options on July 7, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2015 Plan is administered by our Board or a committee designated by the Board (as applicable, the Administrator). The Administrator
has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make
any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions
of the 2015 Plan. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options and other
awards to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange Act and not subject
to Section 162(m) of the Code, subject to certain limitations and guidelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Persons
eligible to participate in the 2015 Plan are full or part-time officers, employees, non-employee directors, directors and other
key persons (including consultants and prospective officers) of our company and its subsidiaries as selected from time to time
by the Administrator in its discretion. Approximately 35 individuals are currently eligible to participate in the 2015 Plan, which
includes officers, employees who are not officers, non-employee director, former employees and other individuals who are primarily
consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2015 Plan provides that upon the effectiveness of a &ldquo;sale event&rdquo; as defined in the 2015 Plan, except as otherwise
provided by the Administrator in the award agreement, all stock options, stock appreciation rights and other awards will be assumed
or continued by the successor entity and adjusted accordingly to take into account the impact of the transaction. To the extent,
however, that the parties to such sale event do not agree that all stock options, stock appreciation rights or any other awards
shall be assumed or continued, then such stock options and stock appreciation rights shall become fully exercisable and the restrictions
and conditions on all such other awards with time-based conditions will automatically be deemed waived. Awards with conditions
and restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with a sale
event in the Administrator&rsquo;s discretion. In addition, in the case of a sale event in which our stockholders will receive
cash consideration, we may make or provide for a cash payment to participants holding options and stock appreciation rights equal
to the difference between the per share cash consideration and the exercise price of the options or stock appreciation rights
in exchange for the cancellation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quotation
on the NASDAQ Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is quoted on the NASDAQ Capital Market under the symbol &ldquo;AYTU&rdquo;. We have two series of warrants quoted
on the OTCQB under the symbols &ldquo;AYTUW&rdquo; and &ldquo;AYTUZ&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent of our common stock is VStock Transfer, LLC. Their address is 18 Lafayette Place, Woodmere, NY 11598.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Delaware
Anti-Takeover Law and Provisions of Our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Delaware
Anti-Takeover Law.</I> We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits
a public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">prior
                                         to the date of the transaction, the board of directors of the corporation approved either
                                         the business combination or the transaction which resulted in the stockholder becoming
                                         an interested stockholder;</FONT></TD></TR>                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">upon
                                         consummation of the transaction that resulted in the stockholder becoming an interested
                                         stockholder, the interested stockholder owned at least 85% of the voting stock of the
                                         corporation outstanding at the time the transaction commenced, excluding specified shares;
                                         or</FONT></TD></TR>                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">at
                                         or subsequent to the date of the transaction, the business combination is approved by
                                         the board of directors and authorized at an annual or special meeting of stockholders,
                                         and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
                                         voting stock which is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
203 defines a &ldquo;business combination&rdquo; to include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>                                                                                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more
                                         of the assets of the corporation to or with the interested stockholder;</FONT></TD></TR>                                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
                                         to exceptions, any transaction that results in the issuance or transfer by the corporation
                                         of any stock of the corporation to the interested stockholder;</FONT></TD></TR>                                                                                                                        <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
                                         to exceptions, any transaction involving the corporation that has the effect of increasing
                                         the proportionate share of the stock of any class or series of the corporation beneficially
                                         owned by the interested stockholder; or</FONT></TD></TR>                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                         pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general,
Section 203 defines an &ldquo;interested stockholder&rdquo; as any person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         owner of 15% or more of the outstanding voting stock of the corporation;</FONT></TD></TR>                                                                                                                                  <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         affiliate or associate of the corporation who was the owner of 15% or more of the outstanding
                                         voting stock of the corporation at any time within three years immediately prior to the
                                         relevant date; or</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         affiliates and associates of the above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
specific circumstances, Section 203 makes it more difficult for an &ldquo;interested stockholder&rdquo; to effect various business
combinations with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation&rsquo;s
certificate of incorporation or bylaws, elect not to be governed by this section, effective 12 months after adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation and bylaws do not exclude us from the restrictions of Section 203. We anticipate that the provisions
of Section 203 might encourage companies interested in acquiring us to negotiate in advance with our board of directors since
the stockholder approval requirement would be avoided if a majority of the directors then in office approve either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Certificate
of Incorporation and Bylaw. </I>Provisions of our certificate of incorporation and bylaws may delay or discourage transactions
involving an actual or potential change of control or change in our management, including transactions in which stockholders might
otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests.
Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         authorization of 50,000,000 shares of &ldquo;blank check&rdquo; preferred stock, the
                                         rights, preferences and privileges of which may be established and shares of which may
                                         be issued by our Board of Directors at its discretion from time to time and without stockholder
                                         approval;</FONT></TD></TR>                                                                   <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">limiting
                                         the removal of directors by the stockholders;</FONT></TD></TR>                                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">allowing
                                         for the creation of a staggered board of directors;</FONT></TD></TR>                                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">eliminating
                                         the ability of stockholders to call a special meeting of stockholders; and</FONT></TD></TR>                                                                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing
                                         advance notice requirements for nominations for election to the board of directors or
                                         for proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_011"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into an underwriting agreement dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 with Ladenburg Thalmann&nbsp;&amp; Co. Inc., as the representative of
the underwriters (the &ldquo;representative&rdquo;) named below and the sole book-running manager of this offering. Subject to
the terms and conditions of the underwriting agreement, the underwriters have agreed to purchase the number of our securities
set forth opposite its name below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> Underwriters </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Shares
    of Common Stock </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Shares
    of Series C Preferred Stock </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Warrants </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"> Ladenburg Thalmann&nbsp;&amp; Co. Inc. </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Northland Securities, Inc. </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Total </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
copy of the underwriting agreement will be filed as an exhibit to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have been advised by the underwriters
that they propose to offer the securities directly to the public at the public offering price set forth on the cover page of this
prospectus. The underwriters may sell shares of common stock Series C Preferred Stock or warrants separately to purchasers or
may sell a combination of such securities to purchasers in any proportion. Any securities sold by the underwriters to securities
dealers will be sold at the public offering price less a selling concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The underwriting agreement provides
that subject to the satisfaction or waiver by the representative of the conditions contained in the underwriting agreement, the
underwriters are obligated to purchase and pay for all of the securities offered by this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> No action has been taken by us or the
underwriters that would permit a public offering of the shares of common stock, shares of Series C Preferred Stock, shares of
common stock underlying the Series C Preferred Stock and warrants to purchase common stock, in any jurisdiction outside the United
States where action for that purpose is required. None of our securities included in this offering may be offered or sold, directly
or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sales
of any of the securities offered hereby be distributed or published in any jurisdiction except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons who receive this prospectus are advised
to inform themselves about and to observe any restrictions relating to this offering of securities and the distribution of this
prospectus. This prospectus is neither an offer to sell nor a solicitation of any offer to buy the securities in any jurisdiction
where that would not be permitted or legal. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Underwriting
Discount and Expenses </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes the underwriting discount and commission to be paid to the underwriter assuming the no exercise of
the over-allotment option and the full exercise of the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 10pt; text-indent: -10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Per&nbsp;Share
    of Common Stock(1) </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"> Per
    Share of Series C Preferred Stock (1) </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Per
    Warrant(1) </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Total
    With No Exercise of the Over-Allotment Option </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Total
    With Full Exercise of the Over-Allotment Option </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"> Public offering
    price </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"> Underwriting
    discount to be paid to the underwriters by us(2) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; text-indent: -10pt"> Proceeds
    to us (before expenses) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="width: 96%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    public offering price and underwriting discount corresponds to &nbsp;(i)&nbsp;a public offering price per share of common
    stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, (ii)&nbsp;a public offering price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    and (iii)&nbsp;a public offering price per share of Series C Preferred Stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
    </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have granted
    a 45-day option to the underwriter to purchase additional shares of common stock and/or warrants to purchase shares of common
    stock (up to 15% of the number of shares of common stock (including the number of shares of common stock issuable upon conversion
    of shares of Series C Preferred Stock) and the number of shares of common stock underlying the warrants sold in the primary
    offering) at the public offering price per share of common stock and the public offering price per warrant set forth above
    less the underwriting discounts and commissions, solely to cover over-allotments, if any. </FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">We
estimate the total expenses payable by us for this offering to be approximately $1.1 million, which amount includes (i)&nbsp;the
underwriting discount of $0.9 million ($1.0 million if the underwriters&rsquo; over-allotment option is exercised in full) and
(ii)&nbsp;reimbursement of the accountable expenses of the representative equal to $85,000 including the legal fees of the representative
being paid by us and (iii)&nbsp;other estimated company expenses of approximately $0.1 million, which includes legal, accounting,
printing costs and various fees associated with the registration and listing of our shares.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities we are offering are being offered by the underwriters subject to certain conditions specified in the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Representative
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have agreed to issue to the representative
warrants to purchase 3% of the aggregate number of shares of common stock sold in this offering (including the shares of common
stock issuable upon conversion of the Series C Preferred Stock). The representative warrants will have a term of five years from
the effective date of this prospectus and an exercise price per share equal to 125% of the public offering price for the shares
of common stock and warrants sold in this offering. Pursuant to FINRA Rule&nbsp;5110(g), the representative warrants and any shares
issued upon exercise of the representative warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be
the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of the securities by any person for a period of 180&nbsp;days immediately following the date of effectiveness or commencement
of sales of this offering, except the transfer of any security: (i)&nbsp;by operation of law or by reason of our reorganization;
(ii)&nbsp;to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii)&nbsp;if the aggregate amount
of our securities held by the underwriter or related persons do not exceed 1% of the securities being offered; (iv)&nbsp;that
is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages
or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity
in the fund; or (v)&nbsp;the exercise or conversion of any security, if all securities remain subject to the lock-up restriction
set forth above for the remainder of the time period. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Over-allotment
Option </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have granted to the underwriters an option exercisable not later than 45 days after the date of this prospectus to purchase up
to a number of additional shares of common stock and/or warrants to purchase shares of common stock not to exceed 15% of the number
of shares of common stock sold in the primary offering (including the number of shares of common stock issuable upon conversion
of shares of Series C Preferred Stock, but excluding shares of common stock underlying the warrants issued in this offering and
any shares of common stock issued upon any exercise of the underwriter&rsquo;s over-allotment option) and/or 15% of the warrants
sold in the primary offering at the public offering price per share of common stock and the public offering price per warrant
set forth on the cover page hereto less the underwriting discounts and commissions. The underwriters may exercise the option solely
to cover overallotments, if any, made in connection with this offering. If any additional shares of common stock and/or warrants
are purchased pursuant to the over-allotment option, the underwriters will offer these shares of common stock and/or warrants
on the same terms as those on which the other securities are being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Determination
of Offering Price </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is currently traded on The NASDAQ Capital Market under the symbol &ldquo;AYTU.&rdquo; On September 24, 2018 the closing
price of our common stock was $2.62 per share. We do not intend to apply for listing of the Series&nbsp;C Preferred Stock or the
warrants on any securities exchange or other trading system.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
public offering price of the securities offered by this prospectus will be determined by negotiation between us and the underwriters.
Among the factors that will be considered in determining the public offering price of the shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         history and our prospects;</FONT></TD></TR>                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         industry in which we operate;</FONT></TD></TR>                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         past and present operating results;</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         previous experience of our executive officers; and</FONT></TD></TR>                                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         general condition of the securities markets at the time of this offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offering price stated on the cover page of this prospectus should not be considered an indication of the actual value of the shares
of common stock or shares of preferred stock sold in this offering. That price is subject to change as a result of market conditions
and other factors and we cannot assure you that the shares of common stock sold in this offering can be resold at or above the
public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
officers and directors have agreed with the representative to be subject to a lock-up period of 90 days following the date of
this prospectus. This means that, during the applicable lock-up period, such persons may not offer for sale, contract to sell,
sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly,
any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock.
Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions. We have
also agreed, in the underwriting agreement, to similar lock-up restrictions on the issuance and sale of our securities for 90
days following the effectiveness of the underwriting agreement, although we will be permitted to issue stock options or stock
awards to directors, officers and employees under our existing plans. The lock-up period is subject to an additional extension
to accommodate for our reports of financial results or material news releases. The representative may, in its sole discretion
and without notice, waive the terms of any of these lock-up agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Relationships </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the satisfaction of certain
conditions, we have granted the representative a right of first refusal to act as lead or sole bookrunner or exclusive placement
agent in connection with any subsequent public or private offering of equity securities or other capital markets financing by us.
This right of first refusal extends for 12 months from the closing date of this offering. The terms of any such engagement of the
representative will be determined by separate agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent and Registrar </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent of our common stock is VStock Transfer, LLC. Its address is 18 Lafayette Place, Woodmere, New York 11598.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stabilization,
Short Positions and Penalty Bids </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters may engage in syndicate covering transactions stabilizing transactions and penalty bids or purchases for the purpose
of pegging, fixing or maintaining the price of our common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Syndicate
                                         covering transactions involve purchases of securities in the open market after the distribution
                                         has been completed in order to cover syndicate short positions. Such a naked short position
                                         would be closed out by buying securities in the open market. A naked short position is
                                         more likely to be created if the underwriters are concerned that there could be downward
                                         pressure on the price of the securities in the open market after pricing that could adversely
                                         affect investors who purchase in the offering.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stabilizing
                                         transactions permit bids to purchase the underlying security so long as the stabilizing
                                         bids do not exceed a specific maximum and are engaged in for the purpose of preventing
                                         or retarding a decline in the market price of the shares of common stock while this offering
                                         is in progress.</FONT></TD></TR>                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Penalty
                                         bids permit the underwriters to reclaim a selling concession from a syndicate member
                                         when the securities originally sold by the syndicate member are purchased in a stabilizing
                                         or syndicate covering transaction to cover syndicate short positions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
syndicate covering transactions, stabilizing transactions, and penalty bids may have the effect of raising or maintaining the
market prices of our securities or preventing or retarding a decline in the market prices of our securities. As a result the price
of our common stock may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters
make any representation or prediction as to the effect that the transactions described above may have on the price of our common
stock. These transactions may be effected on The NASDAQ Capital Market, in the over-the-counter market or on any other trading
market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with this offering, the underwriters also may engage in passive market making transactions in our common stock in accordance
with Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and
extending through the completion of the distribution. In general, a passive market maker must display its bid at a price not in
excess of the highest independent bid for that security. However, if all independent bids are lowered below the passive market
maker&rsquo;s bid that bid must then be lowered when specific purchase limits are exceeded. Passive market making may stabilize
the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may
be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
we, nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the prices of our securities. In addition, neither we nor the underwriters make any representation
that the underwriters will engage in these transactions or that any transactions, once commenced will not be discontinued without
notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Indemnification
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have
agreed to indemnify the underwriters against certain liabilities, including certain liabilities arising under the Securities Act
or to contribute to payments that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_012"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have elected to incorporate the following documents into this prospectus, together with all exhibits filed therewith or incorporated
therein by reference, to the extent not otherwise amended or superseded by the contents of this prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         Annual Report on Form 10-K for the year ended June 30, 2018, as filed with the SEC on
                                         September 6, 2018; and</FONT></TD></TR>                                                                                <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         Current Reports on Form 8-K filed with the SEC on July 2, 2018 and August 10, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we incorporate by reference in this prospectus any future filings we make with the SEC under Sections 13(a), 13(c),
14, or 15(d) of the Exchange Act (excluding any information furnished and not filed with the SEC) after the date on which the
registration statement that includes this prospectus was initially filed with the SEC (including all such documents we may file
with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement)
and until all offerings under this prospectus are terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for all purposes
to the extent that a statement contained in this prospectus or in any other subsequently filed document which is also incorporated
or deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You may request a copy of these filings
(other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost
by writing, telephoning or e-mailing us at the following address or telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aytu BioScience,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">373 Inverness
Parkway, Suite 206</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Englewood,
CO 80112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel: (720)
437-6580</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attn:
Elizabeth Creason</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">ecreason@aytubio.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Copies
of these filings are also available through the &ldquo;Investors&rdquo; section of our website at www.aytubio.com. For other ways
to obtain a copy of these filings, please refer to &ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_013"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus, which constitutes a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities
Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect
to us and the common stock offered by this prospectus, you should refer to the registration statement and the exhibits filed as
part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred
to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an
exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current
reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement,
over the Internet at the SEC&rsquo;s website at <I>http://www.sec.gov</I>. We also maintain a website at <I>http://www.aytubio.com</I>,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with,
or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580,
Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section
of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the
operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning
us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, (720) 437-6580.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_014"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
validity of the securities being offered by this prospectus will be passed upon for us by Dorsey &amp; Whitney LLP, Salt Lake
City, Utah. Certain legal matters in connection with this offering have been passed upon for the underwriters by Ellenoff Grossman
&amp; Schole LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_015"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of Aytu BioScience, Inc. at June 30, 2018 and 2017, and for each of the two years in the period
ended June 30, 2018 have been audited by EKS&amp;H LLLP, independent registered public accounting firm. Such financial statements
have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <B>839,695 Shares
of Common Stock, </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <B>4,198,473 Warrants
to Purchase Shares of Common Stock and </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <B>3,358,778 shares
of Series C Convertible Preferred Stock</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>(and Shares of Common Stock Underlying
Shares of Series C Convertible Preferred Stock and Warrants)</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Sole Book-Running Manager</I> </P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Ladenburg Thalmann</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Co-Manager</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Northland Capital Markets</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>,
2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth all costs and expenses paid or payable by us in connection with the sale of the securities being registered,
other than underwriting discounts and commissions. All amounts shown are estimates except for the Securities Exchange Commission,
or SEC, registration fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> Expense </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Amount
    Paid or<BR> to be Paid </TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left"> SEC registration fee </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 3,197.10 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> FINRA filing fee </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4,351.93 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Printing expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10,000.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Legal fees and expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 100,000.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Accounting fees and expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 20,000.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Miscellaneous expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 7,304.00 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Expense reimbursement to
    underwriters </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 85,000.00 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"> Total </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> 229,853.03 </P>


</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;14.
Indemnification of Directors and Officers. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a
Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right
of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation,
or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise.
The indemnity may include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in
good faith and in a manner he reasonably believed to be in or not opposed to the corporation&rsquo;s best interests and, with
respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation
may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit
by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such
corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation
or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees) actually and reasonably incurred by such person
in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests except that no indemnification is
permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or
director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify
him against the expenses which such officer or director has actually and reasonably incurred. Our certificate of incorporation
and bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General
Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach
of fiduciary duties as a director, except for liability for any:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">transaction
                                         from which the director derives an improper personal benefit;</FONT></TD></TR>                                                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">act
                                         or omission not in good faith or that involves intentional misconduct or a knowing violation
                                         of law;</FONT></TD></TR>                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">unlawful
                                         payment of dividends or redemption of shares; or</FONT></TD></TR>                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">breach
                                         of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action,
suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf
of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer
is not entitled to be indemnified by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
permitted by the Delaware General Corporation Law, we have entered into indemnity agreements with each of our directors and executive
officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted
by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising
under the Securities Act of 1933, as amended, or the Securities Act, or otherwise.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;15.
Recent Sales of Unregistered Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following transactions give effect to the 1-for-12.174 reverse stock split effected on June 8, 2015, the 1-for-12 reverse stock
split effected on June 30, 2016, the 1-for-20 reverse stock split effected on August 25, 2017, and the 1-for-20 reverse stock
split effected on August 10, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Aytu
BioScience, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         February 10, 2016, we completed the conversion of $4,125,000 in convertible notes and
                                         $143,000 of accrued interest. The notes were issued in financings that closed in July
                                         and August 2015. Upon the conversion, we issued an aggregate of 1,642 shares common stock.
                                         After this conversion, an aggregate of $1,050,000 of principal of convertible notes remained
                                         outstanding.</FONT></TD></TR>                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         May 5, 2016, as an inducement to enter into lock up agreements with the underwriters
                                         of our public offering, we issued 767 shares of common stock and warrants to purchase
                                         767 shares of common stock to holders of convertible notes that automatically converted
                                         into shares of common stock and warrants to purchase common stock, which conversion was
                                         triggered by the closing of our public offering of common stock and warrants on May 6,
                                         2016.</FONT></TD></TR>                                                               <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         July 27, 2016, we issued 131 shares of common stock to Lincoln Park Capital Fund, LLC
                                         as a commitment fee and sold 335 shares of common stock to Lincoln Park Capital Fund,
                                         LLC, both pursuant to the Purchase Agreement dated July 27, 2016 between us and Lincoln
                                         Park Capital Fund, LLC.&nbsp;&nbsp;Between September 2016 and June 2017, Lincoln Park
                                         purchased an additional 500 shares.</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         May 3, 2017, we issued 6,250 shares of common stock to the preferred stockholders of
                                         Nuelle, Inc. pursuant to the Merger Agreement dated May 3, 2017 between us and Nuelle,
                                         Inc.</FONT></TD></TR>                                                              <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         August 11, 2017, we issued an aggregate of 159,834 shares of common stock, 113 shares
                                         of Series A Preferred Stock and warrants to purchase up to an aggregate of 315,755 shares
                                         of common stock to investors pursuant to the Securities Purchase Agreement dated August
                                         11, 2017 between us and various investors.</FONT></TD></TR>                                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         March 23, 2018, the Company entered into a Warrant Exercise Agreement with a holder (&ldquo;Holder&rdquo;)
                                         of the Company&rsquo;s outstanding warrants (the &ldquo;Warrant&rdquo;). Pursuant to
                                         the Exercise Agreement, the Company agreed to reduce the exercise price of the Holder&rsquo;s
                                         Warrant from $72.00 to one cent less than the closing price on the last trading day prior
                                         to the exercise date ($8.20 per share) provided that the Holder exercised the Warrant
                                         for cash by March 23, 2018 and the Company also agreed to issue the Holder a new Warrant
                                         to purchase 100,000 shares of the Company&rsquo;s common stock at an exercise price of
                                         $10.80 per share. In accordance with the Exercise Agreement, the Holder exercised the
                                         Warrant and the Company received net proceeds of $615,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offers, sales and issuances of the securities described in this section were exempt from registration under Section 4(a)(2) of
the Securities Act, and where noted above, pursuant to Rule 506 of Regulation D, in that the transactions were between an issuer
and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2). The sales of these
securities were made without any general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;16.
Exhibits and Financial Statement Schedules. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)</B></FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibits.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 9%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; vertical-align: bottom; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 51%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registrant&rsquo;s
                                         Form</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Date
                                         Filed</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         Number</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Filed
                                         Herewith</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="fs12018a1ex1-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Form
    of Underwriting Agreement</FONT></A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Incorporation</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/09/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation effective June 1, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/02/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective June 30, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/01/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed on August 11, 2017.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective August 25, 2017</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/29/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018002319/fs12018a3ex3-6_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock filed on March 2, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/27/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective August 10, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/10/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex32.htm"><FONT STYLE="font-size: 10pt">Bylaws</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/09/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="fs12018a1ex3-9_aytubio.htm"><FONT STYLE="font-size: 10pt">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock</FONT></A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515262003/d50939dex42.htm"><FONT STYLE="font-size: 10pt">Form
    of Placement Agent Warrant issued in 2015 Convertible Note Financing</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/24/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416099585/v439153_ex4-1.htm"><FONT STYLE="font-size: 10pt">Warrant
    Agent Agreement, dated May 6, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/06/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416124782/v449009_ex4-5.htm"><FONT STYLE="font-size: 10pt">First
    Amendment to May 6, 2016 Warrant Agent Agreement between Aytu BioScience, Inc. and VStock Transfer LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/21/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416131142/v450891_ex4-1.htm"><FONT STYLE="font-size: 10pt">Warrant
    Agent Agreement, dated November 2, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/02/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-1.htm"><FONT STYLE="font-size: 10pt">Form
    of Amended and Restated Underwriters&rsquo; Warrant (May 2016 Financing)</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/01/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-2.htm"><FONT STYLE="font-size: 10pt">Form
    of Amended and Restated Underwriters&rsquo; Warrant (October 2016 Financing)</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/01/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex4-1.htm"><FONT STYLE="font-size: 10pt">Common
    Stock Purchase Warrant</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018002319/fs12018a3ex4-8_aytubio.htm"><FONT STYLE="font-size: 10pt">Form
    of Warrant for March 2018 Offering </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/27/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <A HREF="fs12018a1ex4-9_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant for Offering</FONT></A> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"> 4.10 </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <A HREF="fs12018a1ex4-10_aytubio.htm">Form of Representative&rsquo;s Warrant</A> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> X </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="fs12018a1ex5-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Opinion
    of Dorsey &amp; Whitney LLP</FONT></A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex105.htm"><FONT STYLE="font-size: 10pt">Manufacturing
    and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September 10, 2012</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-4_aytubio.htm">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex107.htm"><FONT STYLE="font-size: 10pt">Distribution
    Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March&nbsp;1,
    2012</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex108.htm" ><FONT STYLE="font-size: 10pt">Distribution
    and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9,
    2014</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex109.htm"><FONT STYLE="font-size: 10pt">Sponsored
    Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September 1,
    2009</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex1010.htm" ><FONT STYLE="font-size: 10pt">Addendum
    No. 4 to Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC,
    dated March 17, 2014</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-11_aytubio.htm">Voting Agreement between the Registrant and Ampio, dated April 21, 2015</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515342680/d58016dex1019.htm" ><FONT STYLE="font-size: 10pt">Master
    Services Agreement between Biovest International, Inc. and Aytu BioScience, Inc., entered into on October 8, 2015, and effective
    October 5, 2015</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/13/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416076273/v429234_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Form
    of Subscription Agreement for January 2016 common stock purchases</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/20/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-1.htm" ><FONT STYLE="font-size: 10pt">License
    and Supply Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/25/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Subscription
    Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/25/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416102582/v440068_ex10-1.htm" ><FONT STYLE="font-size: 10pt">First
    Amendment, dated May 15, 2016, to Employment Agreement dated September 16, 2015 between Aytu BioScience, Inc. and Jonathan
    McGrael</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/16/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Purchase
    Agreement, dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Joshua R. Disbrow.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/18/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Jarrett T. Disbrow.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/18/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417026452/v465720_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Asset
    Purchase Agreement, dated March 31, 2017, between Allegis Holdings, LLC&nbsp;and Aytu BioScience, Inc.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/11/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417053230/tv477229_ex10-25.htm" ><FONT STYLE="font-size: 10pt">Merger
    Agreement, dated May 3, 2017, between Nuelle, Inc. and Aytu BioScience, Inc.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417032942/v469126_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of June, 2017, between Aytu BioScience, Inc. and Gregory A. Gould.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417038709/v471569_ex10-1.htm" ><FONT STYLE="font-size: 10pt">2015
    Stock Option and Incentive Plan, as amended on July 26, 2017.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/27/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Securities
    Purchase Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390017013436/f8k121717ex10-1_aytubio.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated December 18, 2017 between Aytu BioScience, Inc. and David A. Green</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018003557/f8k032318ex10-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Warrant
    Exercise Agreement dated March 23, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/28/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-31_aytubio.htm">Amended and Restated Exclusive License Agreement between Aytu BioScience, Inc. and Magna Pharmaceuticals, Inc.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"> 10.26* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Warrant Agency Agreement between Aytu BioScience, Inc. and VStock Transfer, LLC </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"> 10.27* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Preferred Stock Agency Agreement between Aytu BioScience, Inc. and VStock Transfer,
    LLC </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/fs12018ex21-1_aytubioscience.htm" ><FONT STYLE="font-size: 10pt">Subsidiaries</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/12/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="fs12018a1ex23-1_aytubio.htm">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="fs12018a1ex5-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Consent
    of Dorsey &amp; Whitney LLP (included in Exhibit 5.1)</FONT></A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">X</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012289/fs12018_aytubioscience.htm#sign"><FONT STYLE="font-size: 10pt">Power
    of Attorney (included on signature page)</FONT></A></FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;09/07/2018</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates is a management contract or compensatory plan
or arrangement.</FONT></TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">he
company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a confidential treatment request.</FONT></TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)
Financial statement schedule. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;17.
Undertakings. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The undersigned registrant hereby
    undertakes:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         file, during any period in which offers or sales are being made, a post-effective amendment
                                         to this registration statement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         reflect in the prospectus any facts or events arising after the effective date of the
                                         registration statement (or the most recent post-effective amendment thereof) which, individually
                                         or in the aggregate, represent a fundamental change in the information set forth in the
                                         registration statement. Notwithstanding the foregoing, any increase or decrease in volume
                                         of securities offered (if the total dollar value of securities offered would not exceed
                                         that which was registered) and any deviation from the low or high end of the estimated
                                         maximum offering range may be reflected in the form of prospectus filed with the Commission
                                         pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
                                         no more than 20 percent change in the maximum aggregate offering price set forth in the
                                         &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         include any material information with respect to the plan of distribution not previously
                                         disclosed in the registration statement or any material change to such information in
                                         the registration statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">That,
                                         for the purpose of determining any liability under the Securities Act of 1933, each such
                                         post-effective amendment shall be deemed to be a new registration statement relating
                                         to the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         remove from registration by means of a post-effective amendment any of the securities
                                         being registered which remain unsold at the termination of the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">That,
                                         for the purpose of determining liability of the registrant under the Securities Act of
                                         1933 to any purchaser in the initial distribution of the securities: The undersigned
                                         registrant undertakes that in a primary offering of securities of the undersigned registrant
                                         pursuant to this registration statement, regardless of the underwriting method used to
                                         sell the securities to the purchaser, if the securities are offered or sold to such purchaser
                                         by means of any of the following communications, the undersigned registrant will be a
                                         seller to the purchaser and will be considered to offer or sell such securities to such
                                         purchaser:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         preliminary prospectus or prospectus of the undersigned registrant relating to the offering
                                         required to be filed pursuant to Rule 424;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                         registrant or used or referred to by the undersigned registrant;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         portion of any other free writing prospectus relating to the offering containing material
                                         information about the undersigned registrant or its securities provided by or on behalf
                                         of the undersigned registrant; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         other communication that is an offer in the offering made by the undersigned registrant
                                         to the purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes that, for purposes of determining any liability
                                         under the Securities Act of 1933, each filing of the registrant's annual report pursuant
                                         to&nbsp;Section 13(a)&nbsp;or&nbsp;15(d) of the Securities Exchange Act of 1934&nbsp;(and,
                                         where applicable, each filing of an employee benefit plan's annual report pursuant to&nbsp;Section
                                         15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
                                         registration statement shall be deemed to be a new registration statement relating to
                                         the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Insofar
                                         as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                         to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                         provisions, or otherwise, the registrant has been advised that in the opinion of the
                                         Securities and Exchange Commission such indemnification is against public policy as expressed
                                         in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
                                         against such liabilities (other than the payment by the registrant of expenses incurred
                                         or paid by a director, officer or controlling person of the registrant in the successful
                                         defense of any action, suit or proceeding) is asserted by such director, officer or controlling
                                         person in connection with the securities being registered, the registrant will, unless
                                         in the opinion of its counsel the matter has been settled by controlling precedent, submit
                                         to a court of appropriate jurisdiction the question whether such indemnification by it
                                         is against public policy as expressed in the Act and will be governed by the final adjudication
                                         of such issue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         purposes of determining any liability under the Securities Act of 1933, the information
                                         omitted from the form of prospectus filed as part of this registration statement in reliance
                                         upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
                                         to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
                                         part of this registration statement as of the time it was declared effective.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         the purpose of determining any liability under the Securities Act of 1933, each post-effective
                                         amendment that contains a form of prospectus shall be deemed to be a new registration
                                         statement relating to the securities offered therein, and the offering of such securities
                                         at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="sign"></A><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on September 25, 2018.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
    BIOSCIENCE, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua R. Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R.
    Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 43%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua R. Disbrow</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R. Disbrow</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David A. Green</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David A. Green</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial and Accounting Officer)</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary V. Cantrell</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl C. Dockery</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John A. Donofrio, Jr.</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 25,
    2018</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Macaluso</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> * /s/ Joshua R. Disbrow as attorney-in-fact&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">II-6</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; margin-right: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%; margin-top: 0; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>fs12018a1ex1-1_aytubio.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>______
SHARES <FONT STYLE="text-transform: uppercase">of Common Stock, </FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>_______
SHARES OF SERIES C CONVERTIBLE PREFERRED STOCK </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>(CONVERTIBLE
INTO ______ SHARES OF COMMON STOCK), AND </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>_________
Warrants (exercisable for ________shares of common stock) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
BIOSCIENCE, INC.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________
__, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladenburg
Thalmann &amp; Co. Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Representative of the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
underwriters, if any, named in <U>Schedule I</U> hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4400
Biscayne Boulevard, 14<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami,
Florida 33137</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Aytu Bioscience, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries and
affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries
or affiliates of Aytu Bioscience, Inc., the &ldquo;<U>Company</U>&rdquo;), hereby confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;)
with the several underwriters (such underwriters, including the Representative (as defined below), the &ldquo;<U>Underwriters</U>&rdquo;
and each an &ldquo;<U>Underwriter</U>&rdquo;) named in <U>Schedule I</U> hereto for which Ladenburg Thalmann &amp; Co. Inc. is
acting as representative to the several Underwriters (the &ldquo;<U>Representative</U>&rdquo; and if there are no Underwriters
other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein
shall have the same meaning as Underwriter) on the terms and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is understood that the several Underwriters are to make a public offering of the Public Securities as soon as the Representative
deems it advisable to do so. The Public Securities are to be offered to the public at the public offering price set forth in the
Prospectus. The Representative may from time to time thereafter change the public offering price and other selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is further understood that you will act as the Representative for the Underwriters in the offering and sale of the Closing Securities
and, if any, the Option Securities in accordance with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, (a) capitalized terms that are not otherwise
defined herein have the meanings given to such terms in the Certificate of Designation (as defined herein) and (b) the following
terms have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls or
is controlled by or is under common control with such Person as such terms are used in and construed under Rule 405 under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Certificate
of Designation</U>&rdquo; means the Certificate of Designation to be filed prior to the Closing by the Company with the Secretary
of State of Delaware, in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Closing Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the hour and the date on the Trading Day on which all conditions precedent to (i) the Underwriters&rsquo;
obligations to pay the Closing Purchase Price and (ii) the Company&rsquo;s obligations to deliver the Closing Securities, in each
case, have been satisfied or waived, but in no event later than 10:00 a.m. (New York City time) on the second (2<SUP>nd</SUP>)
Trading Day following the date hereof or at such earlier time as shall be agreed upon by the Representative and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Preferred Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b), which aggregate purchase price shall
be net of the underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Securities</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(iii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<U>Closing
Warrants</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a)(iii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Combined
Preferred Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Combined
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Auditor</U>&rdquo; means EKS&amp;H LLLP, with offices located at 8181 East Tufts Avenue, Denver, Colorado 80237, or any successor
entity thereto, including without limitation Plante Moran.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Dorsey &amp; Whitney LLP, with offices located at 111 South Main St., Suite 2100, Salt Lake City, Utah
84111.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion
Shares</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Execution
Date</U>&rdquo; shall mean the date on which the parties execute and enter into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, options or other equity-based awards to employees, officers
or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee
members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose,
(b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, and (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration
rights that require or permit the filing of any registration statement in connection therewith within 90 days following the Closing
Date, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or
through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company
and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business
is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FINRA</U>&rdquo;
means the Financial Industry Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred
in the ordinary course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (c) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreements</U>&rdquo; means the lock-up agreements that are delivered on the date hereof by each of the Company&rsquo;s officers
and directors, in the form of <U>Exhibit E</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole or (iii) a material adverse effect on the Company&rsquo;s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Offering</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Closing Date</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Closing Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(b), which aggregate purchase price
shall be net of the underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Securities</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Shares</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(a)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Option
Warrants</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Over-Allotment
Option</U>&rdquo; shall have the meaning ascribed to such term in Section 2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Stock</U>&rdquo; means up to _____ shares of the Company&rsquo;s Series C Convertible Preferred Stock issued or issuable pursuant
to Section 2.1(a)(i) and having the rights, preferences and privileges set forth in the Certificate of Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Stock Agency Agreement</U>&rdquo; means the preferred stock agency agreement dated on or about the date hereof, among the Company
and VStock Transfer, LLC in the form of <U>Exhibit E</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means, if any, any preliminary prospectus relating to the Securities included in the Registration Statement
or filed with the Commission pursuant to Rule 424(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means, if any, a supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed
with the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Securities</U>&rdquo; means, collectively, the Closing Securities and, if any, the Option Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means, collectively, the various parts of the registration statement prepared by the Company on Form S-1
(File No. 333-227243) with respect to the Securities, each as amended as of the date hereof, including the Prospectus and Prospectus
Supplement, if any, the Preliminary Prospectus, if any, and all exhibits filed with or incorporated by reference into such registration
statement, and includes any Rule 462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Closing
Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to
Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Closing Securities, the Option Securities and the Underlying Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Share
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means, collectively, the shares of Common Stock delivered to the Underwriters in accordance with Section 2.1(a)(ii) and Section
2.2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Certificate of Designation, the Preferred Stock Agency Agreement, the Warrants,
the Warrant Agency Agreement, the Lock-Up Agreements, and any other documents or agreements executed in connection with the transactions
contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, with offices located at 18 Lafayette Place, Woodmere, New York 11598, and any successor
transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Underlying
Shares</U>&rdquo; means, collectively, the Conversion Shares and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means the warrant agency agreement dated on or about the date hereof, among the Company and VStock
Transfer, LLC in the form of <U>Exhibit D</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Purchase Price</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Underwriters in accordance with Section 2.1(a)(iii) and
Section 2.2(a), which Warrants shall be exercisable immediately and have a term of exercise equal to five (5) years, in the form
of <U>Exhibit C-1</U> attached hereto and the Common Stock purchase warrants delivered to the Representative in accordance with
Section 2.3(iv), in the form of <U>Exhibit C-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Closing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the terms and subject to the conditions set forth herein, the Company agrees to sell in the aggregate ________ shares of
Common Stock, _______ shares of Preferred Stock, and ___________ Warrants, and each Underwriter agrees to purchase, severally
and not jointly, at the Closing, the following securities of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the number of shares of Preferred Stock (the &ldquo;<U>Closing Preferred Shares</U>&rdquo;) set forth opposite the name of such
Underwriter on Schedule I hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
the number of shares of Common Stock (the &ldquo;<U>Closing Shares</U>&rdquo;) set forth opposite the name of such Underwriter
on <U>Schedule I</U> hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Warrants to purchase up to _____% of the sum of the number of Closing Shares set forth opposite the name of such Underwriter on
<U>Schedule I</U> hereof plus the aggregate number of Closing Preferred Shares set forth opposite the name of such Underwriter
on <U>Schedule I</U> hereof (the &ldquo;<U>Closing Warrants</U>&rdquo; and, collectively with the Closing Shares and the Closing
Preferred Shares, the &ldquo;<U>Closing Securities</U>&rdquo;), which Warrants shall have an exercise price of $______, subject
to adjustment as provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The aggregate purchase price for the Closing Securities shall equal the amount set forth opposite the name of such Underwriter
on <U>Schedule I</U> hereto (the &ldquo;<U>Closing Purchase Price</U>&rdquo;). The combined purchase price for one Share and a
Warrant to purchase ____ Warrant Share shall be $_____ (the &ldquo;<U>Combined Purchase Price</U>&rdquo;) which shall be allocated
as $_______ per Share (the &ldquo;<U>Share Purchase Price</U>&rdquo;) and $_______ per Warrant (the &ldquo;<U>Warrant Purchase
Price</U>&rdquo;). The combined purchase price for one Closing Preferred Share and Warrants to purchase ____ Warrant Shares shall
be $_____ (the &ldquo;<U>Combined Preferred Purchase Price</U>&rdquo;) which shall be allocated as $______ per Preferred Share
and $___ per Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
On the Closing Date, each Underwriter shall deliver or cause to be delivered to the Company, via wire transfer, immediately available
funds equal to such Underwriter&rsquo;s Closing Purchase Price and the Company shall deliver to, or as directed by, such Underwriter
its respective Closing Securities and the Company shall deliver the other items required pursuant to Section 2.3 deliverable at
the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the
offices of EGS or such other location as the Company and Representative shall mutually agree. The Public Securities are to be
offered to the public at the offering price set forth on the cover page of the Prospectus (the &ldquo;<U>Offering</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company acknowledges and agrees that, with respect to any Notice(s) of Conversion (as defined in the Certificate of Designation)
delivered by a Holder (as defined in the Certificate of Designation) on or prior to 12:00 p.m. (New York City time) on the Closing
Date, which Notice(s) of Conversion may be delivered at any time after the time of execution of this Agreement, the Company shall
deliver the Conversion Shares (as defined in the Certificate of Designation) subject to such notice(s) to the Holder by 4:00 p.m.
(New York City time) on the Closing Date. The Company acknowledges and agrees that the Holders are third-party beneficiaries of
this covenant of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Over-Allotment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
For the purposes of covering any over-allotments in connection with the distribution and sale of the Closing Securities, the Representative
is hereby granted an option (the &ldquo;<U>Over-Allotment Option</U>&rdquo;) to purchase, in the aggregate, up to _____1 shares
of Common Stock (the &ldquo;<U>Option Shares</U>&rdquo;) and Warrants to purchase up to ____2 shares of Common Stock (the &ldquo;<U>Option
Warrants</U>&rdquo; and, collectively with the Option Shares, the &ldquo;<U>Option Securities</U>&rdquo;) which may be purchased
in any combination of Option Shares and/or Option Warrants at the Share Purchase Price and/or Warrant Purchase Price, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In connection with an exercise of the Over-Allotment Option, (a) the purchase price to be paid for the Option Shares is equal
to the product of the Share Purchase Price multiplied by the number of Option Shares to be purchased and (b) the purchase price
to be paid for the Option Warrants is equal to the product of the Warrant Purchase Price multiplied by the number of Option Warrants
(the aggregate purchase price to be paid on an Option Closing Date, the &ldquo;<U>Option Closing Purchase Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Over-Allotment Option granted pursuant to this Section 2.2 may be exercised by the Representative as to all (at any time)
or any part (from time to time) of the Option Securities within forty-five (45) days after the Execution Date. An Underwriter
will not be under any obligation to purchase any Option Securities prior to the exercise of the Over-Allotment Option by the Representative.
The Over-Allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative,
which must be confirmed in writing by overnight mail or facsimile or other electronic transmission setting forth the number of
Option Shares and/or Option Warrants to be purchased and the date and time for delivery of and payment for the Option Securities
(each, an &ldquo;<U>Option Closing Date</U>&rdquo;), which will not be later than two (2) full Business Days after the date of
the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of EGS or at such
other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the
Representative. If such delivery and payment for the Option Securities does not occur on the Closing Date, each Option Closing
Date will be as set forth in the notice. Upon exercise of the Over-Allotment Option, the Company will become obligated to convey
to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will become obligated to purchase,
the number of Option Shares and/or Option Warrants specified in such notice. The Representative may cancel the Over-Allotment
Option at any time prior to the expiration of the Over-Allotment Option by written notice to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Deliveries</U>. The Company shall deliver or cause to be delivered to each Underwriter (if applicable) the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
At the Closing Date, the Closing Shares and, as to each Option Closing Date, if any, the applicable Option Shares, which shall
be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
15% of the Closing Shares and Closing Preferred Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
15% of the Closing Warrants.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
At the Closing Date, the Closing Preferred Shares, which shares shall be delivered via The Depository Trust Company Deposit or
Withdrawal at Custodian system for the accounts of the several Underwriters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
At the Closing Date, the Closing Warrants and, as to each Option Closing Date, if any, the applicable Option Warrants, which shall
be delivered via The Depository Trust Company Deposit or Withdrawal at Custodian system for the accounts of the several Underwriters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
At the Closing Date, to the Representative only, a Warrant to purchase up to a number of shares of Common Stock equal to 3% of
the Closing Shares and Closing Preferred Shares issued on the Closing Date, for the account of the Representative (or its designees),
which Warrant shall have an exercise price of $____, subject to adjustment therein, and registered in the name of the Representative,
otherwise on the same terms as the Closing Warrants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
At the Closing Date, evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Delaware;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
At the Closing Date, the Warrant Agency Agreement duly executed by the parties thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
At the Closing Date, the Preferred Stock Agency Agreement duly executed by the parties thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
At the Closing Date, a legal opinion of Company Counsel addressed to the Underwriters, including, without limitation, a negative
assurance letter, substantially in the form of <U>Exhibit B</U> attached hereto and as to each Option Closing Date, if any, a
bring-down opinion from Company Counsel in form and substance reasonably satisfactory to the Representative, including, without
limitation, a negative assurance letter, addressed to the Underwriters and in form and substance satisfactory to the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Contemporaneously herewith, a cold comfort letter, addressed to the Underwriters and in form and substance satisfactory in all
respects to the Representative from the Company Auditor dated, respectively, as of the date of this Agreement and a bring-down
letter dated as of the Closing Date and each Option Closing Date, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
On the Closing Date and on each Option Closing Date, the duly executed and delivered Officer&rsquo;s Certificate, substantially
in the form required by <U>Exhibit F</U> attached hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
On the Closing Date and on each Option Closing Date, the duly executed and delivered Secretary&rsquo;s Certificate, substantially
in the form required by <U>Exhibit G</U> attached hereto; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
Contemporaneously herewith, the duly executed and delivered Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.4
<U>Closing Conditions</U>. The respective obligations of each Underwriter hereunder in connection with the Closing and each Option
Closing Date are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects when made and on the date in question (other than representations and warranties of the
Company already qualified by materiality, which shall be true and correct in all respects) of the representations and warranties
of the Company contained herein (unless as of a specific date therein);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the date in question shall have
been performed in all material respects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.3 of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the Registration Statement shall be effective on the date of this Agreement and at each of the Closing Date and each Option Closing
Date, if any, no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings
for that purpose shall have been instituted or shall, to the Company&rsquo;s knowledge, be pending or contemplated by the Commission
and any request on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction
of the Representative;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
by the Execution Date, if required by FINRA, the Underwriters shall have received clearance from FINRA as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
the Company shall have submitted a &ldquo;Listing of Additional Shares notification&rdquo; to the Trading Market covering the
Closing Shares, the Option Shares and the Underlying Shares, and the Trading Market shall have completed its review of such submission;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
prior to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have been no material adverse
change or development involving a prospective material adverse change in the condition or prospects or the business activities,
financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement
and Prospectus; (ii)&nbsp;no action suit or proceeding, at law or in equity, shall have been pending or threatened against the
Company or any Affiliate of the Company before or by any court or federal or state commission, board or other administrative agency
wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or financial
condition or income of the Company, except as set forth in the Registration Statement and Prospectus; (iii)&nbsp;no stop order
shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission;
and (iv)&nbsp;the Registration Statement and the Prospectus and any amendments or supplements thereto shall contain all material
statements which are required to be stated therein in accordance with the Securities Act and the rules and regulations thereunder
and shall conform in all material respects to the requirements of the Securities Act and the rules and regulations thereunder,
and neither the Registration Statement nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Execution
Date, as of the Closing Date and as of each Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens,
and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no Subsidiaries, all other
references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents to which it is a party and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or
the Company&rsquo;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This
Agreement and each other Transaction Document to which the Company is a party has been (or upon delivery will have been) duly
executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)
and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other
than: (i) the filing with the Commission of the Prospectus, (ii) the filing of the Certificate of Designation with the Delaware
Secretary of State; (iii) the application to the Trading Market for the listing of the Shares and the Underlying Shares for trading
thereon, (iv) the notices, forms and authorizations of The Depository Trust &amp; Clearing Corporation related to the account
and transfer of the Warrants, (iv) the application to FINRA, and (vi) such filings as are required to be made under applicable
state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)
<U>Registration Statement</U>. The Company has filed with the Commission the Registration Statement, including any related Prospectus
or Prospectuses, for the registration of the Securities under the Securities Act, which Registration Statement has been prepared
by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations
of the Commission under the Securities Act. The Registration Statement has been declared effective by the Commission on _________
__, 2018 (the &ldquo;<U>Effective Date</U>&rdquo;). Any reference in this Agreement to the Registration Statement, the Prospectus
or any Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein; and any
reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect
to the Registration Statement, the Prospectus or any Prospectus Supplement shall be deemed to refer to and include the filing
of any document under the Exchange Act after the date of this Agreement, or the issue date of the Prospectus or any Prospectus
Supplement, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial
statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo;
&ldquo;referenced,&rdquo; &ldquo;set forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Prospectus or any
Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements
and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Prospectus
or any Prospectus Supplement, as the case may be. No stop order suspending the effectiveness of the Registration Statement or
the use of the Prospectus or any Prospectus Supplement has been issued, and no proceeding for any such purpose is pending or has
been initiated or, to the Company's knowledge, is threatened by the Commission. For purposes of this Agreement, &ldquo;<U>free
writing prospectus</U>&rdquo; has the meaning set forth in Rule 405 under the Securities Act. The Company will not, without the
prior consent of the Representative, prepare, use or refer to, any free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Issuance of Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued,
fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized
capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement, the Certificate of Designation,
and the Warrants. The holder of the Securities will not be subject to personal liability by reason of being such holders. Except
as set forth in the Registration Statement and the Preliminary Prospectus, the Securities are not and will not be subject to the
preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. All corporate
action required to be taken for the authorization, issuance and sale of the Securities has been duly and validly taken. The Securities
conform in all material respects to all statements with respect thereto contained in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Capitalization</U>. The capitalization of the Company is as set forth in the Registration Statement and the Preliminary Prospectus.
The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than
pursuant to the exercise of employee stock options or vesting of other equity awards under the Company&rsquo;s stock option plans,
the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. Except as set forth in the Registration Statement and the Preliminary Prospectus, no Person has any right
of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as set forth in the Registration Statement and the Preliminary Prospectus and as a result
of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable
for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common
Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Underwriters) and will not result in a right of any holder of Company securities to adjust
the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights
to subscribe for or purchase securities. The authorized shares of the Company conform in all material respects to all statements
relating thereto contained in the Registration Statement and the Preliminary Prospectus. The offers and sales of the Company&rsquo;s
securities were at all relevant times either registered under the Securities Act and the applicable state securities or Blue Sky
laws or, based in part on the representations and warranties of the purchasers, exempt from such registration requirements. No
further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of
the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s
stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
together with the Prospectus and any Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. The agreements and
documents described in the Registration Statement, the Prospectus, any Prospectus Supplement and the SEC Reports conform to the
descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the rules
and regulations thereunder to be described in the Registration Statement, the Prospectus, any Prospectus Supplement or the SEC
Reports or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed.
Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may
be bound or affected and (i)&nbsp;that is referred to in the Registration Statement, the Prospectus, any Prospectus Supplement
or the SEC Reports, or (ii)&nbsp;is material to the Company&rsquo;s business, has been duly authorized and validly executed by
the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s
knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws, and (z)&nbsp;that the remedy of specific
performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefore may be brought. None of such agreements or instruments has been assigned by
the Company, and neither the Company nor, to the best of the Company&rsquo;s knowledge, any other party is in default thereunder
and, to the best of the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default thereunder. To the best of the Company&rsquo;s knowledge, performance by the Company of the
material provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation,
judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any
of its assets or businesses, including, without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i)
there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse
Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to
be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)
the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its
capital stock, (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to
existing Company equity compensation or stock option plans and (vi) no officer or director of the Company has resigned from any
position with the Company. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, properties, operations, assets or financial condition that would be required to be disclosed by
the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least 1 Trading Day prior to the date that this representation is made. Unless otherwise disclosed in an SEC Report
filed prior to the date hereof, the Company has not: (i)&nbsp;issued any securities or incurred any liability or obligation, direct
or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or in respect
to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Litigation</U>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge
of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by
any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably
be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof,
is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws
or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or
any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its
Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company
and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement
or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to
employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in
compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any
of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree
or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance
or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters,
except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described
in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material
Adverse Effect (each, a &ldquo;<U>Material Permit</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice
of proceedings relating to the revocation or modification of any Material Permit. The disclosures in the Registration Statement
concerning the effects of Federal, State, local and all foreign regulation on the Company&rsquo;s business as currently contemplated
are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable
rights to lease or otherwise use, all real property and all personal property that is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of
such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the
Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in
accordance with GAAP, and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities
held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which
the Company and the Subsidiaries are in compliance, except where failure to be in compliance could not reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in
the SEC Reports and which the failure to do so could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual
Property Rights</U>&rdquo;). Neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of,
the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the
latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge
that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably
be expected to have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is
presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring
payments to or from, any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner,
in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement
for expenses incurred on behalf of the Company and (iii) other employee benefits, including equity award or stock option agreements
under any equity compensation or stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects
with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and
all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as
of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization,
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls
and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures
of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange
Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under
the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control
over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except as set forth in the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or will be
payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement
agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. To
the Company&rsquo;s knowledge, there are no other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s
knowledge, any of its stockholders that may affect the Underwriters&rsquo; compensation, as determined by FINRA. Except with respect
to payments made to the Representative in connection with this offering and to other FINRA members in connection with other public
offerings, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person,
as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing
to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp;any person or entity
that has any direct or indirect affiliation or association with any FINRA member, within the twelve months prior to the Execution
Date. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not required to register as, and is not an Affiliate of, and immediately after receipt
of payment for the Securities will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the
Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment
company&rdquo; subject to registration under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Except as disclosed in the SEC Reports, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date
hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the
Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing
corporation and the Company is current in payment of the fees of the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable as a result of the Underwriters
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(y)
<U>Disclosure; 10b-5</U>. The Registration Statement (and any further documents to be filed with the Commission in connection
with the Offering) contains all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and
any post-effective amendment thereto, if any, at the time it became effective, complied in all material respects with the Securities
Act and the Exchange Act and the applicable rules and regulations under the Securities Act and did not and, as amended or supplemented,
if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus complies in all material respects with the
Securities Act and the Exchange Act and the applicable rules and regulations. The Prospectus, as amended or supplemented, does
not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The SEC Reports,
when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable
rules and regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement of
a material fact or omitted to state a material fact necessary to make the statements therein (with respect to the SEC Reports
incorporated by reference in the Prospectus), in light of the circumstances under which they were made not misleading; and any
further documents so filed and incorporated by reference in the Prospectus, when such documents are filed with the Commission,
will conform in all material respects to the requirements of the Exchange Act and the applicable rules and regulations, as applicable,
and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration
Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental
change in the information set forth therein is required to be filed with the Commission. There are no documents required to be
filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant
to the Securities Act or (y) will not be filed within the requisite time period. There are no contracts or other documents required
to be described in the Prospectus, or to be filed as exhibits or schedules to the Registration Statement, which have not been
described or filed as required. The press releases disseminated by the Company during the twelve months preceding the date of
this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made and when made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable
shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s
assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. The SEC Reports sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all applicable United States federal,
state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate
for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company or of any Subsidiary know of no basis for any such claim. The provisions for taxes payable, if any, shown on the
financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether
or not disputed, and for all periods to and including the dates of such consolidated financial statements. The term &ldquo;taxes&rdquo;
means all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer,
franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation,
premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatsoever, together
with any interest and any penalties, additions to tax, or additional amounts with respect thereto. The term &ldquo;returns&rdquo;
means all returns, declarations, reports, statements, and other documents required to be filed in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made
by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of FCPA. The Company has taken reasonable steps to ensure that its accounting controls and procedures are
sufficient to cause the Company to comply in all material respects with the FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. To the knowledge and belief of the Company, the Company Auditor (i) is an independent registered public accounting
firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included
in the Company&rsquo;s Annual Report for the fiscal year ending June 30, 2019. The Company Auditor has not, during the periods
covered by the financial statements included in the Prospectus, provided to the Company any non-audit services, as such term is
used in Section 10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such
product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar
laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There
is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative
or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the
Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental
entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of,
the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)
withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation
by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries,
(v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or
(vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either
individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the
FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to
approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ff)
<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the
Representative&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve
System (the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent
(25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body
or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires completed by
each of the Company&rsquo;s directors and officers immediately prior to the Offering as well as in the Lock-Up Agreement provided
to the Underwriters is true and correct in all respects and the Company has not become aware of any information which would cause
the information disclosed in such questionnaires become inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(kk)
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, no officer, director or any beneficial owner of 5% or more of the
Company&rsquo;s unregistered securities has any direct or indirect affiliation or association with any FINRA member (as determined
in accordance with the rules and regulations of FINRA) that is participating in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Officers&rsquo; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the
Representative or EGS shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered
thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Board of Directors</U>. The Board of Directors is comprised of the persons set forth under the heading in the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended June 30, 2018 captioned &ldquo;Directors and Executive Officers, and Corporate
Governance.&rdquo; The qualifications of the persons serving as board members and the overall composition of the Board of Directors
comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of the
Trading Market. At least one member of the Board of Directors qualifies as a &ldquo;financial expert&rdquo; as such term is defined
under the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder and the rules of the Trading Market. In addition, at
least a majority of the persons serving on the Board of Directors qualify as &ldquo;independent&rdquo; as defined under the rules
of the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
AGREEMENTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Amendments to Registration Statement</U>. The Company has delivered, or will as promptly as practicable deliver, to the Underwriters
complete conformed copies of the Registration Statement and of each consent and certificate of experts, as applicable, filed as
a part thereof, and conformed copies of the Registration Statement (without exhibits) and the Prospectus, as amended or supplemented,
in such quantities and at such places as an Underwriter reasonably requests. Neither the Company nor any of its directors and
officers has distributed and none of them will distribute, prior to the Closing Date, any offering material in connection with
the offering and sale of the Securities other than the Prospectus, the Registration Statement, and copies of the documents incorporated
by reference therein. The Company shall not file any such amendment or supplement to which the Representative shall reasonably
object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance</U>. During the time when a Prospectus is required to be delivered under the Securities Act, the Company will use
its reasonable best efforts to comply with all requirements imposed upon it by the Securities Act and the rules and regulations
thereunder and the Exchange Act and the rules and regulations thereunder, as from time to time in force, so far as necessary to
permit the continuance of sales of or dealings in the Securities in accordance with the provisions hereof and the Prospectus.
If at any time when a Prospectus relating to the Securities is required to be delivered under the Securities Act, any event shall
have occurred as a result of which, in the opinion of counsel for the Company or counsel for the Underwriters, the Prospectus,
as then amended or supplemented, includes an untrue statement of a material fact or omits to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, or if it is necessary at any time to amend the Prospectus to comply with the Securities Act, the Company will notify
the Underwriters promptly and prepare and file with the Commission, subject to Section 4.1 hereof, an appropriate amendment or
supplement in accordance with Section 10 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Filing of Final Prospectus</U>. The Company will file the Prospectus (in form and substance satisfactory to the Representative)
with the Commission pursuant to the requirements of Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Exchange Act Registration</U>. For a period of three years from the Execution Date, the Company will use its reasonable best
efforts to maintain the registration of the Common Stock under the Exchange Act. The Company will not deregister the Common Stock
under the Exchange Act without the prior written consent of the Representative, subject to the exercise of fiduciary duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Free Writing Prospectuses</U>. The Company represents and agrees that it has not made and will not make any offer relating
to the Securities that would constitute an issuer free writing prospectus, as defined in Rule 433 of the rules and regulations
under the Securities Act, without the prior written consent of the Representative. Any such free writing prospectus consented
to by the Representative is herein referred to as a &ldquo;<U>Permitted Free Writing Prospectus</U>.&rdquo; The Company represents
that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus&rdquo; as defined in the
rules and regulations under the Securities Act, and has complied and will comply with the applicable requirements of Rule 433
of the Securities Act, including timely Commission filing where required, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Delivery to the Underwriters of Prospectuses</U>. The Company will deliver to the Underwriters, without charge, from time to
time during the period when the Prospectus is required to be delivered under the Securities Act or the Exchange Act such number
of copies of the Prospectus as the Underwriters may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Effectiveness and Events Requiring Notice to the Underwriters</U>. The Company will use its reasonable best efforts to cause
the Registration Statement to remain effective with a current prospectus until the later of nine (9) months from the Execution
Date and the date on which the Warrants are no longer outstanding, and will notify the Underwriters and holders of the Warrants
promptly and confirm the notice in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto;
(ii)&nbsp;of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for
that purpose; (iii)&nbsp;of the issuance by any state securities commission of any proceedings for the suspension of the qualification
of the Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that
purpose; (iv)&nbsp;of the filing of any amendment or supplement to the Registration Statement or Prospectus; (v)&nbsp;of the receipt
of any comments or request for any additional information from the Commission; and (vi)&nbsp;of the happening of any event during
the period described in this Section 4.4 that, in the judgment of the Company, makes any statement of a material fact made in
the Registration Statement or the Prospectus untrue or that requires the making of any changes in the Registration Statement or
the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company
will make its reasonable best effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Expenses of the Offering</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and each Option
Closing Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations
of the Company under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to
the registration of the Securities to be sold in the Offering (including the Option Securities) with the Commission; (b) all FINRA
Public Offering Filing System fees associated with the review of the Offering by FINRA; all fees and expenses relating to the
listing of such Closing Shares, Option Shares and Underlying Shares on the Trading Market and such other stock exchanges as the
Company and the Representative together determine; (c) all fees, expenses and disbursements relating to the registration or qualification
of such Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other foreign jurisdictions as the Representative
may reasonably designate; (d) the costs of all mailing and printing of the underwriting documents (including, without limitation,
the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&rsquo;
Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments,
supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary;
(e) the costs and expenses of the Company&rsquo;s public relations firm; (f) the costs of preparing, printing and delivering the
Securities; (g) fees and expenses of the Transfer Agent for the Securities (including, without limitation, any fees required for
same-day processing of any instruction letter delivered by the Company); (h) stock transfer and/or stamp taxes, if any, payable
upon the transfer of securities from the Company to the Underwriters; (i) the fees and expenses of the Company&rsquo;s accountants;
(j) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; and (k) the Underwriters&rsquo;
costs of mailing prospectuses to prospective investors. The Underwriters may also deduct from the net proceeds of the Offering
payable to the Company on the Closing Date, or each Option Closing Date, if any, the expenses set forth herein to be paid by the
Company to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Expenses of the Representative</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section
4.6(a), on the Closing Date, the Company will reimburse the Representative for its out-of-pocket expenses related to the Offering
up to an aggregate of $85,000 (which shall include any expenses incurred under clause (c) of Section 4.6(a) herein), which shall
be paid by deduction from the proceeds of the Offering contemplated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Application of Net Proceeds</U>. The Company will apply the net proceeds from the Offering received by it in a manner consistent
with the application described under the caption &ldquo;Use of Proceeds&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Delivery of Earnings Statements to Security Holders</U>. To the extent not otherwise available on the Commission&rsquo;s EDGAR
filing system (or any successor system), the Company will make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth full calendar month following the Execution Date, an earnings statement (which
need not be certified by independent public or independent certified public accountants unless required by the Securities Act
or the Rules and Regulations under the Securities Act, but which shall satisfy the provisions of Rule 158(a) under Section 11(a)
of the Securities Act) covering a period of at least twelve consecutive months beginning after the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Stabilization</U>. Neither the Company, nor, to its knowledge, any of its employees, directors or shareholders (without the
consent of the Representative) has taken or will take, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result in, under the Exchange Act, or otherwise, stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Internal Controls</U>. The Company will maintain a system of internal accounting controls sufficient to provide reasonable
assurances that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii)&nbsp;transactions
are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Accountants</U>. The Company shall continue to retain an independent certified public accounting firm registered with the Public
Company Accounting Oversight Board for a period of at least three years after the Execution Date. The Underwriters acknowledge
that the Company Auditor is acceptable to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>FINRA</U>. For a period of six months from the Execution Date, the Company shall advise the Underwriters (i) (who shall make
an appropriate filing with FINRA) if it is aware that any 5% or greater shareholder of the Company becomes an affiliate or associated
person of an Underwriter and (ii) if it learns that any officer, director or owner of 5% or more of the Company&rsquo;s outstanding
shares of Common Stock or Common Stock Equivalents is or becomes an affiliate or associated person of a FINRA member firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is
solely contractual and commercial in nature, based on arms-length negotiations and that neither the Underwriters nor their affiliates
or any selected dealer shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company
or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding
anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the
success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to
the Company by the Underwriters for the shares and the Underwriters have no obligation to disclose, or account to the Company
for, any of such additional financial interests. The Company hereby waives and releases, to the fullest extent permitted by law,
any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Underlying Shares</U>. The shares of Common Stock underlying the Preferred Stock shall be issued free of legends. If all or
any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance of the
Warrant Shares or if the Warrant is exercised via cashless exercise at a time when such Warrant Shares would be eligible for resale
under Rule 144 by a non-affiliate of the Company, the Warrant Shares issued pursuant to any such exercise shall be issued free
of all restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent registration
statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the issuance
of the Warrant Shares upon exercise of the Warrants, the Company shall promptly notify the holders of the Warrants in writing
that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration
statement is effective again and available for the sale of the Warrant Shares (it being understood and agreed that the foregoing
shall not limit the ability of the Company to issue, or any holder thereof to sell, any of the Warrant Shares in compliance with
applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Board Composition and Board Designations</U>. The Company shall use its reasonable best efforts to ensure that: (i)&nbsp;the
qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley
Act of 2002 and the rules promulgated thereunder and with the listing requirements of the Trading Market and (ii)&nbsp;if applicable,
at least one member of the Board of Directors qualifies as a &ldquo;financial expert&rdquo; as such term is defined under the
Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<U>Securities Laws Disclosure; Publicity</U>. At the request of the Representative, by 9:00 a.m. (New York City time) on the date
hereof, the Company shall issue a press release disclosing the material terms of the Offering. The Company and the Representative
shall consult with each other in issuing any other press releases with respect to the Offering, and neither the Company nor any
Underwriter shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of such Underwriter, or without the prior consent of such Underwriter, with respect to any press
release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by
law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
The Company will not issue press releases or engage in any other publicity, without the Representative&rsquo;s prior written consent,
for a period ending at 5:00 p.m. (New York City time) on the first business day following the 45th day following the Closing Date,
other than normal and customary releases issued in the ordinary course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.17
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that any Underwriter of the Securities is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in
effect or hereafter adopted by the Company, or that any Underwriter of Securities could be deemed to trigger the provisions of
any such plan or arrangement, by virtue of receiving Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Option Shares pursuant to the Over-Allotment Option and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19
<U>Listing of Common Stock</U>. The Company hereby agrees to use its reasonable best efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall
apply to list or quote all of the Closing Shares, Option Shares and Underlying Shares on such Trading Market and promptly secure
the listing of all of the Closing Shares, Option Shares and Underlying Shares on such Trading Market. The Company further agrees,
if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all
of the Closing Shares, Option Shares and Underlying Shares, and will use its reasonable best efforts to cause all of the Closing
Shares, Option Shares and Underlying Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company
will then use is reasonable best efforts to continue the listing and trading of its Common Stock on a Trading Market and will
use its reasonable best efforts to comply in all material respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to use its reasonable best efforts to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.20
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until the ninety (90) day anniversary of the Closing Date, neither the Company nor any Subsidiary shall issue,
enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock
Equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until the one (1) year anniversary of the Closing Date, the Company shall be prohibited from effecting or
entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise
price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares
of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or
exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or
upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market
for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity
line of credit, whereby the Company may issue securities at a future determined price. Any Underwriter shall be entitled to obtain
injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect
damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.20 shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21
<U>Research Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments,
if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations
and internal policies, and that such Underwriter&rsquo;s research analysts may hold and make statements or investment recommendations
and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers.
The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such
Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent
research analysts and research departments may be different from or inconsistent with the views or advice communicated to the
Company by such Underwriter&rsquo;s investment banking divisions. The Company acknowledges that the Representative is a full service
securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account
or the account of its customers and hold long or short position in debt or equity securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULT
BY UNDERWRITERS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">If
on the Closing Date or any Option Closing Date, if any, any Underwriter shall fail to purchase and pay for the portion of the
Closing Securities or Option Securities, as the case may be, which such Underwriter has agreed to purchase and pay for on such
date (otherwise than by reason of any default on the part of the Company), the Representative, or if the Representative is the
defaulting Underwriter, the non-defaulting Underwriters, shall use their reasonable efforts to procure within 36 hours thereafter
one or more of the other Underwriters, or any others, to purchase from the Company such amounts as may be agreed upon and upon
the terms set forth herein, the Closing Securities or Option Securities , as the case may be, which the defaulting Underwriter
or Underwriters failed to purchase. If during such 36 hours the Representative shall not have procured such other Underwriters,
or any others, to purchase the Closing Securities or Option Securities, as the case may be, agreed to be purchased by the defaulting
Underwriter or Underwriters, then (a) if the aggregate number of Closing Securities or Option Securities, as the case may be,
with respect to which such default shall occur does not exceed 10% of the Closing Securities or Option Securities, as the case
may be, covered hereby, the other Underwriters shall be obligated, severally, in proportion to the respective numbers of Closing
Securities or Option Securities, as the case may be, which they are obligated to purchase hereunder, to purchase the Closing Securities
or Option Securities, as the case may be, which such defaulting Underwriter or Underwriters failed to purchase, or (b) if the
aggregate number of Closing Securities or Option Securities, as the case may be, with respect to which such default shall occur
exceeds 10% of the Closing Securities or Option Securities, as the case may be, covered hereby, the Company or the Representative
will have the right to terminate this Agreement without liability on the part of the non-defaulting Underwriters or of the Company
except to the extent provided in Article VI hereof. In the event of a default by any Underwriter or Underwriters, as set forth
in this Article V, the applicable Closing Date may be postponed for such period, not exceeding seven days, as the Representative,
or if the Representative is the defaulting Underwriter, the non-defaulting Underwriters, may determine in order that the required
changes in the Prospectus or in any other documents or arrangements may be effected. The term &ldquo;Underwriter&rdquo; includes
any person substituted for a defaulting Underwriter. Any action taken under this Section shall not relieve any defaulting Underwriter
from liability in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Indemnification of the Underwriters</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold
harmless the Underwriters, and each dealer selected by each Underwriter that participates in the offer and sale of the Securities
(each a &ldquo;<U>Selected Dealer</U>&rdquo;) and each of their respective directors, officers and employees and each Person,
if any, who controls such Underwriter or any Selected Dealer (&ldquo;<U>Controlling Person</U>&rdquo;) within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense whatsoever
(including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending
against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between such Underwriter
and the Company or between such Underwriter and any third party or otherwise) to which they or any of them may become subject
under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries,
arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (i) any Preliminary
Prospectus, the Registration Statement or the Prospectus (as from time to time each may be amended and supplemented); (ii) any
materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the
offering of the Securities, including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether
in person or electronically); or (iii) any application or other document or written communication (in this Article VI, collectively
called &ldquo;<U>application</U>&rdquo;) executed by the Company or based upon written information furnished by the Company in
any jurisdiction in order to qualify the Securities under the securities laws thereof or filed with the Commission, any state
securities commission or agency, Trading Market or any securities exchange; or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading, unless such statement or omission was made in reliance upon and in conformity with written information
furnished to the Company with respect to the applicable Underwriter by or on behalf of such Underwriter expressly for use in any
Preliminary Prospectus, if any, the Registration Statement or Prospectus, or any amendment or supplement thereto, or in any application,
as the case may be. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Preliminary
Prospectus, if any, the indemnity agreement contained in this Section 6.1 shall not inure to the benefit of an Underwriter to
the extent that any loss, liability, claim, damage or expense of such Underwriter results from the fact that a copy of the Prospectus
was not given or sent to the Person asserting any such loss, liability, claim or damage at or prior to the written confirmation
of sale of the Securities to such Person as required by the Securities Act and the rules and regulations thereunder, and if the
untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result
of non-compliance by the Company with its obligations under this Agreement. The Company agrees promptly to notify each Underwriter
of the commencement of any litigation or proceedings against the Company or any of its officers, directors or Controlling Persons
in connection with the issue and sale of the Public Securities or in connection with the Registration Statement or Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Procedure</U>. If any action is brought against an Underwriter, a Selected Dealer or a Controlling Person in respect of which
indemnity may be sought against the Company pursuant to Section 6.1, such Underwriter, such Selected Dealer or Controlling Person,
as the case may be, shall promptly notify the Company in writing of the institution of such action and the Company shall assume
the defense of such action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter
or such Selected Dealer, as the case may be) and payment of actual expenses. Such Underwriter, such Selected Dealer or Controlling
Person shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall
be at the expense of such Underwriter, such Selected Dealer or Controlling Person unless (i) the employment of such counsel at
the expense of the Company shall have been authorized in writing by the Company in connection with the defense of such action,
or (ii) the Company shall not have employed counsel to have charge of the defense of such action, or (iii) such indemnified party
or parties shall have reasonably concluded that there may be defenses available to it or them which are different from or additional
to those available to the Company (in which case the Company shall not have the right to direct the defense of such action on
behalf of the indemnified party or parties), in any of which events the reasonable fees and expenses of not more than one additional
firm of attorneys selected by such Underwriter (in addition to local counsel), Selected Dealer and/or Controlling Person shall
be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter, Selected Dealer or Controlling
Person shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of any
settlement of such action which approval shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.3
<U>Indemnification of the Company</U>. Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company,
its directors, officers and employees and agents who control the Company within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity
from the Company to such Underwriter, as incurred, but only with respect to untrue statements or omissions, or alleged untrue
statements or omissions made in any Preliminary Prospectus, the Registration Statement or Prospectus or any amendment or supplement
thereto or in any application, in reliance upon, and in strict conformity with, written information furnished to the Company with
respect to such Underwriter by or on behalf of such Underwriter expressly for use in such Preliminary Prospectus, if any, the
Registration Statement or Prospectus or any amendment or supplement thereto or in any such application. In case any action shall
be brought against the Company or any other Person so indemnified based on any Preliminary Prospectus, the Registration Statement
or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against
such Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other Person
so indemnified shall have the rights and duties given to such Underwriter by the provisions of this Article VI. Notwithstanding
the provisions of this Section 6.3, no Underwriter shall be required to indemnify the Company for any amount in excess of the
underwriting discounts and commissions applicable to the Securities purchased by such Underwriter. The Underwriters' obligations
in this Section 6.3 to indemnify the Company are several in proportion to their respective underwriting obligations and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Contribution Rights</U>. In order to provide for just and equitable contribution under the Securities Act in any case in which
(i) any Person entitled to indemnification under this Article VI makes a claim for indemnification pursuant hereto but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal
or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact
that this Article VI provides for indemnification in such case, or (ii) contribution under the Securities Act, the Exchange Act
or otherwise may be required on the part of any such Person in circumstances for which indemnification is provided under this
Article VI, then, and in each such case, the Company and each Underwriter, severally and not jointly, shall contribute to the
aggregate losses, liabilities, claims, damages and expenses of the nature contemplated by said indemnity agreement incurred by
the Company and such Underwriter, as incurred, in such proportions that such Underwriter is responsible for that portion represented
by the percentage that the underwriting discount appearing on the cover page of the Prospectus bears to the initial offering price
appearing thereon and the Company is responsible for the balance; provided, that, no Person guilty of a fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation. For purposes of this Section, each director, officer and employee of such Underwriter or
the Company, as applicable, and each Person, if any, who controls such Underwriter or the Company, as applicable, within the meaning
of Section 15 of the Securities Act shall have the same rights to contribution as such Underwriter or the Company, as applicable.
Notwithstanding the provisions of this Section 6.4, no Underwriter shall be required to contribute any amount in excess of the
underwriting discounts and commissions applicable to the Securities purchased by such Underwriter. The Underwriters' obligations
in this Section 6.4 to contribute are several in proportion to their respective underwriting obligations and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Contribution Procedure</U>. Within fifteen days after receipt by any party to this Agreement (or its representative) of notice
of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be
made against another party (&ldquo;<U>contributing party</U>&rdquo;), notify the contributing party of the commencement thereof,
but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party
other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party
notifies a contributing party or its representative of the commencement thereof within the aforesaid fifteen days, the contributing
party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any
such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action
or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution
provisions contained in this Section 6.4 are intended to supersede, to the extent permitted by law, any right to contribution
under the Securities Act, the Exchange Act or otherwise available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Termination Right</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing
Date, (i)&nbsp;if any domestic or international event or act or occurrence has materially disrupted, or in its opinion will in
the immediate future materially disrupt, general securities markets in the United States; or (ii)&nbsp;if trading on any Trading
Market shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum
ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority
having jurisdiction, or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities,
or (iv)&nbsp;if a banking moratorium has been declared by a New York State or federal authority, or (v)&nbsp;if a moratorium on
foreign exchange trading has been declared which materially adversely impacts the United States securities markets, or (vi)&nbsp;if
the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity
or malicious act which, whether or not such loss shall have been insured, will, in the Representative&rsquo;s opinion, make it
inadvisable to proceed with the delivery of the Securities, or (vii)&nbsp;if the Company is in material breach of any of its representations,
warranties or covenants hereunder, or (viii)&nbsp;if the Representative shall have become aware after the date hereof of such
a material adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions
as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the
Securities or to enforce contracts made by the Underwriters for the sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
<U>Expenses</U>. In the event this Agreement shall be terminated pursuant to Section 7.1(a), within the time specified herein
or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Representative, subject to
the amount of reimbursable expenses set forth in Section 4.6(b), its actual and accountable out of pocket expenses related to
the transactions contemplated herein then due and payable, including the fees and disbursements of EGS up to $25,000 (<U>provided</U>,
<U>however</U>, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Article VI shall not be in any
way effected by such election or termination or failure to carry out the terms of this Agreement or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, and the Prospectus contains
the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules. Notwithstanding anything herein to the contrary, the Engagement Agreement, dated August 20, 2018 (&ldquo;<U>Engagement
Agreement</U>&rdquo;), by and between the Company and the Representative, shall continue to be effective and the terms therein,
including, without limitation, Section 5(b) and Section 6 with respect to any future offerings, shall continue to survive and
be enforceable by the Representative in accordance with its terms, provided that, in the event of a conflict between the terms
of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication
is delivered via facsimile or e-mail attachment at the facsimile number or e-mail address set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile or e-mail attachment at the facsimile number or e-mail address as set
forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on
any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and the Representative. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of any party to exercise any right hereunder in any manner impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a
party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to
the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including
with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any action, suit or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Article VI, the prevailing party in such action, suit or proceeding shall be reimbursed by the
other party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.8
<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the Option Closing, if any,
and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.10
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.11
<U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, the Underwriters and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained
in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.12
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.13
<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity
to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be
subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.14
<B><U>WAIVER OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY,
TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER
ANY RIGHT TO TRIAL BY JURY. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space
provided below for that purpose, whereupon this letter shall constitute a binding agreement among the Company and the several
Underwriters in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
    BIOSCIENCE, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
for Notice</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">373
Inverness Parkway, Suite 206</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Englewood,
CO 80112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Controller</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Copy
to</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dorsey
&amp; Whitney LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111
South Main St., Suite 2100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt
Lake City, UT 84111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Nolan Taylor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
on the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LADENBURG
THALMANN &amp; CO. INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Representative of the several</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters
listed on Schedule I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Nicholas Stergis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Managing Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
for Notice</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4400
Biscayne Boulevard, 14<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami,
Florida 33137</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
General Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Copy
to</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellenoff
Grossman &amp; Schole LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1345
Avenue of the Americas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10105</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
(212) 401-4741</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Michael Nertney</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SCHEDULE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Schedule
of Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Closing Shares</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Closing Preferred Shares</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Closing Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Closing Purchase Price</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Ladenburg Thalmann &amp; Co. Inc.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.9
<SEQUENCE>3
<FILENAME>fs12018a1ex3-9_aytubio.htm
<DESCRIPTION>FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C PREFERRED STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>aytu
bioscience, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES,
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RIGHTS AND LIMITATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERIES <FONT STYLE="text-transform: uppercase">c
</FONT>CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">PURSUANT
TO SECTION 151 OF THE </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Delaware
GENERAL CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned, __________ and ____________,
do hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. They are the President
and Secretary, respectively, of Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The Corporation
is authorized to issue 50,000,000 shares of preferred stock, ________ of which have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. The following resolutions
were duly adopted by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the certificate of incorporation
of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 50,000,000 shares, $0.0001
par value per share, issuable from time to time in one or more series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the Board of Directors is authorized
to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation preferences
of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof,
of any of them; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, it is the desire of the Board
of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating to
a series of the preferred stock, which shall consist of, except as otherwise set forth in the Underwriting Agreement, up to ________
shares of the preferred stock which the Corporation has the authority to issue, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NOW, THEREFORE, BE IT RESOLVED, that the
Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities,
rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series
of preferred stock as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS OF PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 1</U>. <U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 6(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the Corporation&rsquo;s common stock, par value $0.0001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof
to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to
receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Amount</U>&rdquo; means the sum of the Stated Value at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in
accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Holder</U>&rdquo;
shall have the meaning given such term in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liquidation</U>&rdquo;
shall have the meaning set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>New
York Courts</U>&rdquo; shall have the meaning set forth in Section 8(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notice
of Conversion</U>&rdquo; shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Original
Issue Date</U>&rdquo; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers
of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferred
Stock</U>&rdquo; shall have the meaning set forth in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Representative</U>&rdquo;
means Ladenburg Thalmann &amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section 6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stated
Value</U>&rdquo; shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or
the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Corporation with a mailing address of 18 Lafayette
Place, Woodmere, New York 11598 and a facsimile number of ___________, and any successor transfer agent of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the underwriting agreement, dated as of _____ __, 2018, among the Corporation and the Representative,
as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with
its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets, Inc. (or a similar organization or agency succeeding to its
functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Preferred Stock then outstanding and reasonably acceptable to the Corporation, the fees and expenses
of which shall be paid by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 2</U>. <U>Designation,
Amount and Par Value</U>. The series of preferred stock shall be designated as its Series C Convertible Preferred Stock (the &ldquo;<U>Preferred
Stock</U>&rdquo;) and the number of shares so designated shall be up to ___ (which shall not be subject to increase without the
written consent of all of the holders of the Preferred Stock (each, a &ldquo;<U>Holder</U>&rdquo; and collectively, the &ldquo;<U>Holders</U>&rdquo;)).
Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $____<SUP>1</SUP>, subject
to increase set forth in Section 3 below (the &ldquo;<U>Stated Value</U>&rdquo;). The Preferred Stock will initially be issued
in book-entry form and shall initially be represented only by one or more global certificates deposited with the Depository Trust
Company (&ldquo;<U>DTC</U>&rdquo;) and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by
DTC. As between the Corporation and a beneficial owner of Preferred Stock, such beneficial owner of Preferred Stock shall have
all of the rights and remedies of a Holder hereunder. In addition, a beneficial owner of Preferred Stock has the right, upon written
notice by such beneficial owner to the Corporation, to request the exchange of some or all of such beneficial owner&rsquo;s interest
in Preferred Stock represented by one or more global Preferred Stock certificates deposited with Cede &amp; Co. (or its successor)
for a physical Preferred Stock certificate (a &ldquo;<U>Preferred Stock Certificate Request Notice</U>&rdquo; and the date of delivery
of such Preferred Stock Certificate Request Notice by a beneficial owner, the &ldquo;<U>Preferred Stock Certificate Request Notice
Date</U>&rdquo; and the deemed surrender upon delivery by the beneficial owner of a number of global shares of Preferred Stock
for the same number of shares of Preferred Stock represented by a physical stock certificate, a &ldquo;<U>Preferred Stock Exchange</U>&rdquo;,
and such physical certificate(s), a &ldquo;<U>Preferred Stock Certificate</U>&rdquo;). Upon delivery of a Preferred Stock Certificate
Request Notice, the Corporation shall effect the Preferred Stock Exchange and shall issue and deliver to the beneficial owner a
Preferred Stock Certificate for such number of shares of Preferred Stock represented by its interest in such global certificates
in the name of the beneficial owner. Such Preferred Stock Certificate shall be dated the Original Issue Date and shall be executed
by an authorized signatory of the Corporation. In connection with a Preferred Stock Exchange, the Corporation agrees to deliver
the Preferred Stock Certificate to the Holder within two (2) Business Days of the delivery of a properly completed and executed
Preferred Stock Certificate Request Notice pursuant to the delivery instructions in the Preferred Stock Certificate Request Notice.
The Corporation covenants and agrees that, upon the date of delivery of the properly completed and executed Preferred Stock Certificate
Request Notice, the Holder shall be deemed to be the holder of the Preferred Stock Certificate and, notwithstanding anything to
the contrary set forth herein, the Preferred Stock Certificate shall be deemed for all purposes to represent all of the terms and
conditions of the Preferred Stock evidenced by such global Preferred Stock certificates and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
The public offering price of one share of common stock and one warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 3</U>. <U>Dividends</U>.
Except for stock dividends or distributions for which adjustments are to be made pursuant to Section 7, Holders shall be entitled
to receive, and the Corporation shall pay, dividends on shares of Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on
shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends shall be paid
on shares of Preferred Stock. The Corporation shall not pay any dividends on the Common Stock unless the Corporation simultaneously
complies with this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 4</U>. <U>Voting
Rights</U>. Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights.
However, as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the
Holders of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences
or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) amend its certificate of incorporation
or other charter documents in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized
shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 5</U>. <U>Liquidation</U>.
Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that
a holder of Common Stock would receive if the Preferred Stock were fully converted (disregarding for such purposes any conversion
limitations hereunder) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock. The Corporation
shall mail written notice of any such Liquidation, not less than 45 days prior to the payment date stated therein, to each Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 6</U>. <U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Conversions
at Option of Holder</U>. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the
Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations
set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders
shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <U>Annex A</U> (a &ldquo;<U>Notice
of Conversion</U>&rdquo;). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the
number of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent
to the conversion at issue and the date on which such conversion is to be effected, which date may not be prior to the date the
applicable Holder delivers by facsimile or e-mail such Notice of Conversion to the Corporation (such date, the &ldquo;<U>Conversion
Date</U>&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such
Notice of Conversion to the Corporation is deemed delivered hereunder. No ink-original Notice of Conversion shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. The
calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.
To effect conversions of shares of Preferred Stock, a Holder shall not be required to surrender the certificate(s) representing
the shares of Preferred Stock to the Corporation unless all of the shares of Preferred Stock represented thereby are so converted,
in which case such Holder shall deliver the certificate representing such shares of Preferred Stock promptly following the Conversion
Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed in accordance with the terms hereof shall be canceled
and shall not be reissued. Notwithstanding the foregoing in this Section 6(a), a holder whose interest in the Preferred Stock is
a beneficial interest in certificate(s) representing the Preferred Stock held in book-entry form through DTC (or another established
clearing corporation performing similar functions), shall effect conversions made pursuant to this Section 6(a) by delivering to
DTC (or such other clearing corporation, as applicable) the appropriate instruction form for conversion, complying with the procedures
to effect conversions that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder&rsquo;s
right to elect to receive Preferred Stock in certificated form pursuant to Section 2, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Conversion
Price</U>. The conversion price for the Preferred Stock shall equal $_____<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>,
subject to adjustment herein (the &ldquo;<U>Conversion Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>2</SUP></FONT>
The public offering price of one share of common stock and one warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">c) <U>Mechanics
of Conversion</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading
Days comprising the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;),
the Corporation shall deliver, or cause to be delivered, to the converting Holder (A) the number of Conversion Shares being acquired
upon the conversion of the Preferred Stock, which Conversion Shares shall be free of restrictive legends and trading restrictions,
and (B) a bank check in the amount of accrued and unpaid dividends, if any. The Corporation shall use its best efforts to deliver
the Conversion Shares required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust
Company or another established clearing corporation performing similar functions. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Corporation&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Conversion. Notwithstanding
the foregoing, with respect to any Notice(s) of Conversion delivered by 12:00 p.m. (New York City time) on the Original Issue Date,
the Corporation agrees to deliver the Conversion Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Original
Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii. <U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or
as directed by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to
the Corporation at any time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event
the Corporation shall promptly return to the Holder any original Preferred Stock certificate delivered to the Corporation and
the Holder shall promptly return to the Corporation the Conversion Shares issued to such Holder pursuant to the rescinded
Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv. <U>Obligation
Absolute; Partial Liquidated Damages</U>. The Corporation&rsquo;s obligation to issue and deliver the Conversion Shares upon
conversion of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action
or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any
judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or
termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any
violation or alleged violation of law by such Holder or any other person, and irrespective of any other circumstance which
might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion
Shares; <U>provided</U>, <U>however</U>, that such delivery shall not operate as a waiver by the Corporation of any such
action that the Corporation may have against such Holder. In the event a Holder shall elect to convert any or all of the
Stated Value of its Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone
associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless
an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Preferred
Stock of such Holder shall have been sought and obtained, and the Corporation posts a surety bond for the benefit of such
Holder in the amount of 150% of the Stated Value of Preferred Stock which is subject to the injunction, which bond shall
remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be
payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall issue
Conversion Shares and, if applicable, cash, upon a properly noticed conversion. If the Corporation fails to deliver to a
Holder such Conversion Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such conversion, the
Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value of
Preferred Stock being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day and
increasing to $200 per Trading Day on the sixth Trading Day after such damages begin to accrue) for each Trading Day after
the Share Delivery Date until such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall
limit a Holder&rsquo;s right to pursue actual damages for the Corporation&rsquo;s failure to deliver Conversion Shares within
the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such
rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v. <U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to
the Holder, if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share
Delivery Date pursuant to Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage
firm to purchase (in an open market transaction or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was
entitled to receive upon the conversion relating to such Share Delivery Date (a &ldquo;<U>Buy-In</U>&rdquo;), then the
Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder)
the amount, if any, by which (x) such Holder&rsquo;s total purchase price (including any brokerage commissions) for the
Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was
entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise
to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such Holder, either
reissue (if surrendered) the shares of Preferred Stock equal to the number of shares of Preferred Stock submitted for
conversion (in which case, such conversion shall be deemed rescinded) or deliver to such Holder the number of shares of
Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under Section
6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In
with respect to an attempted conversion of shares of Preferred Stock with respect to which the actual sale price of the
Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under
clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder
shall provide the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon
request of the Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to
pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Corporation&rsquo;s failure to timely deliver the Conversion Shares
upon conversion of the shares of Preferred Stock as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vi. <U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available out of
its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock as
herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holder
(and the other holders of the Preferred Stock), not less than such aggregate number of shares of the Common Stock as shall be
issuable (taking into account the adjustments and restrictions of Section 7) upon the conversion of the then outstanding
shares of Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon
issue, be duly authorized, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">vii. <U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred
Stock. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the
Corporation shall round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent
with the provisions of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from
converting fractional shares of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">viii. <U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge
to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such
Conversion Shares, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any
transfer involved in the issuance and delivery of any such Conversion Shares upon conversion in a name other than that of the
Holders of such shares of Preferred Stock and the Corporation shall not be required to issue or deliver such Conversion
Shares unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of
such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. The Corporation shall
pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees to the Depository Trust
Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery
of the Conversion Shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Beneficial
Ownership Limitation</U>. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the
right to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the
applicable Notice of Conversion, such Holder (together with such Holder&rsquo;s Affiliates, and any Persons acting as a group together
with such Holder or any of such Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by such Holder and its Affiliates and Attribution Parties shall include the number of
shares of Common Stock issuable upon conversion of the Preferred Stock with respect to which such determination is being made,
but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining, unconverted Stated
Value of Preferred Stock beneficially owned by such Holder or any of its Affiliates or Attribution Parties and (ii) exercise or
conversion of the unexercised or unconverted portion of any other securities of the Corporation subject to a limitation on conversion
or exercise analogous to the limitation contained herein (including, without limitation, the Preferred Stock) beneficially owned
by such Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of
this Section 6(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder. To the extent that the limitation contained in this Section 6(d) applies, the determination
of whether the Preferred Stock is convertible (in relation to other securities owned by such Holder together with any Affiliates
and Attribution Parties) and of how many shares of Preferred Stock are convertible shall be in the sole discretion of such Holder,
and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination of whether the shares of Preferred
Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates and Attribution Parties)
and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership Limitation. To ensure
compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers a Notice of
Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely
on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by
the Corporation or (iii) a more recent written notice by the Corporation or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request (which may be via email) of a Holder, the Corporation shall within
one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Corporation, including the Preferred Stock, by such Holder or its Affiliates or Attribution Parties since the date as of
which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any shares of Preferred Stock, 9.99%) of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion
of Preferred Stock held by the applicable Holder. A Holder, upon notice to the Corporation, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 6(d) applicable to its Preferred Stock provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon conversion of this Preferred Stock held by the Holder and the provisions of this Section 6(d) shall
continue to apply. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day
after such notice is delivered to the Corporation and shall only apply to such Holder and no other Holder. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(d)
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 7</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Stock Splits</U>. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common
Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion
of, or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the
Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event, and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section
7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Preferred
Stock (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or
sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right
to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by
way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Preferred Stock, then, in each such case, the Holder
shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Preferred Stock (without regard
to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to
the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall
be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one
or more related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Corporation or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more
than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other
Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion
of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon
such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section
6(d) on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring corporation
or of the Corporation, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred
Stock is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) on the
conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share
of Common Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock
following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation
or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions
and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&rsquo; right to
convert such preferred stock into Alternate Consideration. The Corporation shall cause any successor entity in a Fundamental Transaction
in which the Corporation is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Corporation under this Certificate of Designation in accordance with the provisions of this Section 7(d) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Preferred
Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard
to any limitations on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price
which applies the conversion price hereunder to such shares of capital stock (but taking into account the relative value of the
shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock and, such number
of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Preferred Stock
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designation referring
to the &ldquo;Corporation&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation
and shall assume all of the obligations of the Corporation under this Certificate of Designation with the same effect as if such
Successor Entity had been named as the Corporation herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice
to the Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation
shall promptly deliver to each Holder by facsimile or email a notice setting forth the Conversion Price after such adjustment and
setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any
sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common
Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be
filed at each office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered
by facsimile or email to each Holder at its last facsimile number or email address as it shall appear upon the stock books of the
Corporation, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required
to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of this
Preferred Stock (or any part hereof) during the 20-day period commencing on the date of such notice through the effective date
of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Conversion, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service, addressed to the Corporation, at the address set forth above Attention: <B>_________________</B>, facsimile
number _______________, e-mail address ____________, or such other facsimile number, e-mail address or address as the Corporation
may specify for such purposes by notice to the Holders delivered in accordance with this Section 8. Any and all notices or other
communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile,
e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e-mail address
or address of such Holder appearing on the books of the Corporation. Any notice or other communication or deliveries hereunder
shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or e-mail at the e-mail address set forth in this Section 8 prior to 5:30 p.m. (New York
City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is
required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Absolute
Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the
obligation of the Corporation, which is absolute and unconditional, to pay liquidated damages, and accrued dividends, as applicable,
on the shares of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Lost
or Mutilated Preferred Stock Certificate</U>. If a Holder&rsquo;s Preferred Stock certificate shall be mutilated, lost, stolen
or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated
certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of
Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of
such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware without regard to
the principles of conflict of laws thereof. All legal proceedings concerning the interpretation, enforcement and defense of the
transactions contemplated by this Certificate of Designation (whether brought against a party hereto or its respective Affiliates,
directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City
of New York, Borough of Manhattan (the &ldquo;<U>New York Courts</U>&rdquo;). The Corporation and each Holder hereby irrevocably
submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New
York Courts are improper or inconvenient venue for such proceeding. The Corporation and each Holder hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by applicable law. The Corporation and each Holder hereto hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or
the transactions contemplated hereby. If the Corporation or any Holder shall commence an action or proceeding to enforce any provisions
of this Certificate of Designation, then the prevailing party in such action or proceeding shall be reimbursed by the other party
for its attorneys&rsquo; fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action
or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Waiver</U>.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as
or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate
of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to
any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or
any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of
Designation on any other occasion. Any waiver by the Corporation or a Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Severability</U>.
If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable
to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates
the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
rate of interest permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Next
Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not
be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Status
of Converted or Redeemed Preferred Stock</U>. If any shares of Preferred Stock shall be converted, redeemed or reacquired by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated
as Series C Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RESOLVED, FURTHER, that the Chairman, the
president or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized
and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the
foregoing resolution and the provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the undersigned have
executed this Certificate this ___ day of _____ 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;&nbsp;&nbsp;Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;&nbsp;&nbsp;Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">(To
be Executed by the Registered Holder in order to Convert Shares of Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby elects to convert
the number of shares of Series C Convertible Preferred Stock indicated below into shares of common stock, par value $0.0001 per
share (the &ldquo;<U>Common Stock</U>&rdquo;), of Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;),
according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person
other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. No fee will be charged to
the Holders for any conversion, except for any such transfer taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date to Effect Conversion: _____________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Preferred Stock owned
        prior to Conversion: _______________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Preferred Stock to
        be Converted: ________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stated Value of shares of Preferred Stock
        to be Converted: ____________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Common Stock to be
        Issued: ___________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable Conversion Price:____________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of shares of Preferred Stock subsequent
        to Conversion: ________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address for Delivery: ______________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>or</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DWAC Instructions:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker no: _________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account no: ___________</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[HOLDER</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 36%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>4
<FILENAME>fs12018a1ex4-9_aytubio.htm
<DESCRIPTION>FORM OF WARRANT FOR OFFERING
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Aytu
BioScience, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Warrant Shares: _______</TD>
    <TD STYLE="width: 40%">Initial Exercise Date: __________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">CUSIP:__________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">ISIN:__________</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on
_____<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT> (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant
shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or
its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this Warrant, subject to a Holder&rsquo;s
right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this
sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &ldquo;Pink
Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest
of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
Insert the date that is the 5 year anniversary of the Initial Exercise Date; provided, however, that, if such date is not a Trading
Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of the day immediately following the first public announcement of the applicable Change of
Control, or, if the Change of Control is not publicly announced, the date the Change of Control is consummated, for pricing purposes
and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of
this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained
from the &ldquo;HVT&rdquo; function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately
following the earliest to occur of (A) the public disclosure of the applicable Change of Control, (B) the consummation of the applicable
Change of Control and (C) the date on which the Holder first became aware of the applicable Change of Control, (iii) the underlying
price per share used in such calculation shall be the greater of (a) the highest Weighted Average Price during the five (5) Trading
Days prior to the closing of the Change of Control and (b) the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Change of Control, (iv) a zero cost of borrow and (v) a 360
day annualization factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of
Control</U>&rdquo; means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification of
the Common Stock in which holders of the Company&rsquo;s voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities
with the authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation)
of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger in connection with
a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or indirectly, by the
Company in such acquisition is not greater than 50% of the Company&rsquo;s market capitalization as calculated on the date of the
consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority of the board of directors
of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction that, directly or indirectly,
results in the Company or the Successor Entity not having Common Stock or common stock, as applicable, registered under the 1934
Act and listed on a Trading Market shall be deemed a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock
Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Parent Entity</U>&rdquo;
of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity whose common stock
or equivalent equity security is quoted or listed on a Trading Market (or, if so elected by the Holder, any other market, exchange
or quotation system), or, if there is more than one such Person or such entity, the Person or such entity designated by the Holder
or in the absence of such designation, such Person or entity with the largest public market capitalization as of the date of consummation
of the Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-227243).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Successor
Entity</U>&rdquo; means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Change of Control or one or more Person or Persons (or, if so elected by the Holder, the Company
or the Parent Entity) with which such Change of Control shall have been entered into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, with a mailing address of 18 Lafayette Pl, Woodmere, NY 11598 and a facsimile number
of 646-536-3179, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant Agency
Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant Agent</U>&rdquo;
means _________ and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before close of business on the Termination Date by delivery to the Company of
a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the
Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)
Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding the foregoing
in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant
held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises
made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation,
as applicable), subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the
Warrant Agency Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of the Common Stock under this Warrant shall be <B>$______</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of
the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of
Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).</FONT> Notwithstanding anything herein to the contrary but without
limiting the rights of the Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; and without limiting the liquidated
damages provision in section 2(d)(i) and the Buy-In provision in Section 2(d)(iv)<FONT STYLE="color: #454545">, in the event</FONT>
there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, under no circumstance will the Company be required <FONT STYLE="color: #454545">to net cash
settle the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical
delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice
of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of
the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a
cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the
Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the
Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP
of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on
the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that
is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. If required to comply with Section 2(d)(i), the Company shall pay all Transfer Agent fees required for same-day processing
of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include
the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made,
but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common
Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes
of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder
that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify
or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission,
as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or
the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder,
the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since
the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section
2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and
the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in
this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Call
Provision</U>. Subject to the provisions of Section 2(e) and this Section 2(f), if, after the Initial Exercise Date, (i) the VWAP
for each of 30 consecutive Trading Days (the &ldquo;<U>Measurement Period</U>,&rdquo; which 30 consecutive Trading Day period shall
not have commenced until after the Initial Exercise Date) exceeds $____<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
(subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the Initial
Exercise Date), (ii) the average daily volume for such Measurement Period exceeds $600,000 per Trading Day and (iii) the Holder
is not in possession of any information that constitutes, or might constitute, material non-public information which was provided
by the Company, any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, then the Company
may, within 1 Trading Day of the end of such Measurement Period, call for cancellation of all or any portion of this Warrant for
which a Notice of Exercise has not yet been delivered (such right, a &ldquo;<U>Call</U>&rdquo;) for consideration equal to $0.001
per Warrant Share. To exercise this right, the Company must deliver to the Holder an irrevocable written notice (a &ldquo;<U>Call
Notice</U>&rdquo;), indicating therein the portion of unexercised portion of this Warrant to which such notice applies. If the
conditions set forth below for such Call are satisfied from the period from the date of the Call Notice through and including the
Call Date (as defined below), then any portion of this Warrant subject to such Call Notice for which a Notice of Exercise shall
not have been received by the Call Date will be cancelled at 6:30 p.m. (New York City time) on the tenth Trading Day after the
date the Call Notice is received by the Holder (such date and time, the &ldquo;<U>Call Date</U>&rdquo;). Any unexercised portion
of this Warrant to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company
covenants and agrees that it will honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice that are
tendered through 6:30 p.m. (New York City time) on the Call Date. The parties agree that any Notice of Exercise delivered following
a Call Notice which calls less than all of the Warrants shall first reduce to zero the number of Warrant Shares subject to such
Call Notice prior to reducing the remaining Warrant Shares available for purchase under this Warrant. For example, if (A) this
Warrant then permits the Holder to acquire 100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant Shares, and (C) prior to
6:30 p.m. (New York City time) on the Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x)
on the Call Date the right under this Warrant to acquire 25 Warrant Shares will be automatically cancelled, (y) the Company, in
the time and manner required under this Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the
exercises following receipt of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25
Warrant Shares (subject to adjustment as herein provided and subject to subsequent Call Notices). Subject again to the provisions
of this Section 2(f), the Company may deliver subsequent Call Notices for any portion of this Warrant for which the Holder shall
not have delivered a Notice of Exercise. Notwithstanding anything to the contrary set forth in this Warrant, the Company may not
deliver a Call Notice or require the cancellation of this Warrant (and any such Call Notice shall be void), unless, from the beginning
of the Measurement Period through the Call Date, (1) the Company shall have honored in accordance with the terms of this Warrant
all Notices of Exercise delivered by 6:30 p.m. (New York City time) on the Call Date, and (2) a registration statement shall be
effective as to all Warrant Shares and the prospectus thereunder available for use by the Company for the sale of all such Warrant
Shares to the Holder, and (3) the Common Stock shall be listed or quoted for trading on the Trading Market, and (4) there is a
sufficient number of authorized shares of Common Stock for issuance of all Warrant Shares, and (5) the issuance of all Warrant
Shares subject to a Call Notice shall not cause a breach of any provision of Section 2(e) herein. The Company&rsquo;s right to
call the Warrants under this Section 2(f) shall be exercised ratably among the Holders based on each Holder&rsquo;s initial purchase
of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>250% of the then Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this
Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall
be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.
Notwithstanding the foregoing, in the event of a Change of Control, at the request of the Holder delivered before the 30th day
after such Change of Control, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the
Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Change of Control), an amount
equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the effective date of such Change of Control,
payable in cash; provided, however, that, if the Change of Control is not within the Company&rsquo;s control, including not approved
by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as
of the date of consummation of such Change of Control, the same type or form of consideration (and in the same proportion), at
the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock
of the Company in connection with the Change of Control, whether that consideration be in the form of cash, stock or any combination
thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in
connection with the Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email
to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which
a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon
such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company
assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
notice. All Warrants issued on transfers or exchanges shall be dated the original Initial Exercise Date of this Warrant and shall
be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant
Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof
or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company
covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall
commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or
proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate Proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile or by e-mail, or sent by a nationally recognized
overnight courier service, addressed to the Company, at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, Attention:
Controller, facsimile number: (720) 437-6527, email address: ecreason@aytubio.com or such other facsimile number, email address
or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or
deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent
by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e-mail address or address
of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on
any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by
U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder or the beneficial owner of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o) <U>Warrant
Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued
subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the
Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>Aytu BioScience, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO:
Aytu BioScience, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full),
and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take
the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[&nbsp;&nbsp;&nbsp;]&nbsp;in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[&nbsp;&nbsp;&nbsp;]&nbsp;if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said
Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">____________________________________<U>&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of
Investing Entity</I>:__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory:____________________________________________________<U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _____________________________________________________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date:________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P></TD>
    <TD STYLE="width: 50%">______________________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Address:</TD>
    <TD>______________________________________</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone Number:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email Address:</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Please Print)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Signature: _____________________</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address: ______________________</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>5
<FILENAME>fs12018a1ex4-10_aytubio.htm
<DESCRIPTION>FORM OF REPRESENTATIVE'S WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; margin-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; margin-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; margin-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Aytu
BioScience, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: __________</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.
(New York City time) on _____<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and
purchase from Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock
under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of the day immediately following the first public announcement of the applicable Change of
Control, or, if the Change of Control is not publicly announced, the date the Change of Control is consummated, for pricing purposes
and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term
of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility
obtained from the &ldquo;HVT&rdquo; function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading
Day immediately following the earliest to occur of (A) the public disclosure of the applicable Change of Control, (B) the consummation
of the applicable Change of Control and (C) the date on which the Holder first became aware of the applicable Change of Control,
(iii) the underlying price per share used in such calculation shall be the greater of (a) the highest Weighted Average Price during
the five (5) Trading Days prior to the closing of the Change of Control and (b) the sum of the price per share being offered in
cash, if any, plus the value of any non-cash consideration, if any, being offered in such Change of Control, (iv) a zero cost
of borrow and (v) a 360 day annualization factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Insert the date that is the 5 year anniversary of the effectiveness date of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control</U>&rdquo; means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification
of the Common Stock in which holders of the Company&rsquo;s voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities
with the authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation)
of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger in connection with
a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or indirectly, by the
Company in such acquisition is not greater than 50% of the Company&rsquo;s market capitalization as calculated on the date of
the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority of the board of
directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction that, directly
or indirectly, results in the Company or the Successor Entity not having Common Stock or common stock, as applicable, registered
under the 1934 Act and listed on a Trading Market shall be deemed a Change of Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Parent
Entity</U>&rdquo; of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity
whose common stock or equivalent equity security is quoted or listed on a Trading Market (or, if so elected by the Holder, any
other market, exchange or quotation system), or, if there is more than one such Person or such entity, the Person or such entity
designated by the Holder or in the absence of such designation, such Person or entity with the largest public market capitalization
as of the date of consummation of the Change of Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-227243).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Successor
Entity</U>&rdquo; means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Change of Control or one or more Person or Persons (or, if so elected by the Holder, the Company
or the Parent Entity) with which such Change of Control shall have been entered into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market
or the New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, with a mailing address of 18 Lafayette Pl, Woodmere, NY 11598 and a facsimile number
of 646-536-3179, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before close of business on the Termination Date by delivery to
the Company of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the
&ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder
shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the
Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of
Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be $______<SUP>2</SUP>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo;
on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice
of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary but without limiting the rights of the Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
and without limiting the liquidated damages provision in section 2(d)(i) and the Buy-In provision in Section 2(d)(iv), in the
event there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, under no circumstance will the Company be required to net cash settle the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>2
</SUP>125% of the public offering price of the Class A Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and
otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or
its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the
Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and
(iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of
Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and
(ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share
Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10
per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for
each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the
date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue by (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. If required to comply with Section 2(d)(i), the Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;Attribution Parties&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect
to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d)
of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent
public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the
number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading
Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or,
upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Call Provision</U>. Subject to the provisions of Section 2(e) and this Section 2(f), if, after the Initial Exercise Date, (i)
the VWAP for each of 30 consecutive Trading Days (the &ldquo;<U>Measurement Period</U>,&rdquo; which 30 consecutive Trading Day
period shall not have commenced until after the Initial Exercise Date) exceeds $____<SUP>3</SUP> (subject to adjustment for
forward and reverse stock splits, recapitalizations, stock dividends and the like after the Initial Exercise Date), (ii) the average
daily volume for such Measurement Period exceeds $600,000 per Trading Day and (iii) the Holder is not in possession of any information
that constitutes, or might constitute, material non-public information which was provided by the Company, any of its Subsidiaries,
or any of their officers, directors, employees, agents or Affiliates, then the Company may, within 1 Trading Day of the end of
such Measurement Period, call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet
been delivered (such right, a &ldquo;<U>Call</U>&rdquo;) for consideration equal to $0.001 per Warrant Share. To exercise this
right, the Company must deliver to the Holder an irrevocable written notice (a &ldquo;<U>Call Notice</U>&rdquo;), indicating therein
the portion of unexercised portion of this Warrant to which such notice applies. If the conditions set forth below for such Call
are satisfied from the period from the date of the Call Notice through and including the Call Date (as defined below), then any
portion of this Warrant subject to such Call Notice for which a Notice of Exercise shall not have been received by the Call Date
will be cancelled at 6:30 p.m. (New York City time) on the tenth Trading Day after the date the Call Notice is received by the
Holder (such date and time, the &ldquo;<U>Call Date</U>&rdquo;). Any unexercised portion of this Warrant to which the Call Notice
does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company covenants and agrees that it will
honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice that are tendered through 6:30 p.m. (New
York City time) on the Call Date. The parties agree that any Notice of Exercise delivered following a Call Notice which calls
less than all of the Warrants shall first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing
the remaining Warrant Shares available for purchase under this Warrant. For example, if (A) this Warrant then permits the Holder
to acquire 100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant Shares, and (C) prior to 6:30 p.m. (New York City time)
on the Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x) on the Call Date the right
under this Warrant to acquire 25 Warrant Shares will be automatically cancelled, (y) the Company, in the time and manner required
under this Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the exercises following receipt
of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to
adjustment as herein provided and subject to subsequent Call Notices). Subject again to the provisions of this Section 2(f), the
Company may deliver subsequent Call Notices for any portion of this Warrant for which the Holder shall not have delivered a Notice
of Exercise. Notwithstanding anything to the contrary set forth in this Warrant, the Company may not deliver a Call Notice or
require the cancellation of this Warrant (and any such Call Notice shall be void), unless, from the beginning of the Measurement
Period through the Call Date, (1) the Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise
delivered by 6:30 p.m. (New York City time) on the Call Date, and (2) a registration statement shall be effective as to all Warrant
Shares and the prospectus thereunder available for use by the Company for the sale of all such Warrant Shares to the Holder, and
(3) the Common Stock shall be listed or quoted for trading on the Trading Market, and (4) there is a sufficient number of authorized
shares of Common Stock for issuance of all Warrant Shares, and (5) the issuance of all Warrant Shares subject to a Call Notice
shall not cause a breach of any provision of Section 2(e) herein. The Company&rsquo;s right to call the Warrants under this Section
2(f) shall be exercised ratably among the Holders based on each Holder&rsquo;s initial purchase of Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>3
</SUP>250% of the then Exercise Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a
record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time
of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the
Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, in the event of a Change of Control,
at the request of the Holder delivered before the 30th day after such Change of Control, the Company (or the Successor Entity)
shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after such request (or, if
later, on the effective date of the Change of Control), an amount equal to the Black Scholes Value of the remaining unexercised
portion of this Warrant on the effective date of such Change of Control, payable in cash; provided, however, that, if the Change
of Control is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder
shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Change of Control,
the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of
this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Change of Control,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are
given the choice to receive from among alternative forms of consideration in connection with the Change of Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
a) <U>Transferability</U>. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon
exercise of this Warrant shall be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging,
short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by
any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of the offering
pursuant to which this Warrant is being issued, except the transfer of any security:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 1in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                         operation of law or by reason of reorganization of the Company;</FONT></TD></TR>                                                                                                                         <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 1in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         any FINRA member firm participating in the offering and the officers and partners thereof,
                                         if all securities so transferred remain subject to the lock-up restriction in this Section
                                         4(a) for the remainder of the time period;</FONT></TD></TR>                                                                                                    <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 1in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                         the aggregate amount of securities of the Company held by the Holder or related person
                                         do not exceed 1% of the securities being offered;</FONT></TD></TR>                                                                                                           <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 1in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         is beneficially owned on a pro-rata basis by all equity owners of an investment fund,
                                         provided that no participating member manages or otherwise directs investments by the
                                         fund, and participating members in the aggregate do not own more than 10% of the equity
                                         in the fund; or</FONT></TD></TR>                                                                         <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-bottom: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 1in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.3in; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify; padding-top: 0; padding-right: 0; padding-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         exercise or conversion of any security, if all securities received remain subject to
                                         the lock-up restriction in this Section 4(a) for the remainder of the time period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the foregoing restriction, this Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares
without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be
divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.
Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the original Initial Exercise Date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate Proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by facsimile or by e-mail, or sent by a nationally
recognized overnight courier service, addressed to the Company, at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112,
Attention: Controller, facsimile number: (720) 437-6527, email address: ecreason@aytubio.com or such other facsimile number, email
address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall
be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City
time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice
is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information
regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>Aytu BioScience, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">TO:
Aytu BioScience, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]&nbsp; in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]&nbsp; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth
in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________<U>&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________&#9;<U>&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>:__________________________________&#9;<U>&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:____________________________________________________<U>&#9;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ______________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:_________________________________________________________________________</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0">______________________________________</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0">______________________________________</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Please
        Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
Number:</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0">______________________________________<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email
        Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0">______________________________________</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>fs12018a1ex5-1_aytubio.htm
<DESCRIPTION>OPINION OF DORSEY & WHITNEY LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[Letterhead of Dorsey &amp; Whitney LLP]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">September 25, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">Re:</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><U>Registration Statement on Form S-1 (File No. 333-227243)</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have acted as
counsel to Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with a Registration
Statement on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;) filed by the Company with the Securities and Exchange Commission
(the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), relating
to the offer and sale by the Company of up to an aggregate of $11,000,000 of (i) shares (the &ldquo;<U>Shares</U>&rdquo;) of the
Company&rsquo;s common stock, par value $0.0001 per share (&ldquo;Common Stock&rdquo;), (ii) shares (the &ldquo;<U>Preferred Shares</U>&rdquo;)
of the Company&rsquo;s Series C Convertible Preferred Stock, par value $0.0001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;)
and (iii) warrants (the &ldquo;<U>Offered Warrants</U>&rdquo;) to purchase shares of Common Stock (the shares of Common Stock issuable
upon exercise of the Offered Warrants, the &ldquo;<U>Offered Warrant Shares</U>&rdquo;). The Registration Statement also relates
to the offer and sale by the Company of a number of warrants as specified in the Registration Statement to be issued to the underwriter
(the &ldquo;<U>Underwriter Warrants</U>&rdquo; and, together with the Offered Warrants, the &ldquo;<U>Warrants</U>&rdquo;) and
which will be exercisable for shares of Common Stock (the shares of Common Stock issuable upon exercise of the Underwriter Warrants,
together with the Offered Warrant Shares, the &ldquo;<U>Warrant Shares</U>&rdquo;). Pursuant to the Certificate of Designation
establishing the powers, designations, preferences and rights of the Preferred Stock (the &ldquo;Certificate of Designation&rdquo;),
the Preferred Shares will be convertible into shares of Common Stock (the &ldquo;Conversion Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have examined
such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions
set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as
originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies.
We have also assumed the legal capacity for all purposes relevant hereto of all natural persons and, with respect to all parties
to agreements or instruments relevant hereto other than the Company, that such parties had the requisite power and authority (corporate
or otherwise) to execute, deliver and perform such agreements and instruments, that such agreements and instruments have been duly
authorized by all requisite action (corporate or otherwise), executed and delivered by such parties and that such agreements and
instruments are the valid, binding and enforceable obligations of such parties. As to questions of fact material to our opinions,
we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 25, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Page 2</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Based on the foregoing,
we are of the opinion that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Shares, when issued and delivered against payment therefor as described in the Registration
Statement, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Warrants, when issued and delivered against payment therefor as described in the Registration
Statement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their
terms.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The Warrant Shares, when issued upon exercise of the Warrants in accordance with the terms thereof
and the Company&rsquo;s Certificate of Incorporation (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;), including, without
limitation, the payment in full of the applicable consideration therefor, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Preferred Shares, when issued and delivered against payment therefor as described in the Registration
Statement, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Conversion Shares, when issued upon conversion of the Preferred Shares in accordance with the
Certificate of Designation and the Certificate of Incorporation, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our opinions are
subject to the following qualifications and exceptions:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Our opinions set forth in paragraph 2 above are subject to the effect of any applicable bankruptcy,
insolvency, reorganization, moratorium or similar law relating to or affecting creditors&rsquo; rights generally (including, without
limitation, fraudulent conveyance laws).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Our opinions set forth in paragraph 2 above are subject to the effect of general principles of
equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability
of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Our opinions set forth in paragraph 2 above are subject to limitations regarding the availability
of indemnification and contribution where such indemnification or contribution may be limited by applicable law or the application
of principles of public policy.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">For purposes of our opinions set forth above, we have assumed that the Warrants will be exercised
by the holders thereof immediately following the issuance thereof and that the Preferred Shares will be converted into Common Stock
by the holders thereof immediately following the issuance thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 25, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Page 3</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">We express no opinion as to the enforceability of (i) provisions that relate to choice of law,
forum selection or submission to jurisdiction (including, without limitation, any express or implied waiver of any objection to
venue in any court or of any objection that a court is an inconvenient forum) to the extent that the validity, binding effect or
enforceability of any such provision is to be determined by any court other than a state court of the State of New York, (ii) waivers
by the Company of any statutory or constitutional rights or remedies, (iii) terms which excuse any person or entity from liability
for, or require the Company to indemnify such person or entity against, such person&rsquo;s or entity&rsquo;s negligence or willful
misconduct or (iv) obligations to pay any prepayment premium, default interest rate, early termination fee or other form of liquidated
damages, if the payment of such premium, interest rate, fee or damages may be construed as unreasonable in relation to actual damages
or disproportionate to actual damages suffered as a result of such prepayment, default or termination.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">We draw your attention to the fact that, under certain circumstances, the enforceability of terms
to the effect that provisions may not be waived or modified except in writing may be limited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Our opinions expressed
above are limited to the laws of the State of New York and the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We hereby consent
to the filing of this opinion as an exhibit to the Registration Statement, and to the reference to our firm under the heading &ldquo;Legal
Matters&rdquo; in the prospectus constituting part of the Registration Statement. In giving this consent, we do not admit that
we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations
of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 43%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>/s/ Dorsey &amp; Whitney LLP</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 3.5in">NST/AE/BRR</TD><TD></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>fs12018a1ex23-1_aytubio.htm
<DESCRIPTION>CONSENT OF EKS&H LLLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We hereby consent to the
inclusion in this Registration Statement (No. 333-227243) on Form S-1 and related prospectus of Aytu BioScience, Inc. (the &ldquo;Company&rdquo;)
of our report dated September 6, 2018, with respect to the consolidated balance sheets of the Company as of June 30, 2018 and 2017,
and the related consolidated statements of operations, stockholders&rsquo; deficit, and cash flows for the years then ended. We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement and prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our report dated September 6, 2018 contains
an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial
doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements.
The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">/s/ EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">September 25, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ +$# 2(  A$! Q$!_\0
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MDBE+B-5:X*&M6VFD=(?,>-G<98(5?:?+5RC2)A'*DG#JD:LNTA.<G_#RU/\
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M DDG<><GEFX.,NV68]2S,>YS_ G_ ,'Q)\I?^":X5R$DF_:J5HBY"$ ?L_\
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M:AJFGZ/)I]]H_B7PS%KZ6'B'29;NUBFBL/%6C//Y=FX_UZO@W\:?"7[1_P
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/]+_Y]?\ R/<?_'J* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0_ SD# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>#@X8'!]#C.#Z X)[4^WGMY^G?Y7%=72NKO975WZ*]WL]DR2BFET!P64'T+
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MX@L3BUU;P[K^G0W^EW*1LJ36\KV\L45U8W$45U974<UI=017$4B1_AU^W/\
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M%1>='V;(XY SU ;'UPP/X^N:/.3W_*@"6BHO.3W_ "H\Y/?\J ):*B\Y/?\
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M0V2A9-*U&'6-'EC1=/B>;^TCR#E0$^XHV-E<AL'H,\%3]TC( X'!('X<7_\
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MK_2;J'3M0-AK<.C3P2QR1Z<]S%<V2A8(UA,31C5_X);?M%_M5>$OVU/VG/\
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MEES(J0/+-,D$$:F2XFD9(T@AC5GFDD9\+&D,0:1Y6*A0I9B,$C^0+X<?L_\
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M_@G)_P %'O#_ ,>/^"=/QA^)?_!0#6?#R^%_@]XY;X"?%GQWKN@7>IZ!X_\
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MP_SQS52:Y*JQ7 (&1N!)Z@%0 06) )[8R*MD>@'3_P#4/IUK.D4O@%!D,!G
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M78*CEV6X.A2C2C0P^"IN%.+G4=3_ +/?#OPUX7\'?"KA/PSX/P<<'P[P;D6
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M"OAA-//]G-^MG[&_[&GP3_8=^#>G_!7X'Z9J\.A#6)?$_B;Q+XDO+'4?&7Q
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MZI?<MON_ ^Q_KJ_R0^BD!!S@YQ2]*8?U]X579593N ^;/)Z@@]"3U"G@@Y&
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MQS;C+"8/$>RKYUQD\-.E@L)*5XT,=0X/P5:I&5#VE2%7B',L7)X>I4HJ</\
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M (8?M>_ 'P%K?B+3?B-/;166C_%CP+X3TU]6O_AY\5Y=,TVXU+4GL]-L9_\
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M5E7BZC@U^A7[)?\ P47_ &3OVV)-3L?V>/BO8^*/$FC:9_;>K^"M3TV\\/\
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M\3=#^(.A:;<6ECK<%DMQ8:WX;U&Y@^TQ6'B'0=2@M-2TN>>,2"VFFADT^_\
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M=6%++ZU+$QS;$RSIX&I7PU'.Z<\OPT:?M:M?"-1P[O\ V)QB1SME8.,J6^0
MY7<Q'7KD*2,$;MR]N/SBU'_@D5_P3JU;5=4UO4OV8O!-YJ6LZMJ6M:G<S76O
MAKO5-8OKC4]1N75-45$>[OKJXG81A$5Y6VA0 !^CL+G<JL#DAMV,D@@/N.&Y
M" _(6QMW<9W$5-LZD8XR"<<\,1@^A;GGL.@[5^4X#.,TRQRJY3F>8Y;]9A25
M6>7XW%X)UZ:M*,:LL)BL-[2";<E&?/&,F[1O='[)F>19-G4*5/.LIRW-EA7-
MT(9G@<)CU0G*+ISE2CB\+B%"<U!1G4@H.JHQE+?W?X__ /@D/^P]^RM^T/\
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MUU/3+F2(DV<DL#6&I*LLVF7M]!$\@X;Q1^W[^R9X'^*OQA^#/C7XT^'O"'Q
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MO%XKO?!/B.'PBZK%+)#=_:1;/K<-E=-&EO%<7&@Q>6]Q%+=1VULLUQ!\"_\
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M(OS#\H?^"V_[%WPK^('[(/C_ /:!\->#M&\(?'/]GNUT;Q[X5\?^#+"W\/\
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MX_\ P_U7XK_ ?XP_"_0[RQT[6OB'\,?&W@G2=0U,3-IUGJ/B;PYJ.C6=W?"
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M)\1C<OQL:V*P]&E3PN(CC,NJXF>$JUJ>#E1J<LG^/?[0G[3/[/7QI_X+-?\
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M\-?LE_LL_L0_LU?$^U\$:!<^/?B7^U!X#\,_"[0K#X+>)O"[7=U;1:!;:/\
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MFED;7,<_X3KULVS/"8OC3$U\SI8F6!X>QN8XNEEF4XS'.51UJV;X;B*K7S3
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MU;]H_P ?3^-_A-X#^(>NZIJFF^%/AZ7UO5HO$?A/1-3E5?!&A?$CQ'XHUA]
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MO7GAK_A+;R."*TAU#Q#I?D7VD7&K);0>5+K%E8V&IWZLIU.ZO6AMVAZO3_\
M@DS^P/I'P+O_ -G&Q^ .A0?#'6M?T/Q1K]O#K?B:U\3^(/$?AQ)%T;5-8\9V
MNJ0^(9ELO/G%OIEO>6NC6_GN+7385++7W>'\0.%H\29=Q/BZ_%U=86C@Z&&X
M/PM/#8/(<A]GE?\ 9F(K86JLR6'Q6'HQ=7$X+!K*XU<3C,14GF&*LH\WYOB?
M#+C*7"N8\(X7#<#T)XC%XK%5N,JT\7B<]XA4LXCG%"CC(U,OJ8K!8RO.%'"9
MACY9I5P]##4%# X/E?)#G_\ @JZO]I?\$O?VF38L)E7X3^%]2#Q@MBSM/%7@
MK4;F;Y58;8[."69F(/EH [$)AAY[_P $RM8^%WQG_P""6O[//P+M?'7A6^UO
MQ3^RKJ_P\\1^&K+6M.NO$>G0"RU/P-XMDO/#WVI=4@30-2U*.UU":2"*U>:[
MMO+D\JYMG?\ 4?4OAWX0U?X?WOPNUK0[77/ 6I^#KCP%K'AK6FGU.QUCPE>:
M/)X?OM&U5KF1I]0MKS2'>RN7N)&EFC<EG\UBX^(OV;?^"5_[%/[*/QDN_CQ\
M"_AE?>$?B'<Z)KGABUOI/&/B75].TOPYXEDTZ36-&L+#4;Z?SK.>32+"2,:K
M-J4]O+:PRQ3JZ C\_P 'GV41X/QV0XN684,QP_$\^)\CQ.$H82MAZ^(>!EE_
MU7'1Q-6%?#1@HX;%*KAHU9.JIP2Y%=_IF-X=SV7&>6Y_A8936RS%\*PX6XAP
M^+Q>*P^*PU"&/_M"6*R[V%*=+'<_ML3A94J_U>,8.G4ES<[A'\2O^"+R?LI^
M&X/B_P#L*?MF?"#]GZW_ &J?@W\6?$UII,GQC^&WPYOM:\;: (]-TB_T/0/$
M7B_0[TZS=Z)K6F7.O:596NMRMK/A+Q-I>K>'[6[TBQO+M?N#]NKXX_\ !/K]
MDK6_AC\+_AQ^Q!^RA^TW^T1\6/&6B^%M%^!?A?P3\&_#VJV>E:U(;===U_6-
M.^$_C[^RDGN7AATW3=1TJS&J1"]O&O;*RL)[@_>7[6?_  31_8X_;8U.WU_X
M\_">SUCQK8V-MI-MX]\.:C>^&/&+:/9O(]OI&J:A8N;+7K*W,L@M8]=T[5'T
MY9)$TZ2R664/B_LI?\$K_P!B3]C#7%\8?!#X.VEEX[2"X@L_'/BO4KSQ5XCT
MJ"Y58[F/0S?,FCZ#+/'YD<]_H^DV6HW$$TMK->/:GR!]/F/%O"^;YGB>)L?B
M.,%C\93J8C'<*X?'8NEDF(SAX:G0J5:6=8?B"CB,+E.(K1^NRPM++8XVBE+"
M4K4:DDODLLX)XPR?*\/PK@,/P.\OP=:.&P7%^(RO"5L_H9'#&5*\:&(R/$\.
MXC XS.L/A)+ T,77S%X.K'DQ-1.I2@?EK_P5[\/>(?V7_CY_P3O_ ."@_A[X
M=K;?#C]GK6=+^'_Q3\(^#K+2X[3X?:'<SRS6NE:3'9/:6DUOJ&@^*/''AW1#
M;:79:-!JFC:=;--:G7K%$_:"7]NO]D"V^"G_  T)/^T=\*Q\(QHCZ^OBL>+=
M,,S6*1M.^DQZ%%<-XAF\5B4'2O\ A$HM)?Q,=;*Z.FD_VIBR/AW_  4U_:KM
M/V1O@KX=\9^.OV?+;X_? ;Q?XTL_A_\ '73KQ[>^MO"7@_78H9+;6KOPY?:7
MJ6FZ]I]Q/!>V?V;4&LX!JJZ/;0SK=WT##\X4_95_X-X=*AB_:&&I_!:3PQ%
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MQV-DJE>>'P<:-*E0HTZ:E>?+S_[%1_XPZ_9)4GD?LR_ (C: #C_A4WA7/'8
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M+:;HLVF70EU6TTZP^&\?@_4[RXA8(MK?66HC[9IZN[)(8HW?Y P+/AT/VJO
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M)'3 Y_PQ2U,DFE=)ZW>E^EO+7\;"MJWWM?SLK:][+1:;66VA$T4;'E>V,=L
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M5!UJ-*JZ&)IQE&GB*#JPFZ->G&I4C"M2Y*L%.:A-*<N:/RD&,@#H!UZXP?S
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MRH_S^G;_ #ZTVD]_*U];:6ZNUNRMZW#OYV;\[:*_>RVO=K74YKQ+X5\-^+M
MU3PSXKT'2/$GAW6K-[#6- UZPMM5TC5+%RI:VOM/O8YK6ZBW(L@26-]DB1RI
MMD1&'YP+_P $<?\ @FFOB$>)1^R1\-?MC1[#8E-8.C#&2)?[,.J>5N.X #.Q
M< ;,*%/ZA,NX<'&,X^OO3/+.>H[COG:3R.O< ?CZCBN[!9OG&6*JLKS3,LNC
M7Y?;QP6-Q6$C5Y(R@G..&Q%-2G&,G&$I13C%N,*B3:/(S'(<ES>=&>:Y-E69
MRPZ:H3S#+\'C)T8R<92ITY8FA5E&E.48RE3C-TY2BI2I.23>'X9\,>'/"6@Z
M3X:\*Z%I/AOP[H=I'8:/H.AZ?;:5I&EV40/EVMAIUG'#:VL"EF?RXHT!=W=M
MSLS'<\M,-@#D;>22 !CJ,]<C/KZFI%&!CZ9^N #^9&:,#D>O)ZUQ2;G)SFW.
M<I.4IS?-.4YW<YRE)RE*<FVYR<I2E)MN3O=^I"$:<(PA",(PA&$*<(J,(0@E
M&$(1C&$80A%*,(QC&,8I)1BDD1"&/ !4$#((.2#R,9Y[ < ^O-*((N/D7C:>
M,]5)([] 3WZC@Y'%28..2 <]OY?X]/3WHYQUY]?YG%*R::>J;UOJOZT7W+Y7
M^&C5^RO^MKC"@!)V@Y&"!GGYLCMVS_.D:&-F+%1DXSG/.,XYZX]<=>G:I>?7
MOZ=O3_Z](<]O3O\ I_\ 7HZW2L_YO2UD^O=W$M-$DEY*RUWVT]61"&,!2$P1
MC!&??KWQZ]Z/*0A@1D%\\$G'USZ$DGZU,.@_S_.BA*U_-M]M7_7_   M:VVB
MLO+2UEV5M%V6FQ#Y,>TAE7KR>>A()_,CD#@]Z=Y:C& !@^I[YSCGKWJ3&>O/
M^?\ /]:*+;:+166WNJUK+RZ66WXA9=ET_"[7W7=O5]V,6-4SMXS^/(Z4^@=!
MWHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *",@CU&*** &>
M6F,!1C.2.??OG/?K1Y:=<<_4^N?T[>E/HH 9L0Y!4$'KGZ8Q]#SD=R2>])Y:
M?W01D'G/&!QWZY]>Q(J2B@!GEI_=&,8QCZ8_ 8Z4GE1C'RCCZ_X\_C4E% #!
M&@.0H!Q@'T[_ .?RZ4GE)UVC.,9Y/&1QU[X'Y#TJ2B@!GEI_='Z]NG>E5 O0
M =>![G/_ .OU/)IU% #=BX P,#./;/7\Z0QJ?X1@YR,<$$DG@<9)/7KR2.:?
M10 SRTX&T<<CZ^N>N>.M*45NH!Z?ITIU% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444?UH **:6P3DC P?P)P<_T
MIOF+D_,,=,]\]_R[BBZ5KNU]O/R7F*_;7T[]O7R1)13"ZC^(9QP/<9SSW]*:
MTRC.&4D$XYR, #)./<]!VYH"ZWNN^_3OZ?TKLEHJDET"7S)& KJH!*@D$XY.
M>IYQTY!')%6!*I'WE^]@C/IPV.O((/Y<TVFFDT[OLG^.G3KV'KU4EY2C*+_\
M!DHRUZ:6=TU>Y+155;A<;G=0-^TDD  =N<]\_GBI?.0XPR\G&=PQU(..>Q_K
MD"AIKIL*Z]+6O=6M=77,GK&ZVYK7W5T2T5%YHW*,@ @G!Z\$9(^F1V[\U"UR
MBLP,B#: 2,KD>H(SD8Y'(YP:$FW9)WZ+J_1;_@/7I&;\HPE)^MHQ>G2^U]+W
M+=%5EN%*%]Z%>>=RX&/0CC(ZD'M]:8MTK=)$;D#"E6.3CN#W_J*.5ZZ/3?1Z
M?A^=MUW0FVDVXRLOB;A)*.VDFXV@]5I-Q>J[ERBH/.7 ^9<Y/4CGTQT]QQGI
M0LZ,N0RGUP1QQD9],_0<<XI6ZK5>6OWVVUT]= ^3T5WY+5W?;17U:TUVO:>B
MHQ(O&2 3^0_'ISCC\J:TR  AUQDC)/&1VZ^Q_+'6C7L_DM]_\GOTUVU&M=?3
MSW]+_P!;$U%1>:A (88X)[X!(YSZ=1]:C,^'P67!&>W4D*!G.>3T]20!Z$C[
MVW]=?R=_379IM7TONGK=:JV][J^FF^RZEFBH3*-I92,<XY!Y7K[?F>,&D68-
MQN0D*&X(SR?0'IU_+\S97>B6COI;UO;[@NO3UT5WLK[-];+6VNQ/14'F_?Y7
M SCIZ9'ZXZCI^--2<$#<R$G/0CJ.PY//Y]Z=KWMK:VVNZOT\K/YKN%_5>J:6
M]M6]$[M63=W=6O<LT5$)4+;=ZY(.!D9X(Y_'(_.HVF(8 %<9P3QUQGUXSQ_A
M0DWM_6^_;:VH76BWOJK*]UW26K7FE9)-MV3M9HJNTZJ#\ZYY)SCC&/?I]>:1
M;A?D)="".<$ Y/L3P/3&<]S19^K6Z6K7G9:V\[6!.[LDWTT3:O9-IM)I-)IM
M-II-2T33=FBH_,3!.X8'.3P,9]?8=_<'O2"5.3O4C.  ??!R>?4?2EKJ[.RO
MK;33SV_KR']_R3?RT3UT;MV1+14 F4YPRL>. 1QQSWR>Y'MR,]V"X&]QN4JH
MX/OGO^'ZT[/L_N=M;6=[6MJM=A7ZK5))MK5)/5-V^%-:J3LFM4W=%JBJ\DVP
MJ-R\L%YQSQT ZDY!/ Z9]*#.HZLHSZXXX)]?3U_*A*]K:WUTU\UMW6J[]+@W
M:][JUMTTM6DK-V3U:6G5J.[2=BBJB7(8$EE.#@]MN1D9Y^F>OY<U()D.,2+]
MWKQ@G YXSC[P/Y>M#33M_7]?\-OH'RDO)QDFNNJ:NM-;.SM[UK69/14?F*%R
M74YSM/ SCM^A_7TI0XQDL,'VX!Y...3C'Z=>M(+KNNJM?5M;KY=>P^BD!SR!
MQV/K_GWI:!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %(?KC'/_P"NEI/7WSC/3IT_3G\:/Z^?8"E(^W+$[AG&W[I)+[>O.6'9>=W3
M@]?.M ^+/PU\4>+O$W@/PYX^\&:]XT\'%F\5>%='\2Z5J/B+P[MF2WF;6M'M
MIWN]/\BX>.VN//B4VUR\=O<>7.ZH?0IU+%" Q:.6&1%X(9@ZXSR-JD9.XD!<
M$GG!'Y9?LU_\$R/"7[.W[5/C_P#:,TWXF^)?$B>('^(,OACP?>Z3'9?V"?B7
MK,FM:]_PD7B5;^>^\9IIQGFL?#Z7]M:/;V[+=:L=8U>"SU&'FK5,3"IAXX;#
MQQ%.K5MCJDZL8/ T5!M5J<'%NM+GY8NG%II-S]/C^(LPXMP6:\'87ASAG!Y[
ME699Y7P?&.88G.(996X8R".%G4HYM@L-*2>;5ZF+]G1="*G)P;:BG[T?U/9@
M(R3STX(Q_"QZD_ETSWXP*^)OVLOCGX_\#:K\)O@K\$+/2I/C=\?]?U70_"^M
M^(K4ZCX:^'GA?PWIR:KXP^(6O:9&\<VJ0:9:-'8Z5IH=%O=5N(XY2(D8U]JF
M(I$%4.Q0  A@2"%X+$Y).,'Z=Z_-+]M"6[^#?QM_9F_:[U33=2O?A9\+9?&_
MP^^,^I:7:76IW'@/P=\0[*S72OB%<:9I]O=W]WH^CZ_:PVGB"6VCS8:?=?;I
M&,4<B4L=+DPTI4IRLZV%A.M&;YZ>'JUH4\16BU=Q<<.ZDG-)N$7*I_R[O'SO
M$O,,?EG"&-Q>"QF)RZ'UW)*&;9K@^:GBLHX<Q?$&7X+B+-\/.-'$2PE; Y+6
MKUEC%1JO+J-3%9I"ESX"%:CD?$/X3?MD? SP-KWQC^&?[4/B;XY>+/ ^CWOB
MWQ/\)/BKX3\.+X0^(FDZ#:G5-8\.>&9M#M[;4_"&OWEG972^'[V*6Y$=T4M9
MH6%P)4^A;C]M_P#9_P!#^"?P:^/OC/Q4W@[X?_''3M#O/!U_J&GWNH_9[_6_
M"^I^*CH^HC28;N6*\M+;1M3TZ;RX7^T:I9FW@622[CKS_P".G[=W[.G@?X2Z
MGKW@CXJ> _C!X_\ &&B7VE?"3X8?"[Q+I?CSQE\2_'FNZ9<6OA/P_H?A[PQ<
MZCJ31:CJ-S:R:C?WEO:VVFZ:MQ>7DD7E;)/CSQ)\&;GX&_!;_@D/\"O&B6-]
MK'@?]IOX4:/XIM7>&_TW_A)7\$^/_$&L:?&\AF@OX-,UO5)K&UE1I4F^P":,
M*C #BKU)T*]2&7I8BC'!T:DY5*]7&4<+B:F/PN&PUI*K[1O&82KB*\X^T?/&
MA3JM0NW/\JS7/:_!F89OA_#O-J6;9;'ACAW$8NGF>;YKQID62\3YWX@\*\-Y
M)B)XR69XW,*5;/,@SO-\SS#+J&;2^NPR_"9[&AETHU'6_1'X/_M:_"/XWZMK
MW@[PG-XM\.>//#NC'Q-=>"/B-X+UOP)XGG\-7$JVD'B/3]*UV%&O]*6_,=K-
M/!(\L$Q"SPQJ0Y\7_8U_:E'BCP)\/]!^,?C2?4OB3\3OB;\<]!\%75YIIAM]
M8L_AWXMO8$T9+^UBCL8+S3]'\HVEK-B>[@B>12S1MFA\6W@M_P#@I;^RHJNL
M<E[^R_\ M1"ZY5;B^CMM8^'$D N,GSKJ.U<R-&'$D=NSY387^;Y#^&OAC4]3
M_P""?UC\4O!T?VGQM^SC^TM\3?CEX>ELXH)KVXT_P9\3]>_X3O0XY9&(\K6O
M UWK<%U%MF\QK>%TMYKBW@4W4Q.+A5K)QC6EA%C7)4J3I4ZU&G' 5H3]G*55
M1G2HUL1&/OOGG!M+WG%&-XTXNR[B7&86K7PV9XK@K!\=T,<L%A<3EN7Y]@,E
M_P"(?9W7Q,LCHXC$4\)FF%X?XAS:&$^K8G$T*6*RJK7I4ZBS#$8:G^S%Q\6O
M!*?%BW^"T6IO/\1IOA]<_$YM$@L[B6*R\&+KB>&X=4O[]4^QV;ZAK(NK;3;.
M:0W%^MC?2PIY=E*P_.1X?VA?CS^V7^V%\.?#?[2_Q"^$'@CX(O\  -?"^@>#
M?#_AC5K>X;XB_#4Z]K+WCZU93RQ1KJ]A->RMYHD4WTI8")X"/4?V&=33XS:M
M\=/VP%M9ET;X\>*[/P[\*GN[>YAOK+X*?"NPD\-^$1+#?QQW%I_PD&N?\)-X
MM>V>VMW5]:1+M9)XGD;YMT']F7X(_M*?\%"/^"@\/QC\)S>*V\%']E9O#Z0>
M(_$>@R::-=^#D::BCKX<U;2TN!>#3[<B.\%PQ-NTJ*J'YG7JSQE#!5*--U85
ML=)THK%UL$ZN$^K8Z5&4Z^'IRJ04XTX8F,%%J?-2C)I\M_2X@S;-.,<H\/,;
MA*'M<!Q3XFYL\JR[!\09QPI'-^$Z7#W%T\@JYCG.6PJXS_;:>6TN((PCAZ>'
MJPQN6X>=./U;VE3U;]J&3X]_LS?LAZ]+I_[1?C;QA\0M5^+GPKT>P^)NNZ/X
M=M-;\/Z#XR\;^&_#6HZ5IUG8VBZ=-;+;37<JW$\#S%[J12<(AJU\0OAK^V9\
M!_">O?%GP%^U5JOQHE\"Z;?>*?$'PK^+'@;PRNE^,O#V@6TNI:[I>C:[H,=C
M?>&]7FTRVGFTC529H7FB\N: ^< .<_;[^&WPZ^ ?["6E> / ]K'X2^'WA'XS
M?!.\M+?4=:OK^'2X+_XSZ)KFLW5WJ_B"^NKKR!=7E]=/)=WC10+B./RX8U1?
M3_V@OVZOV8] ^%7C73?!WQH^''Q/^(7C+PWKOA/X=?#;X<>*=.\=>-O&_BKQ
M)I=[HOA[2=(\/^&)]4U!TEU"\A?4I[E;/2=*M5EFN;NUC0LL5%0@\3'$8BIA
M/J^782K0MF-5SA5DL=*;CSRY\9.-2G0LJU";J>Y3Y7S-'A9Y3R3+<[XIP^>\
M59CPM6X:\-^#\9PY1P_B)G<<5EV:U\%QQB:];+Z%?&PJ\48JIF>$RC#*68Y3
MF]7-JCHY?/#)5Z>'?=?$[]K33])_8@O/VI/ 5NUY?^-?AIH6H?"/2981<S:G
M\0_B8;'P_P##C06MF ^VR2^-==TFVDM% >Z@@G"@*Q(R_P!B#XH?$S5=/^,?
MP$^/^OGQ'\>/V</B''X;\4>(7@MX+CQOX#\<:)9>//A;X]6WM8X[=+?4](U/
M4O##*NZ:/4O"=Y'<X<JTOPU/\)_BWKEK^PU^P_X(\7^'?!WCK]F?X2^'?VC/
MBMXE\1>"HOB5X8T+QKHJCP=\,_#FH^$+?Q1X;%WJ/]JZMXS\0Z>CZPMO:-HE
MAJ<<%XZV13N]2T+X^_LK?M?_  +_ &@?V@/C-X*^*OAC]H&6P_8T\9ZEX-^$
MVI_"JU\/7^MW>L^-O@5J^OV</CCQI9Z]=)X^&J^#+/7KB#23I5IXJFT^:XND
MN[!(\*>+Q;Q5'%U85Z=#"O"X'&J$J<,)&I7H4JN.Q$X.49REA,9B,!13C2<8
M^WKQB^5594XH<:\72XEX?XFS# <0T^&^'\/PMP9Q;BZ4LNH<*T<?Q!EF5KC;
M,LTRQYI1Q\LRX6XOS?@G#T:]/)\1A<LH8GB/ SQ$(/&RP7[-><N2#O97)(.W
M  &W@],YR23QT.!S7YV_MV?%GXV:>WPQ^"?[,>KIHOQH\>S^+_'#WQM(+R33
MO OPRT"\US4$>SGBD66#Q1K@TSPN@39.[74GE,"2P]0\:_##]L;6/BE>>(O!
M/[6OAGP;\+YM<TNXM?AC=?L\>%O$VH66C6<=I%K&C_\ ";WGB.UU&\GU*Y@O
MI%U&:RA-E]L1(/-6!-WQ;X4T;]H7]IS]I?X__M(?L^_''P#\*_"'@[5C^S3X
M.OO%WP?/Q=BUFS^'-T-0\=ZKH,I\?>$?^$?$WBZZ;2]1S:WKZC-IH1)4@AD5
M^S,:E>I2^J1H8NE4Q%94Y5,/7PT:ZPU).IBL30E[=1A&G!483E)TZJC7O3A*
M;:7VWB'Q#GF-RZ7"F!X>XVRO->(<[_L;#XC*L7D>$SC%</Y;A:N=<2<0</8W
M#\1*C@(X3 X7+\)3KYUB<HQ4:F<>RHX:O6G*G#] _A;^T=X.\;_LQZ)^TCJ=
MPVF^%HOAU-XW\8RQQ_;+C0G\-:?/-XSLFM;0%Y;O1[_3]2@DM(P)1)%Y.SS
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MNROK;57UT('ARI*[0>I.PL03]Y@6?TZ]SC@@\U3GM?.699)$>-X]KQB,;7
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M=PZCIERVGZJEY:"YT[4;>UU&PG,):TO+:WN;<131I(OR5^T'^V=\-/@-XG^
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M^O6N@27TEO=:M8:;,D=VD*LUO--%$1S_ ,'_ -F[P#\/](^&^JZQX*^'5_\
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M&A:A:A@RP7FDZ@;BRN((VCB>&&=7CADB1XA&T:;>>\+_  @^&?@JRTNW\&>
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M^MA\#@J5/#X>OB,11]G7A'"PC!?F#\5_#VA>$OCO_P %!='\+Z+I6@:1KO\
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M:SKHO+R;3+2>*U7Q+;1JO^DQ?9V^C?AI>)!^T3\6/@W\<OV;_@[X.^-/C?\
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M[7H9)WN?$4G@;2I=$\+FZ22:6VB_LG3YY+>-+:%5E1V><RRG<. ?]F'X#O\
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M)VJX2*6U*IKT=ZCD_P 7^!TT/AE_B_06BBBN,W"BBB@ HHHH **** "BBB@
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M[9@MOXC\;W\;:;;W*B273M.74=82-FL@:_IGZ/E3*LCR;COC7-IK#X7+(8#
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M?X_\*W?B>?Q1H$=V^O>'8/#\.JMJSZUH@L;UM6TP6GV_3TL;V2]M8D@D">O
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MK>"WB54@@MX8XXH(D54BA1(U&T#'P#^PX<?&#_@H,02O_&5VW*#YN?AYX3R
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MI3A4G[..$]V7)"%5U%[.^LCR<!XQYYF>)P^6X+)LBJ8_-<ZX%R_*,95S7B;
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MS#\</%>I+N\810QW#67P8^(6MZE=*L?B^T@A@TWX7ZU<E?\ A,8#!X.NI/\
MA+8M$C\29^+?AOA,WR__ (B3P-['&X/,,//,<UP>#Y9PKQ5*<ZV=X*A0C[2F
MXTTUG&#<*==588BO2I2JTL539P1Q=B\%BUP?Q0YX?'86;P^ Q6)=HRC%J$,-
M7FVE*4H7EA*R;A5I<D:DE.*1X1^P[I'VO_@ZO_:>E8972?B+^U[JR_[!NOAO
MX9TQG/< C7".<#+G!R0#_8_^T]^T/X$_9,^ /Q3_ &C?B=%KUQX!^$'A2^\7
M^)X/#&F'6-=GT^Q"JT6GV'FPH[RRO&CRS3Q06Z%KB:1(XV8_R+?\$_K5)_\
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MOAF_DT;QAX)UMK8>7+=:)J<!EL;^-8H]:T&\T?7;:*.VU&)!_'!_P<*?%_\
MX*-^//">C>$?VM?V:OAS\)_V=?"'[5_CA/V??BEX8\1_VIXF^(-I8Z;XYTKP
M<OB#0QJM^FF#6O )?7KQTMX&2]B$#+$2$/Z:_P#!I7>W\G[%?[4EC--))IMA
M^V#?W%C;EODAN+[X%?!N346B5N$$YBM990H4O('=AND8GG?^#MR\6']E_P#9
M$L-V&N_VDM<G"8Y*VWPL\7_/R1C89D[<9^IKPN#\KPG"WCB^&L/@L%C<-'/J
MF$P&,QT*E;&992^HXG'TZV!G&M2IPQL(5WA)8BI3JJ5*,)\CJ\TI>GQ#C,1G
M/AM5S6K6JX:M6R:%?$4,,Z<:.(YZE*G.G44J;?LI>Q<W&'*TZDXJ2M%K\*/^
M"&GQ/_X*$?"GQY^T=J__  3[_9V^'O[0?BO4_ _@_3OB+IWQ \2'PY;^%]+B
MUB\N] NM)D74=/6_N-1O?M$5U;-)($B0R[5*[A_?OX)^.GB3X<_L=>'OV@_V
MUK;PU\$?%_@_X.6GQ!_:)TZWO$F\.> M<L=(:^\4:1I5RDUS_:9@N\:;HMG:
M3W5[K%[-9V-@D][=PQ/_ "G?\&C>FJWBC]N+5RH,L>G?"#2UD.0?+D_MN]*9
M!/<*0<'MDXZ_8'_!UU\:]>\'_L@? ?X%:'?3V%G\=OC3=:OXR^R3RQ/JGA3X
M3Z&NJIH-XJNL4VFWGB;Q%X>UF6&=6$EWX?L2N KJW;XCX&/&7B]AN$*67X#
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MW:WN@>._@7IOBF[TJUU&WN((]?\ !OBZUM[35C:PSLPN1I>I7-D7*.5A8*2
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MK6= \7ZEX8LKZ'6)I=*NK/PYXI@TBZUC21J,\%W;Z;/:R32R!TD?\K_V;/\
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MW^F&#Q!X%\8V$3F&:*[TZ[:2RO[9OLFL:7<PW]G(C,5B_&G_ (.M? ^DZO\
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M0/!9ZE, UQ"4)0^B?&']D7X0?%?7/#GBRZ@\5^!/&GA?0AX4TGQE\*?%6H>
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M/]U-_+\5JOO_ ."<CHZCR(!DAC"JMDXQE/E!_P"!;?H< ]:ZB*(%?F!]% X
M XR.^&P3SWSZ5S6D7-FT48C=Y!L4%A:WB(2I!X>6WC4J<<%&8YQ@$=>G5XF&
M7+'@ *(I@5 P22"@.6 P,Y!].*]I[R_Q-_B_/Y7...R6K^7]?<8]X1'JWA?:
M<(/&O@Q6R!P3XGT52<\?+M"CT'+8/?ZU5@1[\DCN,DFOD?59;<7V@%9%5H_%
M/A"8(Y*.1'XET5]R^9M# \(5#;MV-J$8S]:1C]Y(=N,,>>A^ZOZ-R?R/>O.S
M&*YL++JJ=73_ +B:=?._ZG3AY74UV<7]Z_X!-1117GG0%%%% !1110 4444
M%%%% !1110 4444 %(1D$'H01^?%+10!5DA3:QQ\V&. S#)4,3@# )Z]0>,C
MD$@_F9_P4/\ V#O#7[4_P#^/FE>$=/33_BUXTT#P?XBT6XS'%I^N^.?A'-JF
MI^!9=06&UDN4U*:RU36?"DEY#*LD^F:LEK<$QV]NT7Z<R@;'(QG8W7_=(_7\
M?\*;Q EB>"26ST(Z\@CG*Y!YSCMTS6=6G&M0Q&&FVJ.*H5</7C&T7.G4<9--
MI?9J1A5BVKJK"%1.,XJ1Y.=Y/@<_RC,LDS*BJ^ S7!8C+L93:CS2PV*HNA5<
M)M.5.K3@J52C4A:<*U&D[\J=_P +_P#@W^\0V+_L5>)OAU=6CZ1XX^%OQQ^(
M&@^/?#U]$;76-$UK4)[>]BM-5M&VSV]VL(D@82DL3"Q7*@,?W,)522 !D-@C
ME@VWU)&>", EL'E5SP?SX\4?LN^(O@S^TKJ_[67[-=I://\ $^RLM+_:=^!Z
M20Z9I?Q5MK!BFD_$[P7*5CL-)^+?AU79-06^>*Q\;:.'M+BY@U6VLS=_H#!,
MT]I;7)CFM_.BBE,=Q'Y4\32*K,EQ$V7CEB8^7,I)VE7S[\N6X>>%P=+"5/?E
MA8.A&HE:-6E#G5.<5;W9.ER0G&W-SQDK-2BSYW@+*\7PWPSEO"V80O6X:H+*
ML/C*<''#YGEE"52GEN8T&ERPJ5<+.E1QF'DHU:&+H8AS@Z%2E4E_"[_P=+ZW
MYG_!07]@[12P<:'\(+37BG4?\3_]H/3+8,X!W-YO_"*$9')*,5_BQ_=A)&CL
MQ(!X !).-NT-@#/.22>03U]@?XUO^"_G_!.G]NS]L/\ ;\^%'Q=_9Q^ >M_$
M3X9_"_\ 9I^$WARZ\1V>O^&=*AD\9V/QL^+OC#Q%H^F6FKZK:7M]=Z9H=[X7
MGNA!;!2;RWB1Y) 43^QZWGEDMK9Y8RDKVL+R0L0725K=&DB8C@%)"Z-C(+ U
M^M\95L!6X&\)\/AL;A<3BL%DF=1S'#4<12JU\#B,1FLZ]..+I0E*>'JU:#C4
M2JJ,I7=]5IT9'2Q-/B+C*M7P]:E0Q&-RU86M4IN%/$TZ6"5*I*C.7NU*:JS4
M9->XG:3=CXA_X*#_ + ?P/\ ^"BO[/>N_ CXQ:<=.O%$NM_##XH:38V=SXS^
M$?CV*W*:?XM\+SW<3QR02 +8^*-!>>&R\3Z#+=Z;<R07#6.HV/\ EV?M:_LH
M?&?]C'XZ>-?V</C]X>.A>./"-Q%+:ZMI;7J^'?&_AN:9[GP[\0? 6N-;VEQ?
MZ%K$$"WEA?0"WO=#U6&\TS48=)U?3+R _P"OP"7SP #C ]P. &[,/IV[YQ7Y
M-_\ !6S_ ()9?#G_ (*7_ 5O#KR:3X,_:(^'D5]JGP&^+EQ;N!H6K3M#<:AX
M(\7O:037FH_#GQ>+9+?5K2..:YT/4UL?$VD(UW836.H^MX2^)];@G'O*,XE.
MOPKF->V)C\53*:]=QI5,=@Z<I2I>PJTI>RS3#SA*.(HVQ%*$*U.HZGF\=\&0
MXCP;QN!2H9]@*<I8.LH\KQ$(7G]5J2BHS]I[2G"6%JMMT9J+A)<Z3_DV_P"#
M;WX@^./BY_P6"\4_$WXG>)]6\<_$3QE^S-\9M9\6^,_$$L5QKGB35K75/@KH
M":GK=S!%$M[JTFFZ;80:AJ,D?VO4[F"74+Z6YO;F>XD_HD_X.&_^"A7Q?_8:
M_91\$>'OV>]=?P;\7OVB_&]]X!L?B):003:Q\/\ P7H^B7FM>+]?\+>>72T\
M77EM';:+H6K-:70T.XU*36+:-;^RLWK\I?\ @@5_P2]_;R_9!_;ZMOC'^T?\
M =6^&OP\O?V>/C!X.;7[CQ)X7UF&V\3:IXJ^&\^EZ1<0:-JM]=POJ4&B:G<:
M=/+$L%Q;6I<2@M&C?MS_ ,%R?^":OBS_ (*/?LKZ)H'PFO=)L?CO\%O&)^(O
MPOLM=O%T[1?%PFTRZTCQ3X'OM0:*5-/FU[2+F0Z)?S[+.UURTT]]0ECLVGD3
MZ7C/-.#,3XT</8G&8K+<;PIA<%P_A:U;#2P];+:4</AL93PT:E.@I894,+CJ
MN#GB\-"'L_J\9TY4W!3@>;P]A.(</X?9I1I4L3A,_JU,SJTX8KVKQ3J3JQYY
MJ5:4ZDI5%"2I2O*[Y9PD[P9_)W_P0 _8/^$7_!1#]KCXQ?$;]KF'4OC=H7P8
M\+:)XXU/PW\0==U7Q7-\4_'_ (NUBXM++4?B=K.MS:AKOB[1]*MK.>^FTC4M
M7GM-9U&:)-7AU#3XVLF^K?\ @ZG\*>!_AW\0OV&/AK\./"_A'P#X1\,_"?XG
MS:1X$\$Z%I'A?PSH6GW?BO1XHFTOPWH-I8:7IEK++:3[!;6<,4C0S[@Q60'X
M1_85^''_  6L_P"":_[0VM^)_@-^PY\<+_Q=XMT)O GC/P5XU^$?B7Q'\./&
M.C07_P!LL;R;6M U?2;-6T:_\V\TOQ-::XUI!!-<BXBNK:1E7] _^"EO_!)/
M_@J_^U=\)/#G[=_QP.B_%G]K&>[.A^*/V2/@Q9L-*^#7P(-M'+X+T+X7V-S?
M:G<^)_&>D^([C5]9^(]C:ZUJMYJ$^O6]QIMQ?-I=[Y/W^98S#X3Q:R3B/,>,
M\B7"7U)X'(LNPV=X7$JCC\9EE/"UJ:RO"2_L_+\+4Q*J8F6;8E0I.-2CAI5H
M55*,/E</A,;B> ,RRJCD.://9U56S&OB\#4IUJW+C7B'56+Q%2<\9:C:,</1
MBJTI+GMRK3]!?^#2ZW5/V'/VG+LH=\_[:.O6^&SD"T^ 7P(50"<$D&>0\\DM
M@D@BO(O^#N6=Q\'_ -B2Q ;R9?C)\1[LMA@BR6_P[O8XU. %+[;AV53EN#\I
M5>.-_P"#<IO^"C'[,&N>,/V:_&O[ WQ5TO\ 9[^*WQ6@^)WB7XU_$=7^% ^$
MNJQ>!['PIXC:+1_$]KYGQ#AU>#PEX,@T_1/#[VVHZ5>_VG-,L]I/";?]C/\
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M';J^FLOAQH'Q#TJSM]?U#PCH"0:;<ZG8MJ$$=K:Q6=K!Y!\1/V%/V;OV9O\
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M;SH5U#Q-XKT?X*:[KE^T#SS;7N]2O[NY*M+++&68-/(<NWY^?"C]@#]EQO\
M@@QXG_;,U7X>?V]^U?9_"/XB_&SP)^T7JFKZI=?&/X.^)_AM\3O%]Q\/=(^"
MGC=KU=;^&'@[PO-IPF@\+^$KK3M*U2XO-0N-<MM5N;DL/Z5/!G_!/CX,^!_&
M?[/GCRP\3_%+4_$/[-W[)^H?L=^!YM9\1>')[?5?A9J5AX4TR76/%\-EX.T\
MZKX]AM?"&E"'7=-?1M-WR7LEQH5PTZ[)=!_X)_?!;P[^PU=?\$^-/USXCO\
M Z]^'/B[X97&MW?B'1IOB<- \9:YJVO:K=1^(AX9CT%=6CO=:NTLKH^$V@@M
MT@CDM9GC,K\RXDI4*N%>#EC,+0CF&1U<7"G2IKVN!R['9Q7K4'245*K2<,=A
MU&A*48U:=.5*M-J,6:/)*M2GB/;_ %>M6GALTAAJDJM5RIXG'8/+\/&JY<RC
M&=\+5=245+E=3GI1;<T_QV_:*_9Z^)OQM^,/PH_:9^*'[%OPQ_X*T?!?Q#^Q
M3\&O#>J?L\>)?BOX$T3XI_LQ>.-5LKWQ%XZ^*?@#X2_&">V^%OC'4OC-975J
M;?Q=:ZYX6^*T6H>'%T/0]3LM'TX3:S^I/_!*GQ7\"_$7[$OPZTC]G?4?VAW^
M''PTU[XG?"6/P1^U?=O<_M"?!/Q%X#\>^(](\2? 3XB&:6^FLW^#-Z#X#\)Z
M/_;GB.#0O!.D^'-$L-?U72[#3[A(/B#_ ,$P?AEXA\;>$/BG\*?CI^TO^R]\
M6_#OP<\(? /Q'\2O@!XU\$:-KOQ8^%_@011>$M*^*^D^-OAOXX\(^*=<\+6[
M:DGA3Q?#X;TSQ!X>;5KZ"RO/[,*::/J7]F+]EWX6_LD?!O0?@G\(+;6E\/:5
M?:WX@USQ+XPUR\\6_$+XB^._%VI7&N>//B;\2?&&HG[?XL^(/CWQ#>WVO^*-
M>N8X4N=1NVBL;/3M*M['3;3FS;-<'CLKI8>G4FZU"OAGA:,<-7PM&EAZ$\:N
M7$T93JX&K6ITL1%8+$X!4,36C4KQS15YT:%0Z\OP&*PV+J3JQIN-2C6]K6G7
MA6;JUJ.&C-T)6^M0IU:E)2KT:_-2A.G3=!PI594U_,;^R3\-_'WP6_X)U?L0
M_P#!4;]GGP[J'B#XK_LNQ_M'>$?VC/AYH%O++J_[17[$6H?M2?&#6OB-X!6U
ML46^USQS\*]3#?%;X0QSG5%M-;L?$>F6>AZC?^*$,#M<UFX_:3_8'_X.*O&'
M[,NM/X\LOBYX[?QW\-];\&7SR2>)?!^J?!?X=>)-2;3;NU>69+P^%[?6]/U6
MP,:7&G7UOJ.DWMNMQ;7$8_ID_98_97^'7[(?P \&_LV_#.^\3:Y\/?!$GC5]
M.G^(E_IOB/Q#>IX[\9^(_'&N6VL7VGZ+H&G7UN-5\4ZE:6<::3"R:4+>TN6N
MY$DN)O-?V/?^"?/[/_[#6G?&S0?@+;^);#PO\=OBCK'Q7\2^%/$VH:3K/AWP
M]J^NPS0W?ASP3I]IH.D?V1X+19YTM=!U&;63:02&RM[N.PBAM8_4GQ3@7/-Z
M_L*];$O-<#B<IJRHTZ4<1E>'SVGF[P>.<IRK8>OAO95/J4X>TC&&+JX6;=)0
M</+P_#N,I1RBFJV'IT\-@\73QT;SFECJV5U,!&OA84E&C4HU93ISQ=.2C*<Z
M*JT[33<_3OV4?%/@'QM^S'^S]XL^%>H:)J_P[UKX,_#NX\'7OAM[=]'ET9/"
MFF6T<%@MG%# L=K+!);2Q0V\)@GMY(6AC=&C3\T?V&6LO$__  5[_P""V/Q
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MG_@M;X0^"/B_X<6_P]^&'[4/[/\ \:9/V?\ Q;HFJZKI_P"V?\<_AO\ L_\
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M ++7P\_:$/C/4KOX%:7)IFK1ZIXT\4^';CP]'I5O'-;/IUE%=Q79N#<R/$Z
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M>W6M>.-1N->U*UU_7KB\UQK"VU74M5N[[Y]UW_@D5\*=/\=?$3QI^SO^TO\
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MT86G44H12<VW=;1T:U9^XXE3(7/SG(*E7#="3G*YP,<'T],@5QOC_P ::/\
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M?#SX3:3X@\0ZG<>(=8\-Z@MSINDV_A/P;IXL+344OK7#\-_MI?M)?L:>#?\
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ME<Z]JFJ>&KF.]%K=0]IXW^.'Q#_X);_M%?\ !03X-_#OXE_%OXS_  B^&/\
MP1U\2?\ !1OX7>$_VCOB)XH^,^I>"/CK\/\ X@?$3X8P^&M+\9^);FZ\;/\
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MO),_Q(A^&_BG4)-&NM9U.YFF\4>'GMK37E5VE$GUI\2/V>?B5\.OVE_V5/\
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M?QK=K8?!_P"!_P"W]_P4(\"?%7Q3LEDL/!NF_M&?%CXX^"/#GBS6V@CFDM-
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M:F#QM3 QC%P51?A_^PQX+_X)C^%/V[;_ ,*?\$_O@?HNOWGA;]EK5_'?CO\
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M?5?#>EZ'XKU+Q%XLO+5IH= \.^'KG4]5DL;.]L))XO$_P*_89O?VI_@IJ?\
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M<Z)X^\-:MX9\0>%/B%X#UBVT^35DTKQ=\/?$=AIWBS0;^_T]/MFCV]_ID/\
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MG0Q=*$%-*,L3R4X5)6YY.G9RBVT_-?VMOV2+K]I_Q1^R1XDM_B'%X _X9?\
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M[JG6]E4="DZ-#VE)58TY3ITXPI1JR4VJ=XR3Y()?A3XB_P""2O[1_C3X,/\
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MHX5QKTY45*.(IU*=:<JE652K"K.-2HJLY574G.I42DYJ46O9PLX]?RE^(W[
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M>HS^O<="/XW/^#@JZLM4_P""N?\ P0S\*I<N^H0_$Z\U.>QCAEA\FTU'XO\
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MV8)R:6T55O.[V225[RT3Y5=MQ3_3O_@HU^UT/V:_VF/V._!VIZ5I_P -=/\
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MOZ5I5^?A1\,_@P_Q0^'=Z;8P7,^N:KXLUSQ4]MI^GS0:786]Y?+]I?\ +?\
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MF1_,$?A2TQ"2BDCYBH)]3UQD_G^=/_G_ "KQ=?Z7ZW^_3\M?9"BBBF 4444
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M.G1A97O>%2K*3U6W+.*C;S36S=X?YX(_0_Y/6B@9QSU[XZ9HKA]=SH"BBB@
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M&-M9:KI]CK,EOKK:7)%:SRV\MO<RHE3]C[]CGXK67[?&I_MH:G^R;\*/V ?
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MERX:@J,)57"A!2]C2A=M?FC^S[^RCXV\)_M2?\%4O'OQ;T7PM>?![]LGXA?
M_4_ -O%K<&JW.O>!O"O[+_A/X/>/8/%FC&UA&A ZYIFJVEM:W$]R=2L&2Y!C
M1E5_AC_@A/\ !#Q78Z9\=/CEX^\4GXBZ7\/?$>M_\$^OV3?',HF*:E^R'^R7
M\2/&VD>%];TVZ#O::I:>*M<O+?0K[6+0O!J;?#33OL<CZ=:V<\W[:_'7X#?#
M+]I/X9>(O@W\9?#+^+?AOXKDTHZ[X?35=5T87XT35++6M+#ZCHMYIVI1BWU7
M3K2Z18+N-))(]DP,9Q77_#GX=>!?A)X$\*?#+X9>$=$\"?#[P+H=AX<\'>#/
M#&G0:5H'AS0M-B6&QTS3+"V2.&""W4$\?O)'+S2O+++(YYYYYB)Y?F>&J<T\
M3FCRRA4<J-.-'#83*:-+"PJ4:CE.K#$8^CA\/AL2Z:AS8:A!3YN9*&T<JA]?
MP6)480I8*.+J4TJLIU<1B<;.I6J1K)1C35#!U*LZN'4FVZE6<DXQ24^^0G8N
M1@X''Y ]?3]?QIP]_P /H<'_ .M^%-4$*"1EMHR!^9 ]>?Y<4_\ EC_#']:\
M9>6SV=WJNF_E;\3V%V;O;\?/LKZZ= HHHIC"BBB@ HHHH **** "C_/Y444
M!Z''7M2+G'/7G/XDTM% "<Y'''?VI:** "BBB@ HHHH **** "BBB@ HHHH
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M35K<CZ?0R$#!R5RO3<,-PPR,D@G)'4G&"3G''S/^U)\(/B]\=O -A\-_A/\
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M^+-.\7:3X8UC6;>.2YT*P\5P6=SX>GU: #[#_: N90UNDH;X&_:L\5_M^_\
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MM_A[TM%%EVZW_+TVMI>[\P_KK_F'^?\ /%%%%, HHHH **** "BBB@ HHHH
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MOP!)+;\V_P VW^/R044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !'7X1?_ #'4?6.&O^@;B3_PX</_ /S(%LQ[X3_P#&?_ "1X]_P]X_X)6_\
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M'4?6.&O^@;B3_P .'#__ ,R!;,>^$_\  ,9_\D>/?\/>/^"5O_21_P#8<_\
M$HO@S_\ -C1_P]X_X)6_])'_ -AS_P 2B^#/_P V->P_\,)_L/?]&:?LI_\
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MCJ/^&$_V'O\ HS3]E/\ \1U^$7_S'4?6.&O^@;B3_P .'#__ ,R!;,>^$_\
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MA/\ 8>_Z,T_93_\ $=?A%_\ ,=1]8X:_Z!N)/_#AP_\ _,@6S'OA/_ ,9_\
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M?A%_\QU'UCAK_H&XD_\ #AP__P#,@6S'OA/_  #&?_)'CW_#WC_@E;_TD?\
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ME;_TD?\ V'/_ !*+X,__ #8U[#_PPG^P]_T9I^RG_P"(Z_"+_P"8ZC_AA/\
M8>_Z,T_93_\ $=?A%_\ ,=1]8X:_Z!N)/_#AP_\ _,@6S'OA/_ ,9_\ )'CW
M_#WC_@E;_P!)'_V'/_$HO@S_ /-C1_P]X_X)6_\ 21_]AS_Q*+X,_P#S8U[#
M_P ,)_L/?]&:?LI_^(Z_"+_YCJ/^&$_V'O\ HS3]E/\ \1U^$7_S'4?6.&O^
M@;B3_P .'#__ ,R!;,>^$_\  ,9_\D>/?\/>/^"5O_21_P#8<_\ $HO@S_\
M-C1_P]X_X)6_])'_ -AS_P 2B^#/_P V->P_\,)_L/?]&:?LI_\ B.OPB_\
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M  #&?_)'CW_#WC_@E;_TD?\ V'/_ !*+X,__ #8T?\/>/^"5O_21_P#8<_\
M$HO@S_\ -C7L/_#"?[#W_1FG[*?_ (CK\(O_ )CJ/^&$_P!A[_HS3]E/_P 1
MU^$7_P QU'UCAK_H&XD_\.'#_P#\R!;,>^$_\ QG_P D>/?\/>/^"5O_ $D?
M_8<_\2B^#/\ \V-'_#WC_@E;_P!)'_V'/_$HO@S_ /-C7L/_  PG^P]_T9I^
MRG_XCK\(O_F.H_X83_8>_P"C-/V4_P#Q'7X1?_,=1]8X:_Z!N)/_  X</_\
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M\/=_^"5QZ?\ !1[]AW_Q*+X-?_-CZ_X>]>P?\,)_L/?]&:?LI_\ B.OPB_\
MF.I/^&$OV'^O_#&O[*8]O^&=?A#[>O@W/)]Z/;\-?] W$G_A?P_V?_4(NM@M
MF/\ -@__  #&?_)'D'_#W?\ X)7]O^"CW[#I_P"[H?@U^/3QB<GVKUSX*?M]
M?L0?M(^-&^'/[/G[7O[-/QO\?)HM_P")'\%_"?XU_#WQ]XI3P_I<]G;:EK;:
M'X8\0:GJ*Z583ZA8PW=\;?[-;RWEJDLB&=,J?V$_V(!C'[&W[*8R0.?V=OA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFL[6-3L-*ABN]2OK+3[-98X'N;ZZ@M+<2SLD5O$9[F6*+S)I7$<,1;?-(51
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M'9.L;''Y9EV.S>A/*GB\P6&A@\<Z=/,*&!I5:6,K?KCG)8DGT&2<9(/7H>Q
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M_P""P'@SPG\<_AGIGPH^(W@'_@G5\8DO+3PGXWD\=_#OQSH&O?M#_ N]\/\
MC?P'KMSI^B:I)87-Y'XH\/:EINO:1!J>DZIX7NH4GO;>X@F;2CPSF3H8_%8I
M4\%#!X+,\2Z-7%818ZM'+*M"A5JT<"ZKK3PKQ%66%6)7-2YX3G&E5I)8F'I4
M/"WBA8#B',<WIX/)X9!PYQ9GE7+L7F>4O/L5'A/'Y;E&*C0R)8]9E6RJIG>-
MEED\\PWUO"4JV&E7HX;&X"4\UH?O;G ]3@Y.<_=XS[@GO^-<5XC\6>'?"D?V
MSQ+X@T'PW93SI!!>Z_K6FZ';33 AFAAN=3N;2":;:0?+C=I,$$J%(-:>HWHT
MRPN;Z>1_(L;.>\FVJ&9HK."6XEVY(&XI%( &PI(48PU?B%^QQ\ ? '[?7AWQ
M-^VI^UKH-K\:M3^+'COX@Z;\(/ ?B>[U*Z\!?"3X+^$O%6H^&_!^EZ!X06\A
MTJ/Q%J<.GS:OXJ\03)<7-U<W*BW>*'='7-EN6X?$X;'9AC\36PV7X"KA,/-X
M7#T\7BL1BLPG76"H4*56KA\-%3AAJV(K5<34]G1HQ5HSJSA&/C\/<.9=F&5Y
M[Q'GV:8K*N'L@Q.3X"M/+,!ALRSG,<WSZKF,<MR_+,+C<9E^6TW]6RK'YECL
M=F>)6%PF!HPC3H8K&8FC2H_N5I-[::A;PWUC=6][97<:3VEY:3QW5K=0N#MF
MM[J!Y(+B)B<K+%(Z,.0Q%:#,=T?/ 8'OGMG/KCIVSUQ7XM?#/PL_["G[>GP\
M^ 'PPOM8A_9F_:Q^&WQ!\5:'\+=2UO4=7TKX4?%WX8S65]JTW@$:M/=WFE>&
M?%WA_45EO-%-RUE:7UM&;*&&-<GO/@=^W#^TM^T=\;O&?@WX:?LT>&+;X/?!
MO]HCQ?\ !#XM?%CQ9\59-/NI$\,:K<6TNJ_#?PK;Z')+KNHZ9H[:5J_B"QU2
M]MK43ZQ%I=A/YEK<3KZ%?A3&>SJXW 5J&)RF.68;-EF&+Q&&R[DPV+K8K"TJ
M&(I8JO*<<<L=@\1@HX:A]9=>K"G/"N=&K#E]_'^%V;K"ULZR#&8#,N$Z?"N3
M\90S[-\=EO"\J.39WF.=9-@L)CL%F>,K\N?+/^'<XR%Y5EU?,'BLPHX6> G+
M!8_#XC#_ *Q;B7C7<W!<D9." !UP>G'KC/()K-N]1L+6YLK6:YM(KF_E>.SM
MY[J"&XO7CC\QX;."61)+IXD&]TMUD9$!9@%!K\HOB3^VI^UWHZ?'#XJ^ OV/
M;>Z_9R_9WUOQMIFLZC\5O'^O?#/XQ?%;1?AOYI\9^//A7X#G\&WEBW@N1;/4
M_P#A"KWQ'JUL/%NGV46NPW%O9ZE##:X'QT^(NB_%?]I?_@D1\3?"<^I#PC\3
M/$OC+QYH*7;2VDLFB>*O@5)XBTA=3LUDV+>16>H6_GPR>:L5RDH4C:&,TN%<
MPDZ<Z]3"T:53"9A65;#8S!X^=*M@,JEFLL%BJ.%JU7AL34P_LTH595N24Y)U
M55H8C#4<,O\ #'/<15PSQ]?+<-@<5E_$>)^MY;FF5<02P68Y!P1B..7D6;T,
MJQTWE>;8C*882K4PF(Q&)GA*&*G.K7EBL'C,LPGZZ:OK&FZ-:S:GJMY9:5IU
MFHEO-0U*[M]/L+5"P3?<WMW+!;6\>]@H>:15R0NXDC*>&?$.A>)[)-6\.:SI
M.O:9-OACU+1-4L-7T^65-C/$E[IT]S;&5%=#(@E+('!*@8-?C1_P4ZM#8?&?
M]F'Q5^T#X%^)_P 4/V&-"M_'+?%OPQ\--$\0>*-'T;XH,EL/ /B[XK^%_"LJ
M:WK7@.PTZ;4+=(?+GLK?4I$FGBWB-9-O]AGPE^R)K'Q[\1_'+_@G[\=? MK\
M'M3^&(\)?&G]FOP5_;UI:Q^.['Q']H\#_$J?P1XIO=.UGX=WMKIXUWP]>,WA
M6WMO$@N"T=\[6_[VY<.4*?#E'.YXK&/VN#Q6+]K0P,L1D]"O1K3A2R;'9E"O
M.O@\VQ$(>VA3Q&%P^ IJM0C+$554]K2[9>&V&I>'^"XWQ&99ZX8W)LPS:GC,
M%PS+-.#,NQN7YA/ 4^$<]XAR_&XW,<@XLS&-.>)PM/,\IRS([3R^E+%XJ&/_
M +0PW[-2OAD^8C,B D<9'(YY_GC/KUJ8-\AY[#WZDYQC/8_UZ"OQB\(?M^_M
M8_'OQ!^T!H_[.'[)?A+Q)IW[,_QR^(GPE\6^*OB-\9+GPII?CNZ\"^(+[3K3
M1?AO:Z;X7U:ZU#QC?:!9VVNZZFM2:;HNB2>(?#UE;7.I-<WDEKV?Q"_X*@Z/
MHW[(?P=_:I^'?PB\4^-[GXJ?%+0/A%>_"*_UBTT;QMX1\=W7B/5?!WB3PE?R
M6]O?6<FN>'/%.ER:<X,20W=D\.I[(HYEA6*_"&?X>O1PE3"4'B*N)I825*EF
M&7UJF&KXC"1S#"PQL:=67U3ZU@I2KT'6FXS=.="7LJ\717/6\'_$&EF6!RC^
MR,NK9GCLRR[*'@<+Q)P]B<5EN/SG(Y\29/A\^ITL=&.0RS;):=;'8">:5Z5*
MI2H8BG6K9?BZ%3+S]8B>I!.,L <GL.,Y]/?KTIT9)B4DYSMY).3R>I/7@XZ#
MD>I%?F1K/[3/[:GA7X<^!;'7?V0]'U;]H;XJ?$#5_"_AGP=X(^(>M:[\)/ O
MA2PL&U*?QQ\7OBK'X2G7PQ;6D8^P)ID6G+<:OJ0:+3Y%$>R3R?7_ /@I%\7_
M (/>$OVD=.^.7[/6C:9\6_V3]%^$'Q:^(^B?#WX@WOBWP7XF_9Q^(GB9-+\3
M?$SP3KMWX=TW65U?X?:18>+-8UCP[KFCP0RVGAJ6XBOS%=@PYTN%LWKJ:PT<
M!BIQJ^S5/"YKEM>I4BL32P<L11A3K1E4PBQ>(H8?ZPO9TYU*G-3A4HPGB8\F
M"\+N+\TE4CE=/A[-:D,5+#1H9;Q?PUC<1B*4<XP>0/-<-1I8V$IY!_;6/P>6
MQSNK4P&"J5\31JTJ%; R>:0_9HG&#UR<<4'!&/7T_,']*^-_C-^TZ?AYX^_9
M7^&O@K0+/Q[XK_:=^*,GAW1[8ZXUA;Z'\*O#'@F_^(?Q+^++/#:W O=/\)^&
MX='M;2S<VT.HZ]XL\-V#W=NMYO'UM#(['![J6&V0%AG<>.2#MX^G/ Q7AU<+
MB</##U*]&5)8F-25*,M).%'$5<+4ERV32AB</7H.Z3YZ51?8DH_&8O+L;@L/
MEV*Q6'GAZ.;4L;6R]5+0K5J67YGB<GQ=2>'=JV'A3S/!8S!Q=>$/:U<)B?9J
M4</6<-(# P.U+_G_ #^5,3)12<Y(!Y//KU]_Y=Z?6)Q_F%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\0%_8N7X>^,M:\/75OX5\<?\(I\%Y-+\4KX2UJZMTL]>;PWJV_3/$2Z?//\
MV9J)@LKHI*(XXOTKT#1=,\.Z5I>A:)IUGI>C:)86>D:3IMC&L-K8Z=I<$-G8
M6ML@)86UO;Q0PQ*[$B.-2Q)!9MA/+'[QD;& I)4;V895C@#?D'*\!L]4^7<3
MP8WB"OB,?Q!BJ5"C1H9WAO[/CATJL/[.P5/'83$8.A1E&5DL-A<NP>&C&3=-
M*-2?,^>#/!SCCK$9CG/B#F.$P%#!X3CK+Y9#3P2G5MP_PYAL]R/,\AR_+91K
MW=3*<MX8R+)HMSJ4/8X?%JE!SE"J?EU_P5L\"^.O%W[&.I:5\-/AOXT^)NO:
M3\8OV?O%9\$?#+PS>^*?%E]HWA7XL>&O$&O7&E>'=)B>YO?LFFV5Q=7'EJH1
M%::1E4.]>0_$W]L;]H_]HWP%XT^"_P"S=^P%^V1X0^(/Q(\-:KX.3XD?M+?#
M_P /? 3X2_#G2?%MK-H&L^*]?UOQ'XKNM;\3#PQIFH76HZ1X;\+:-<ZWJUS#
M'%'#$R$5^S\LL3_N-LA; P0A88P0K!@RJ,[0 ,C+#&<MBH%2,L,+M925YWCR
M^,@_O)7V$9R2B@C(ZY K3!<0T\+AL'A,1E."QT\NS#%YG@JV+Q68PM7Q<L%+
M_:,)AY1P^+P].O@</.G2KSA"HTZ56<J<G$WR3CW"99D^199C>#LEXCK<,\0Y
MUQ/DF.S'.>)L-2H9GG-?(,34CF&4974H99GN"PF,X;RW$TL%C<;@UB9^UPN+
MJU,+6E"I^%S_ + Y^)7Q<_9M_9,\>>%/B7/^R=^PK^S#IHTSQYI>N?$?X5#X
MG?M ^-CIVA6]YX3^(O@_7= UF_@\&^"M$U.?5K;1=;WV.K>)FTS5W>)WMGU_
MB?\ L2:?^Q?\:OV8_P!J_P#91\'_ !W^(%YX?^*UA\$OVCO#(^)/QH^/?B76
M?V;?C=!'H.N>);'0O'/B3XAZ_!IOPA\<6_A/X@W>A^#[2TMKJSM;K7=2 AT&
M2>+]O7>/&&3AE(?:"Q*X\M]F,;2-^5/R@ 'G!-/9@6!5MP0*=H4YY+,NX+]S
MYE5G.55E/S= :ZI<:Y[)0I3Q$WE_U/%87$Y7[2N\!CJ.8/&RS6M7P[4DJ^/Q
M.-^L5>3DC3KX3"5*$:7U2C*/M/QKXVG+"TIXV<\BCDV9Y)FW"3Q>(CPYQ%_K
M+_K#5XHS'.,&Z<G_ &CG^9\3?VSBZF$E16"S3)N'9Y=&$,HH43X*^('_  3A
M_97^)_QEU'XZ^,/"OQ%N_B7J/B+1O$NHZEI?QS^.7A_1+G4?#5O8V.EW$/@S
MP_\ $#3O"4-JD6E6;SV-CH<4-\RE[R&XDNIY)?C3X-_L+Z3^V!\2_P!I']JG
M]K/P7\>/A[XL\??%O6O ?PM\*6_Q0^,_P%U[1/@9\*V_X1SP?>:OI/PZ\:^#
MIM:L/&5^-5\4:*_B*R>XMK"\AFM8$BN2TO[@*4 5D)<?,"=J_.&120X<@JQ?
MD\%LG#=\*P0;6W]"4.T ;6) !R""!G=PIQ@D&N7"\5Y[A:$J-',<34E]6H9;
MA\3*M.>(P&!I8B.*Q&&P$O9M8:EBJM/#K$Q@Y.M3HTH2<J<YJ?CY5XJ<>Y1E
M^)PF'XESJ6)GE>6Y#EF;U<TQ-3,>'\APF9T<RQ.3Y#4494\NR_.JV RREFM*
MG&56IA,KP^&H3=-U8O\ GE^(?P UO]B_1_\ @HY\$? 7A7XE7/[)WQV_8G^(
M_P ;?"?B[5KOQQ\1]#^'7QC\,>!-7\'?$GPKXM^)_B_4O$FO3ZYX^L1HWBO0
M[77M<CEEBT_4(K);@6KJG%M\;?C]\>_^"=WA#]A3P1^QK^T'9_'3XP?L\> O
M@M:>./$?@NRTS]E;0OA[K/@S2=)U'XZS?M 6-]J?A>;PV_P]O8O%">'=-LKS
MQG!XKO6\#P:+=:] &/\ 09\7?AIX<^,_PN^(WPD\7S:G#X7^)G@?Q1X!\1RZ
M+<Q6FLP:)XMTBXT35)=+O9[:\M[;4$MKN1[.YN+*\BBF6*22"9%,;/\ AM\/
M-!^%_@#P3\,_#K:A+X=\ >#?"O@S1SJUV+_5)M&\(:39Z%I,NJ7$2003WRVE
MA:I=31VD"S31-(JQ9\M?7_URI5,OH2Q^#AC\YH9OALRIXFM7QU!3KX#)9Y?A
M<PQ%7#-O$U\16="6,P\_94ZSPM!QJTW]8A4^UJ>,]/&Y-EV,S[AK <1\;9;Q
M?D7$D,VS#,N(,)4QF8\,\!5^%<OXASG'9?B'2SC&YEBUE-3/<FQ.&H4,P_L#
M+,PI9E@:E;,Z.*_"RX^)>L?LA_\ !2[Q_::'\&_C-\>?AUX6_82_9S^'/B[5
MO@KX5A^(/Q$\'V&A>*?%-CX1\6/\.8-0A\3>)]#U2YT>YTOQ*WA@:A<^'9;B
M#5]2A.FV]Q=)RGQ7^#7[0'Q]^!W_  4+_:=E_9_^*O@K5OVD?^%)>#?@G\#-
M6T"6X^-&J_#CX:>*-%GF\8^+OA[HHOKSPOJ^N75Q?WD/AZ\EN-6M=$L9;W5H
M;.)X _[?:)^SOX$\/?M$?$#]I;3Y_$7_  L;XA?#CPE\+]>L9M1AD\,Q>&_!
MFNZKX@T:YTS3H[&#4+35YKW5YUOKM]5FM[F!((EM(GC\Y_H"-3C# @A5\Q,/
MP^ 1GS&)SSN.X$.",D\9TK\94</7PN+RW 498Q9;D>'Q^88JOC'+%2RVO6S+
M$48X53CA:-*KF-2FGBL+*//AJ,:5*CAW[2K4K&>,F&P>89/FN0<-X&IGM+A;
M@+*<]S[,,5GE.IFU7A?,\?Q'F-!Y+"K_ &7@X9AQ!B:,*V:Y?5I5J^5X6AAL
M)EV J>VQM7\I_P!K?X>?%GP9XK_8K_:N^'?PS\4?&'_AF.^\8Z=\5/@]X*M+
M2[^)5_\ #OXH_#[2/#NM>(OA_H5_?Z?!X@\6^!-6T+3[Q_"EK+)K6L65Q<V^
ME0O);2 \?X(O_'W[;?[<7[.O[2.E_ WXV_ WX'?L??#W]H"PTSQ9^T#X%NOA
M3XS^*?Q5^/NA>#/![>'_  M\-=:N3XJ7P9X$\-Z%>ZSJ7C'5[6TT;4=?N5TK
M2A?^3<7=E^Q#1HH)\ODXPRKM..<[F4%>H)[8']W@K&HW+M(D4E6RS.SY"MNR
MS-)(Q"D<H9-KJ'&/F4GQ(<1U(X>$/JM">-I87-,NP>8NMB(RI9?G$L94QV'^
MJ6>&JU5'&XRGAL;*?ML/2KU8NE7Y:%6E\1AO$/$X?*J&$ED>75,XP7#_ !AP
MKE/$+Q>:TL3EF0<<X_-L7G>&>5TIO*LPQU/_ %AX@PN3YIB9X;$9=A,ZJRK8
M7&XS!97C<#^&O[/O[+?QIT']LZT^"WBSP%J-A^QS^QA\1/B_^TI^SEXFGTU+
M7P3XRU_]I*"74O /@#P^6@C,T_[.^N^,?CM#-;?:;V72GF^'][+;Z1:IX7:_
M^1=>_9+^"7P(^+_[0?A_]J?_ ()T?M!?M0:MX]^+WC3XF_ +XQ_ CPMX[^(N
MB>/O#WCR].L1>!/&7_"&^-M&L?A7XE\,Z]<R:;+>>,K:+3KO1Y'UL7\5G!(@
M_J$R"[$AD+'>ZGRR% 0. 3O&\,>=Q#,JD!MH;--*E=C;F#L2S"-BN_\ A <)
M(HVC@Y)=%STZUZ='C?-*5:O5=/V=+%8+!X7$4LNQ>/RNK.M@,2\PAC_K>!J3
MQ'M\5CK8G%P4'2Q$I.'+2:I5*/TN&\<>)*&.S'$3P4*.%S/(\CRG,<+D&><0
M\*XBKCLBSB'$?]O/-\FKRS*GF><9Y.6:Y]05&OEV81G]6I0P/U7+<9A?P+M_
M@%\4?V4;?]B?]K#P3^R%)IEC\)_"WQ=\&?'S]E+X ZW=?$[QI\-?"/QLU73/
M$X\5>"8-?US4+KXF>)O">MZ#8Q>-M)\/:S<7LS:A/<>'+:[TJSNF@[WX,>-/
MB[\>O^"F/A_]I8_LR_M ?"GX :+^P+\:?AGX(\4?%SX;S^!/%'C7QA9_'KX+
M^*[N/4]#GDN;[P3)XDAFO+?X;^%O&<]AX@\1Z1X.\4>+]-TS^PYI7C_;IL>7
MPKE@K;0J[V5@3@@JV0RDC!W8 S@J,U (4EMW4Q>=NBG&V3+^8S8#[Q)+*&#
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M6/%.J:1?:KX<M)M,?2/!&BOH]GXD\211Q:#::M_:4R7DUFD5]<_L'\!/V:O
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MM_['DUJ6T%O!=FVAN7C$Z./3AD.28J6=4,'EN.JT<KQ>:QP^5QS.K4Q>.Q.
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MMS(()KFQU/1M:TRXBN]-U?3YY+2ZV31H 86)_-C]K?Q]H_CW]OB?]FO]I?\
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M.\UJ<,</9OCJ6,\,\%G>6Y;D6,RC-^,^'L;Q+D>48['8W@6EQ+EF/PG$>?\
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M"> 0#G)SVSR"#7T;\/=+M-0\:^%+F[MHKAM(U>?4+"65 WV&[.D7]DMS;NQ
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MG4(V2N[?CKCIG:"0=O7KT./8<U^<7_!4_P#;)M_V*OV0/'WQ!T6ZMX_BOXT
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MQG_!4[]JW]C;]JCP1\%OV>->^'>E^'+KX#>'?B+XK7Q9\/K?QC?/XF\4>/\
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M\5>*(_#^FQ6(\3>.=>N/$WBW6$@$S?VCXA\2:@J7>IW[ABEQ>7(60*L:EB%
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M7VK'Q3:/?SB25RUS-:P/(,@H-HS^U?\ P2T_X);^%/V!_!=[XG\8W'AGQ_\
MM->-[=K?QIX_T>":;P_X9T6*YF^Q^"_AM<:QI=CK>G>'YX1;7OB&[NH;:]U[
M5%47<2V=E:0U\6?M/_\ !OUJ?[1O[17QF^/*_M6IX/3XL^-KWQBGAC_A4?\
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MI"3I1Q%\1/DA.K&4\/BITXPG452ARSJ+] #I\$48MHH8D@'F-Y(A58R\KL9
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M7OV9O@#X+_9?^ ?PJ_9_^'\)C\+_  N\(Z7X9M;MXUCO-<U.V5I_$/BG5#&
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M*35*,HTXN7LHR?Y ?LS0Z?)_P6G_ ."G=X! ^K0?L^_L*6#3;HVO8M/E\/\
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M/XI_!'_@V/A^'?CWPOXQG^&?QF\!?"KXAP:!J]KJ=SX*^)GAG_@F#\5+O7_
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MQBB:* GXG?M:6EK&'6-W@_X8C\9LUM#A@TD*B*&9X5W1EK>*5DW0QLGZV_\
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M?VHR7EQJ;W9,]VDDD2E@QBD5'X&1_/\ :!>RPVZ!=I"!$*3#!X+$98C&!V.
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MK=DD_1W^_P C_/G&<T*U.BKRO6G3UTUYYPC?R5E==$GK<^T- N(S$$8@*%+
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M9=@,RRG&9@I5ZF-IN>-JT\'B?8PEA7&5>:E*M"-23/\ .&E5[;PZ^-I>#16
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MFI6GBGPYI?Q'\9P>)?'W_"+Z;9-H=S/H4MY-;W1_*GX-^+[_ .)'[)/_  =
MOIWQ^LOVI-9O_!/C@3?&'PEX-TGX=:%\2-;;]@=O"FI>(O!_P^\*ZQKNA:=X
M6N;SPO-X0\+ZUI6KZR/'6B^$['Q)<Z[K<M^UZ^F6\/Y?6P6&S&M'$N'M,EQ4
M\+'%TY^VP699Y2R]J56.5QPV%]K3<HTIU,95Q4W3J^TP.'H3A.GMBLVQ5/%5
ML'!TE)0QM)8KV#ITZ5?"Y?/$)SC+,GB*WLI+GJJ&'CAUS14:\Y*51?N3\/?^
M"IW[**_L9?"W]K+XQ_& >#?#OBH^#/A]J\FH_"7XU>'/$7BSXYZCX8T.^U_P
M3\)?@[JG@1OBQ\29+K4]1N;OPVOP[\*^,['5]#AEU71M4U;2[&[U"+Z6_9C_
M &S_ -FK]KR+QJOP'^(USXFUCX::S%X?^(O@;Q;X%^(_PB^*7@#5;NV2[L8/
M&7PH^,/A#P%\2?#<&IVS?:=)U'5_"MGINK1([Z5=WBH^S^>3X^>)];U[XP?\
M$-?BO\/_ -J#X:_ ?X??\,J^,/AMX6_:)\8_#SPY\=/A7X%^/WBWX+?"/4-!
M\*^(-*U'Q]X'\/:!X[\<^"8]<TOPEJ>I>(X-0L93>VD5H4U5_-^P_P!FV'P]
MX$_X*"_'GX\_'+_@HQX%_: ^(OP0_9+L-"^/5Q\/_P!E6W^!_P +O"/PVG\2
M7/BOPO>?$SXN^'?BC\1?!>I>+O#C0ZMJ&F^$;N\37M.T2\N=0%I;6;M*]XWA
MO+J6&KXJG5QM/$5J&:XW"814\3B(0EAN(,3EE# 5%1RB.'3<84X2KSS.A4IU
M:N$C'!3IU(/$8X7.L=4K4,/*C0J485<OHXC$2K4:,94ZV34<=6QL%4QDJW,I
M2=2%#ZK.+I1Q#EB?:1O1_=;QUXS\/?#GP=XP^(/BJYO[7PGX#\*^(/&7BBYT
MO0=?\4:I:>'O"NDWFNZW<Z7X:\+:7K7B;Q#J46FV-Q-8Z'X<T;5]?U>ZC33]
M(TV^O[BUM9?YT=-_X+(^,/VB/^"5G_!0O]H/X1^*X_A]^U/^SCX1_:"\5^$)
M-!^"7Q%T[PMX.\):+\1O&OAGX"ZY;:A\=O 5]\//B%XOUKPEX2MM7\8^'5GU
MF^T#Q!J5QIGBOP?X/G>VTBU_HG^'OQ \&_%CP3X0^)OPX\3:-XR\ >.M#TOQ
M/X/\6:!=IJ&B^)/#NL6\=YI6L:5>Q_)<V-]:2)/;2I\K)(K*2,[OY2])\3:0
MO_!N]_P5+\!R>)-+_P"$\\ ^+O\ @I[9>+/"3ZO:S>)?"5T_[47Q5OH(M:T5
MKG^T=,\Q;VWN+>6ZMHHYOM:31^:9B'Y.'<'@JRJ1QV E7K0S[A:@W+V;=&CB
M,UQ%/&TJU*M'E<*T:<:-6-2=.'/3C"I.$?<EZ.8U\3&OAGAL3"-&M@,VJ<J4
MVJU6-#"2PTXU:<M>53E4BX1G)PG*4$W>2_:CX%?\%9?V%_C'XT^&?P:\._M#
MQ:Y\4/'\USX,\+:YJ7PN^+WA7X4_%7XE>%+&%/&OA;X5_';7OA[H'P ^)GB2
MTU..\CBT#X;_ ! UR2]N%DMM"M[S[,\-OZQ^T7_P43_9!_94\<Z1\,_C-\5M
M8M?B;J_AF^\;1_#3X8_"3XV_M!?$73?!NGEOM/C+Q-X$_9_^'?Q/\3^#_")"
M2BV\3>*],T71+Y[:[2PNYWM+H1?"G_!2O0?#O@W]C3_@GGI/AO3=*T#2/!'[
M97_!.+2O ]GIUM!86WA73]+\:^$-!TVR\-K#M71TMM$9])M1IWD-'ILTME&P
MAD(/R7X0T[X^Z1_P5/\ ^"F/AOPU^W5\(/V,?B1XO\0_"'Q]X:T_XR?LV>$?
MBYK?Q0^!%GX"33?#.K>"O&WBWXP?#*6'PCX1UJV\0Z;J?A32X]0M]-U:>YU2
M9H);B8CHH9#E6,ABL;"MB<)1C3S::H5*U.M6G4P6<T<OHNC+!91BZL,-"CC%
MB*V&678F=&-!QIXN.'J.K2XJV:XW"2PN'E1HXBI4JX"E5K4H>RITXXC+:V+J
MSDL1C,,H5)U*#H4JGUNTW44JM.I421_1?\&?CA\)_P!HWX6^%/C#\#/B'X:^
M*'PS\<Z8-3\*^,_"6HK?:7J<22FVN(&=E2ZTW4].NTET_6='U2UM-9T/4H+G
M3=8L++4+:>U7X&\;_P#!9[_@FU\.]?\ &OAKQ-^T?<G5/AAXH\3^#OBO%X>^
M"'[1?C2T^$.K^$/'*_#;7K[XS:KX+^$NO:/\)/"<OC5SH?ASQO\ $2\\.>"/
M%FV;4_"?B#6=&M+F_BY/_@C?X.\#^'_@5\:O%'PZ_:+;]I?PC\5/VK?C)X_'
MCK2?@#J/[.GPX3QC=:W!I/Q(B^$W@VY\1>)=)U;P'J/CG3-9UJR\5^%=1E\.
MZYJFH:A<6$UX/,NI?AK]G_0- T[_ ()C_P#!?+Q'8VEE'J?BW]I+_@L;=^*M
M2$5OYNHRZ%X6\6^%]-BO[A-CS6VF:+I%K:V]K<2-':%KIH%@29A7+0RC*U4S
M:%:KC\3A\%F?#N!PDL.Z.%G-YWFD,%6JXA9A@O:N6$IN?LZ;PN$EB,132G'#
MTZBE3UJYICE2RZ:I8:A5Q.!SG%8FG)3Q+3RW!O$PAAZV$Q/L*7MG&#]HYXEQ
MIU?9TG[2,YO]4_ ?_!5']@CXE_&+P[\"O W[0EGX@\:>,_%VN^ / >NVOP[^
M+MK\%_B/XY\,6LEYKG@OX9?M(ZCX"M?V>?B7XKLH8+B#_A'O OQ1\0:O<7UG
M>:99V]QJ%I=6D74_M+_\%%/V/_V2/&OAOX<_&[XKZMI?Q(\4>'=2\5:-\,_A
MS\)OC1\>?B0OA32&/]H^+M:\!? CX??$GQ1X<\)VX294\3>)-*TC1;B2"XCM
M;Z:2WFC3\J/C!H^B>&/^"6O_  1)M-#L['2K#2/CO_P2#GT8644-N+.ZO;_X
M;_:[RR:W$034-274-0-]=Q8GOI-1O9)F=[N<R>X?LU>-?AY\'?\ @J[_ ,%.
M=+^.OBKPQX&^*?Q1T[]GOQO\&-7\<ZCIOAN3Q-^SOX7\"WFF:K8^$]?U>>RA
MU/3/"WCA=3NM?TBRNY7TY[J.\NK9$+2TIY)@HT,9C*$<UQ%*A#.E#!1K866.
MQ-7*<ZI9.I<T,-4A1IU*5=XK$1I8;$SC'V<:=1TXNLK>:XIRP=.JL'2EBZV!
M3K35:-"@L5EL\P?/"51*I4]K&%"ASUZ<7.%5RU<8GZ':3^WA^R!K/[+5Y^VU
MIW[0G@*Y_99TW1[K6]1^,!OKZ'0M-AL=0&C76BZCI%S90^*;'QG'KDL'AS_A
M ;S0(_'#^)YK?PVOAY]<N;>QDXCX)_\ !2O]C+]H'4?BAH7PR^*?B:3QA\&_
MARGQ?\?_  Y\?_ [X^_!SXLV/PK:"XF_X6+X=^$OQC^%_@/XD^/?!S&W6T&M
M^ /"_B>P_M;4=$T5I1K.N:)I^H?A%HD7[-/Q(^!7_!5WXJ^/OBAXS^#7[(OQ
M._X*<?#SQ3^SI^TS\*?#<WBK1? GQK\)WWPVTRS_ &AM$6#1=7\'W?PKTWXX
M:1"?&&N^(]/;P%/:Q:W/JNL6-S=)KEM]V_LX?'+X]^"_^"C_ ,)/V8?V@OB1
M^R3^W1JWCK]F7XL>./A]^UA\&/A7I7P]_:+^#?A7PCXC\$/J>@_&G3?#WB'Q
MWX4T3X:?&>]O;"/PK<^$M9\*Z?KWC#PA=K<Z5J9L[;[!T8OAS"T:./>'J8RK
M7P<<3B71J^QPWL\)1P.6XR=-UOJ53#5L=A/KM?#X^@\3@,0ZM.C/"4L3*56E
M###9WB*M3!^VIX>E2Q,Z=-5(NI4<Z[Q6-PW/[%XBC6IX3%/#4ZV!FJ.+IN-2
MI#$2A'V52?N'_!+S_@IYX5_X*"K\>],%Q+;^+_AY\<?C/8^#M'TGX0_''P-H
M$O[._A?QU'X1^$_B;5O%?Q.\)Z;H%[\1O$VD+:>(?&G@A=9L?&WA+4-<;3]>
M\"^%TT_['#Z]\6O^"J_[!OP2^)OC?X,^/?C=JY^,7PYU&ST[QC\*_ GP3_:!
M^+?Q'TQ;WPR?&"ZQ:>"_A-\+?&OB+7?"=CX?V7FO>-="TW5/!_AV2:#2]>U[
M3=4GM[23YU_X(R>*M&D\!_MN>")O$&FS^-_#_P#P5%_X*)7^N^%9M6M9/$^F
MV6H_M!:CK-EJ-[H[7#:E'87>G^(])NX[^>!;:X_M6TD24_:X]WB7['OQ;^ 7
MP_\ ^"Q?_!7#PUX_\7^"_!7Q>\5WG[.NH>"K[Q7JNEZ#<:U\._#WPJCF\5Z7
MI&JZG-:0S_V;KD]EK&HZ1%=27"VJ#5&M1;6T\M1BLHP<LTXFC3P>/AA\KPE/
M%83!8.=*4KRQ&4474JUJN%JOZM&&,J5_:TZ52<FX0BYQ]HXZ4\QQ,,OR64\3
M@I5,;7="M7K1J*DU[/'S]E2A"O1;KS>'C1@JE:,%*$IM*T(O]28/V]OV1;O]
ME<?MNV/QR\.ZC^RTEC87]U\6=,TKQ7JFG:<FI>(K#P@EIKGAK3] G\:Z!JVG
M>)=2M-)\1:-K/ANRUGPI="X'B6RTF.SO7M^1^#7_  4I_8H^/O@7XX_$[X9_
M'&&]^&/[.^DV?B'XM?$SQ=X#^*?PK^'.@^%=1L_$-]8^,=!\>_%/P7X.\*^/
M_!E]I_A;6-2M?%_P[UKQ5X>O-.AMK^UU"2+5]$FU'^</XOC1_%?_  3&_P""
M]OQ*\&K;7'[-_P 8OV\;+6_@EJMC/:2>"_%?A_\ X3CX">%/B)XG\&I%%#IH
M\-^(_B!9^)YEFMH&@U&]:\OFENGN7G?]6/\ @N?X8UA/^"9WAV#PXUGH'PG^
M'7QW_8N\6?&^*'P%#\1?#_AS]G;P'\8? FH>*M<U7X4B\TNT\?>"OAW=6OAG
MQSXG\#M?Z/IVM>%_"FH:=J6J:9I1N;VUNMP_EE/$X7!3KYA1JXW/:N ]M4K8
M9T<'@Z>"R_'25:C2PCJ8G,XU<3]3<HQHT_:J-L-*KS42*&<8JK]9JQAA:M/"
MY7A\:XT83Y\16K5\;AVZ=6IB73HX>7U:-6G%2FH0E)RJ\MI1^T_V>?\ @IS^
MQ3^U+\0O#_PJ^#OQBUF[^(/C'P3/\1_AYX;^(WP8^/7P)N/BQX&LD\V_\6?"
M"Y^.OPR^'.F_&#P_:6^=3O-0^&E_XICM=&']L7)CT@_;7YKQ9_P5M_X)\^!_
MBCJGPA\3?M"+9>(_#_Q&T[X1>)/%5I\*?CCK/P.\)?%#5)+>&V^'WBS]I'0O
MAKJ?[//A?Q=!<7=OI^J:+X@^)^G7>C:I)_9>L1V&H@VM?FK\2/!?BGXL?M"_
M\$WHOCC_ ,%;/A/^T7JD?[4W@;X]_L[> _V=/V+M&7Q7XQG\#>'?$.J^)-6O
M?'7PN_:#\=WW@?X(:]X"U/5_#'CGQUK^DW/@JWMO$.D6VJSW$D]O%+\^>._'
MB_LQ_L]_MF?&?]CO]K3]GWX]?LD>'_V@?CGK'QH_X)P?MR? NTA\4+\5-3^)
M5]J?QM^%O@CQ<U_H/CZ]O/'WCF\OM2^&?A[Q[\,_%OAV2+5--O=)O=9TBXCG
M.D.',JK5H8>ABLQG4KQBX4:L,11I_6)9EB,+&@LPQ/#U!Q]I25&%!XC**.%^
MMPQ>%JXV%.4*U%2SC&4J%2K*A0A&DW&<N>A7J.G]4IUY5EA\-FLI-1GSRK*G
MBZN)E1]E.C0LI*M_0)^T?^WY^RE^R=XI\#^ OC1\3]6L_B/\1]-U+6O!OPS^
M&GPK^,?Q^^*6M>'=)21]3\3Q?#3X"> OB9XWL?"MMY4T;>*]4T.S\./<02VL
M.HR3PR0#&D_X*0_L1)^S5X(_;!E_:*\)VO[-/C_QMX;^'_A_XN7.F^+[?0+3
MQGXH\32^#K/0O&MA/X=CU_X87&D>(XKK3_&]S\2='\+6/P^^QWU[\0+GP[I^
MG7UU%^>?[)7Q,\ >#_\ @J9^VEJ7QAM-'^$'Q _:&_9S_8\^(?P$D\:75GX3
M74/@CH7PT2W\1?#3P==:C%HME>O\+_'=W?P>+K#3(X+F&ZNK6[OK&.,P^7\O
M?MC^*OV.?VHOV7[V/]G[X1I9?!SXD?\ !=K]C;P%\9_%\^DZ;_PK?]JGQWKG
M[1WPF\)_&?XE^";NWU[6[/QIX.\3Q7%SX*U3Q'':Z3;:_J&A:Q%%9W5I&;VY
MYHY#A*>)P>'KT<XC2<<FQ&)QU">#^INGF%+'2K4L.ZF%=.DX?5JE##26(QKJ
M8S#5X5<-AZ4Z<Z>SS6O.G6=&K@764LQHT,/4^LK$<V"A3JT75E2JN4N>REB/
M:4L+%8>M!4ZE6KS4ZWWYH?\ P4>^"?[47QL_9GU7]E[]M7Q%X6\&ZW8_M7:'
MJO[/7BS]C7XN>'-0_:?\4>!O@1X+^*.B:II/Q'^-OPP\&:Q\+-.^"OA[QCX;
M^)]G?:9 WAOXLZ?XKM?#@N=1N+.>RM/"_P!A;_@MM^S'=_LE_LWWW[8?[4;:
MK^T!XB\,>'K3XS>/[#X)_$2^^&7A+QSXR\9^)M)\*:/\6?BA\%OA&_[.7P4\
M2:EIMCIKGPOXS\3^"+^QTV6PUG5=-M;+4[74K[TS]OUU7_@JY_P2*B>4;YOA
MI_P5)\OS)0& _P"&<O!9=(E?YS&H16(B9=@168[0H'P/_P $\?VC_P!B/PG_
M ,&\FNZ)XO\ &?PH-CH/P5^/G@[XV_#J>31;CQ-XA^*/C75_&MKI&E:EX/DM
MWU;Q;XE\:0ZIX5@\/W,6D:LVIPK9P6,TZZ9)';^A3RK+Z^18/%T\%F59XO%9
M)R2P_P!3J8O"4,7CN)L%4CB\9'!1^M0=/!4YPD\-05;$QI0JU:5+#4^;R_[2
MQU+-\;2CBL-2CAJ>=4I0KO%>PKU<-A>'\31G1IU,6O9U%4Q-2G."J*,,-*I4
MIMU:M2)_01^TC^VQ^S)^R7HO@76?CM\4D\//\4]930OA;X;\)^$O'OQ;^(7Q
M,U1[5+XP_#OX8?"#PMX^^(?C."WLYK>\OM1\-^&-0T_2[2X@N=0NK6":-Y)?
M@G^VI^R_^T3\)/&GQP^%'QF\.ZG\,OAGJ/BS2OBOKOBVTU_X5:C\(=1\!VLM
M_P",M.^,/A;XK:/X+\7_  EO?#6F0OK6M6WQ"\/>&Y[;0RNL&)M+N8+R3^97
MX5^"_P!J3X8?M,_\$WM-^(G[4'A3]D+XE:__ ,$HO ?PR^&WQ1^-OP7\/_&S
M2[_QOI7BH:S\0O@U8W?BOXC_  RT[PS\1;GPZ_A;57B&L:IJFNZ7I:Z<=,MX
M]*0)A?M>_"34_%G[.7_!;/QUI_[4UW^W5\1I;3_@GQX<_:YTGX'_ ++VK?!7
MP)/X2_9]^+NB^.?B39>%_&7AKXA_$SPA\2_'-A^SS>ZUH_Q=TSPCJ3ZGX.T3
MPCIF@^+[7-Y:Z:LU>$LMC]7H/-*[KUX86I];IT:E3"N%;/L9E=X4XY6\#3?U
M?"Q="M/.9R6-J4Z=3"QI34'M'/\ &2E5FL'"%.BZW+2J5X*M>EE.&S""E;&+
M$SFJE9JO1CA(TWAXWCB54O6E^D7[6'_!:CX!>+/AK\*=._8E_:/UC1_B[\0?
MVB/V4;;PQ_PF/P!^)7P^A^,7P'\=?M#> / ?Q6U'X*W/[2GP=\/>$/C%X=F\
M)Z[?_P!I>)_@])XJOO#.BW8\4V&I:59BVUROV9_:-_:5^!O[)WPTU'XN?'[Q
M_I_PY\ 6&K:5H:ZK<:;XB\1:GJOB#7;N/3M$\,^%?"'@_2?$'C#QEXHUF]EC
MM]*\,^%-!UG6]1F'EVEB[!BOX@?\%BOVA/V/_B-^S_\ L Z9X ^(OPN\>^(/
M'7[<W[$OCS]FR'P'KN@:P;#P?8?$?0!K_C'2K+2_/DT#P6?AQJNI>%7N3'IM
MD-0\2Z)H+$W,T.G/]P?\%7=$^">M?#W]GX?%']H'QA^R?\0-/_:=\!7O[-/[
M27AWP1;>.O#WPM^.YAU*V\.7'Q)T[Q#87?P\@\$>)+*XU'PY?MX_OO#VDW4V
MI6]E8>(--U::UD;BJ99@IX?AJ$L%F6"CC\9Q%2Q;JTJ53&58X3$PC1=&-'#1
ME7IPIJ*G">'E4P]\5/#PQ4HTZ$N[Z_7C/.Y_6<%B/JE'*Y4;U)PP\95Z;=6-
M:4JCC"K.3]QJM"$W[#VTZ4?:->C:%_P4 ^ ?[1GP3_:IU_\ 9?\ BIJ5[\2_
MV?/AOX]O_%'A;QG\+OB1\(_B=\-_%EGX!UCQ%X4U/Q'\'?C_ . / _C.#39[
MRVANM,OM7\(W?AC5YK6YL1/?&WO;9/)?V</^"BGP]^'/_!,K]AK]JS]N;XW6
M.D^,?C[\%O@A-J/B#_A#+K5?&/Q:^,/C_P (66HSZ/X ^#WP6\'WWB#Q3XIU
MN^FGU%/"7PR\ 7(MK9)9+;2;2QA)B^1? _QV^,TWQ._X*!_LT_M :Q^RG^T;
MX^\)?L'^+/'5O^V+^S;\/!X#\83^%[K0/&NE:=\(?V@=,36?&>G:-XD@<3>+
M_#&E:)XT&C#3+V::'1(W>2[K\W/AG%\2M#L/^#=SQWI_[1?@G]E?PAJ7_!-3
M7_AG\*/CM\3_ (0Z)\8_A_X3^/\ XJ\'?"RZO_"LFF^(_'?P]T'P?XN^*7PR
ML;W0?#/BN?Q*;R^AT;5_"%CIM\OB&ZDL^JAPW@Y2>"K5)4*3Q%/&4\6I_6L1
MB,,N%L1CZ<85H9?1Q2H8BO#VDJ=3*)8NC*E+FP5?%0BZF%;.<13I?6H4_:R4
M98>5!1]A3A5GG=/"MSC4Q56BZE*FW&4XXZGAJNB52C2LH_U/_LS?ME?LZ_M=
MV7CZ?X!_$2;Q3J?PJ\2VGA;XH^!_%/@OXC?"+XI_#/6]2L3J>DV?C_X1?&/P
MMX%^)_@Z'7+".YO/#NH>(/"EAI'B2WL-0DT"]U!-,U#[-\[67_!7S_@G9>_$
M=?AI;_M(1R:E+\4)O@S%X];X5?'-/V?'^*L4WV5_A_#^U'-\.%_9LE\2&_7^
MRXM/A^*I\_5V31H&DU.1+1_S>\+_  ?^(/BO]JS]OKQ9H_[>FE?M;?ME>'O^
M"7OBCX :MH?P2_9CE^"_PZ\-:AX[\1^(/''P!;QO\1?"GQ9^)/@2_P#CAX>U
M>R\5MX:\%Z@UEXZM? ?CTZW#'#H3I]K^$OAOIUSXT_X(S> O"/CC_@JS\"?A
MS^RUJ/P,\%_!+QG^SOHG[ WAOQ9\:? ?CYDTW0=7^$5CH'A[X_Q_$;Q%\:])
M^(JW)M;O3_ UGXJU_P 1I'XQMM+@DO 5,/PWE%6-2;Q^,<%B,JP].G3HX[V\
M%C\OQ.-QLE#^P98C$JE4P]*C@93P&48?%*M4Y\1"<6R:^=8RG[."P,5/V68U
MN:IB<$HU/JN,PV'PZJU7F2HTY3AB)SFE7Q-7"QIJ56C*4H0/Z2_CE_P4P_8K
M_9P^*>J_ SXN?&6]T?XS:9I/A76D^$OA3X5?&SXH?$S7=,\8K?2Z)=>"_!7P
MK^''C/Q#\0"MOI=]=:Y%X$L/$$WA.P@6_P#%<6CV4T,\GM_[-?[4_P !?VO?
MAG;?%[]G/XD:?\2O 4FMZQX=N]2ATOQ)X9UKP_XDT"X:UUOPOXR\$>,M'\-^
M-_!7B;2Y!&UWX<\8>'M"U>*"XM[\Z>EE<VDTOXA? 3Q;\&O@A_P6S^(O@OXM
M_$'2++Q[J7_!-G]D[P%\+?&OQ*C7P;XA\5ZAX;;5SXVB*>(+GSO#_BOQ%:6F
MEZMJOAZ[U,ZI+-!+92-=W&GL:^D/^"=NH:/XZ_X*&?\ !7;XP?!VZTO5/V;/
M%GQ&_9L\):+XD\*R6+>"/&?[07P_^$!T[]H+Q%X?DT^&"SUC4HYKSP=H'BCQ
M'9RWT&K:[HMY(=1GN8IR//Q^387"X:I5HT\SBZ6293FOUW$K#?V?B*^/Q.)P
M=2C3I>QIUHP<:=*=*V*JUW4AB:%6C+V2Q$NC"9O7KUHPJRP4U/-<PP'U:A[5
M5Z%/!X6E652LY5:L)U(SE)U)QITJ-6#P]2*HQJ2@OJCX]?\ !4G]B']FKXC>
M-/A'\5OB[XF7X@?"_P ,:)XU^+FC?#/X$_M"_'FV^#/A;Q%IU[K.A:M\:-?^
M!GPL^)'ASX/1:KH=HWB6QMOB/K'AS4I?"LUEXIDLE\,WMKJ;7_VAOVA/#CZ9
M^P]XY^''[8>B?"/P)\>OVDO@WI7A;5M#^$*_'C0/VL/"/CS1M3U71_@KH7B"
MQL]1A^%=G\2K#R-2L?C()[&V\.)8*LE^BWC1G\H;C]ISXC^,/%G_  4O\3_#
M+X[?LB?\$O/@/\!OVI_B=\,_C+J^M_!;3?BS^U1\=_BOX(\$^"M#U[X\Z]HV
MM_$/X?>#-(L?BMX;7PGI/P@@/A'QWXK\3Z;H&G:E+=:BNI6^GP_*GP%OEN?^
M"7__  ;AO//,<?\ !0[X(6%O%>7#O<6L>G?$+XVV%II$@E9C ^DV]M%I@TV,
M+%IPLQI]O'#!;1QIV4^',)1PM"O.K6I5G45"O1FZ59*5?AK'YOSODRVE@857
MB:-!4:-'%9FJ&'K4XU:ZQ*=6EE/.:]3%UL-&G%TO8^VAB(QG3<G0SS!8&5/E
M6,EB'!TJLW4E/#X15)1E)1=%NG4_H&^/?_!3_P#8@_9F^)FH_"'XR_&S4-'^
M(7AS0](\6^-]$\'_  E^-_Q;L_ACX3UV\CLM(\0?&/Q-\(?AQXZ\*_!S0[Z6
M02P:Q\3M<\):>;$2:F]PNF0RW4?$?\$EOVE?B1^U?^R=JGQ@^)/Q$L/BEJ-U
M^TC^U1X2\,>-='T_PAIFDZC\-O GQT\:^%OAM%IH\#Z3HF@:E8V?@S3=)M;3
M6TLY[W6$C34=5U&_OYI;F?Y'_P""=?Q0^#GP*^(7_!5'P7^TCXS\$> /C5IO
M[8_Q%^+?Q>OOB/K.D^'[CQA\"O%'AS1U^%7B^&'6OL;>(? ]EX3M[GPU:SV:
M:CIZ7L%QI@5+J;R9>M_X-ZKWPGJ?_!.6UO\ P';-:>![[]JG]LZ;P?9R8$EI
MX9N_VE_B/-HT#1HD0B,-@8%6(1QB.,K'L51MK+'Y5A,ORS,O9T,5.6'QG#].
MGF5>%!X;$K&X&OC,1]1E3HPE"G4JU%-PA7Q:GA:=-UI4*D5 VP6-K8O&8/\
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MV-/U+1?B)\8=-L)O"_AZ;P]J3QZ=XMO3/<Z9X0O9)+?Q+?:9)9WHL^W^/_\
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M-5\+6UQ;VUYXF\/Z)XVTC2)O$.B6%S<P6NHW>C->#3IYH5ODM_-C+_F1\5]
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MMW;I+Y#NAVNT+L49U 5MA8 9YZ2H^ZYZD9*48R6TDFO1^MOR04444%!1110
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MJ,GCXC_9O\;ZY^SG^UCJVB_#/]E?X\?M.Q>#(/\ @H-/I'AGX"7_ ,#-.NO
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M?XJW^I_&S4+6:YL?$WQ_\/WWB2?2/B7XJMS9R:_*FDZG=Z5874TJS?*W@/\
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MXAGF6.SL- \,:IJEW+%:Z?+*GZ'_ !\_8_\ V<_VGO _P_\ AG\;?AI9^+O
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M^ _P]\6Z39>&=7L[:WO=&TSPW>V5GXVT/PY T&GRZSINE7EK8SR-8R3?N/\
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M0\=>.;O2[WX@^)M173]1\8>*;JYGL=&35=)\)Z5/>+:Z9:Z+IJ+%'\+?L'?
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MGD$Y(^Y7^5UVV_K8_K=OW]NKWW[+\8M[[-6W.=O_ "Q"6"$,ZLP5E/W0 V"
M2!\X)''')Z5]K?\ !(QQ!^WEX>5V"B\^$OQ5MPK95]S+X:E[@, 5C)RGS!@
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M"BBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOPWE9,Y.U3S!$0#R'^8C"LN'(#9RHZ]FR 7!([]%:PABV. =OS#<W&T$;@0
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M2/&GPGUSXA>()[SQ1XRT>'Q1H(\1>#+GQ'>W.I:'I%Y=:++=ZA!#;3I\Z?M
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M;Q_<_#/X7_ML?LX?'?2-8\3^#?\ A9GP-\!6VG_#^\T'Q3X*N(?$/PV\<_\
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M^PQ^T3_P<0?M2_"SQ-\8M3^)G[(\7[+MY\'H?%'Q=\?>+/#U_P"+/VC?V1=
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MGA*E3$U(T\+[).GB*V;4<1]:E+%XF4J#K86G&+JT(5*T(1=%4HRG%OP?X9?
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M+Q#\.]#^(^I,_B"ZM=4T75KP3:I TTOZN>./^"=7QGA^*6A_M-? #]L7Q/\
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M3%-\I_[XZY&1GMC_ #_*K%% " 8 Z9 &3COCDTM%% !THHHH **** "BBB@
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MG\OS_P @O_5T245'O'JWY+_A1O'JWY+_ (4<_E^?^07_ *NB2BH]X]6_)?\
M"C>/5OR7_"CG\OS_ ,@O_5T245'O'JWY+_A1O'JWY+_A1S^7Y_Y!?^KHDHJ/
M>/5OR7_"C>/5OR7_  HY_+\_\@O_ %=$E%1[QZM^2_X4;QZM^2_X4<_E^?\
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MDI-Z'/4H*MRR=7$4FH\MJ5>5*-E)M7ITX2C=I[IWM9/8_#?_ (5=_P '#O\
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MCR!_>/Y"CR!_>/Y"C^U\1_T+>&__ !','_\ -P?4E_T%X[_PJJ?_ "L_#?\
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M#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '#O\ T=M_P2^_\1J^//\
M\\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__ #<'U)?]!>._\*JG_P K
M/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\ !P[_ -';?\$OO_$:OCS_
M //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\ $<P?_P W!]27_07CO_"JI_\
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ME_T%X[_PJJ?_ "L_#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '#O\
MT=M_P2^_\1J^//\ \\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__ #<'
MU)?]!>._\*JG_P K/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\ !P[_
M -';?\$OO_$:OCS_ //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\ $<P?_P W
M!]27_07CO_"JI_\ *S\-_P#A5W_!P[_T=M_P2^_\1J^//_SQ:/\ A5W_  <.
M_P#1VW_!+[_Q&KX\_P#SQ:_<CR!_>/Y"CR!_>/Y"C^U\1_T+>&__ !','_\
M-P?4E_T%X[_PJJ?_ "L_#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '
M#O\ T=M_P2^_\1J^//\ \\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__
M #<'U)?]!>._\*JG_P K/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\
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M7?\ !P[_ -';?\$OO_$:OCS_ //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\
M$<P?_P W!]27_07CO_"JI_\ *S\-_P#A5W_!P[_T=M_P2^_\1J^//_SQ:/\
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M;;6SNK]>5[2C>]I+22M)*S%HHHJAA1110 4444 %%%% !1110 4444 %%%%
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M8+34M*U.T2XMYY;.^M89FM;JUNXE>VN8)I/79)1@\]%Z;".H4=CG!R.>"!G
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MP64T]V)H;+PL?)BL(4>Z=H?(+R6ZHTFV%ALX(KQGX8_#[4OV0OB'!\(M-O\
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MN9Y['*:? U/$?VO"AALMH9%E&;9UGE&O#A'"TZ/$]#%8M?3_ .T=\:[+XA^
M?V#OBG\*=?UY/"/Q2_::^#&K6+V<]WH=[KGAW7;+5[N?PYK=EYT>)6GW6&IZ
M-?.UE#?6CI<R>3$+@>??"?\ :/\ C;\4-'_;UTOQA\/_ (G>&+3PE=_%2T\*
M:WK.K_#F/3_AFFD_#..;3?AY.OACQ;?ZO)XC,\TGB--7T>SUC2 EW +CQ#'>
MQ?94\9^''A_7U_8G_P""6FEOH6L0:EX:_:A^'UCXCTS^Q=1AN]!N/#_C;XB:
M9JJ:G9FV2;3K?3K^VDMI;BZAAMT*K*THCDC<^I>"?$VF^'?%'_!3'X+ZU!KM
MA\1O%?B#XI?$OPIHUQX9\016OB;P5J/P:L+.UUG0-9_LLZ+?127T4]F(H]0:
MXDN8YH(X6=&0>A5RS*<%E&/P%#!X?,ZN69AC:&%Q=>I&6-PV#POBWD6"J8Y2
MPE14*DHY;.$L4Z_ML/*A)I1EAZDY+PZN?<1YIQ-EN=XG.,?D]#/LGRK$YCEN
M&I5*.69KF>8_1ZXMS+#9=26*PTZV#D\WIU5A:-&>&Q+Q4;QE3S+#T(.U^SG^
MWCJ7@O\ 9V^ 'B'Q_P# KXZ2_!J30?AK\.]<_:9UFY\&7&@W/BW79]/\.P>*
M9_"]WXM;XB7WPWDUJZ6VN?B-=Z7#'+(\4D&G7$-S;3R_7W[;_P =O&?P3^!3
MWOPO&E-\7/BEXX^'OP/^#5SJT4=SI%I\2?B_XAC\+Z#K-[;S>=;7,/AZTN+W
MQ#';7D,UC=7&GVMK?0S64ERJ_%GQ@\/ZU<?\$>?#&E6^CZM)K$7P7^"4)T6#
M2[N74TD@\3^%6GA.F10O>B2U4,US']G\R-8Y&95"M7UA^VG\&/'7Q<_9QTJ;
MX7VMGJOQA^#GC#X4?M!?"G0M1DCM+7Q!X]^#.IV'B>S\+R23H(8Y_%&GPZEX
M>TZ2[GLK2+5]1L3J-];:>+F5/$S"CPY4XLP6-KX##8#!U./N*\JS'#UL?B:^
M78C#9?C\;4RW%8F<E+ZK1J8S$X&&9?5X4\OE@%&-&G3IJNU]AD..XZH<!Y]D
ME/,\SS;,\+X2< YYD>+PV68#"9Q@\7G.38##9SEN7O"I+'8K!X+!9E7RFICY
M8G-(X]5'6Q.)Q-?"0AYK/_P3B\+CPN^JQ_'?]HYOVB)---S'^T-+\8O&8\2/
MXS%J3#JG_"-IJ$GA.+PV=2,OD^$6T"73+31I!I26\^QFE]WUWX[>+OV<_@+\
M.]4^/FER_$KXV:K-X:^'[>%O@CICZI=_$WXG:K(UI!'X-M=;?P_:V<&IQPOJ
M^J7.KOI6GZ1$M].XAMHH8SXF_P#P4S^"$_A:.*Q\*_&6X^.4MA]C@_9OF^#O
MQ"@^*:^/&MO+/@FY@NM%MM"62TUASI=]X@GUZ#P[F.:Y;4TC/F+ROQ^^*G[6
M'@?]FWX#:U\2-2MOA7XF\;>/='TS]J'XB_ [P3>>);KX$^ =634;UKKPOI6M
MO\2[>+5K#=I'AKQ#XNGL/$>GV=\VH:K8V5O!Y"PY5,#Q9FN.RO \7TJ$J=7.
MZM'#4,QK9?E>,FX8#'8C&T,GK990J8MY#+ZGA:,*.54JN"K8NMEN$R6N\9F%
M*I#:&=>'/#.4<19IX:8K,:>*PG"<,5F>*R?"9IGV4X5ULTRC#X+&<3T,\Q=+
M+J7&:>88NM*MG>(PV987!1SO,>):*R;)\12K?4/P;_:EU7Q]\1]5^#7Q*^"W
MC?X#_%>P\+VOC?3?#7BW5O!WBS1_$WA.ZU Z7)JOAOQ9X&US5M,N[C2KQHH-
M<TF_CTV[L'N(/*>[5RR?/?\ P\DN-8\.>//'O@']D_\ : \>_#;X1ZIXST_X
MM^--,N/AEI%OX=3P1JE]9ZO_ ,(AI?B#QIIU_P#$?4+72[-?$&HV6BK:VNE6
M-S#IUSJC:[#J.F6/SI^RTG@Z?]O3P?XB^'/BS]I3XL^"=3^ _CW1O^%W_'K7
MOB%XJT_QQXKLO$WA^\U;3_ =]XML='\/Z7HVCVSP17<'@OPKX4T&_O?,N+>T
MO)HWNS[M^R;I&J6/[#GQAL+C2=1L]0E\8_MGS+8W-E<P7LW]H?$SX@36LD5F
M\*W,OV^*2)[-HXB9HC&8-XE4MV9AD/#64NKBZ^4SQBK1X$=/+JF.SC*:>#7$
M&.SW"9RG1J8O%9QAZM&CE^'GA\/F=>KBLMQ,G/'PY/\ 9)>?E'&G'7$<<'EV
M#XD>!C0Q?BW&KGN'R/AW/:F94.#\GX7S3AM/$1P& X?Q%/$8G.L51Q>.R3!4
M<+G>!P\Z65U:=64<QA]-_$[]KWPGX/\ !?P<\4?#_P *>+/CGK7[11T^3X&^
M"_AW::?;ZIXVT_5/#">+5\0WFJ^*=2T/1?"WA+2O#\]IJGB'Q!K%TDFEVUU%
MY.EWLJRQI3^%O[7NB>+G^*^C_%#P5XB_9^\;?!+0K'Q7\2/"_P 0-0\-:S:V
M/A#5;&\O]/\ &/A_Q1X/UG5M'\0^'W2PN[2:2(07L>HV\EC]B,FS?^<)\?\
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MXK?7[S2I-80PZ5):PM9I9QS0,'G-R"LN\>6 Q&<@5^P8_P"#=OQ>P('[4FB
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M3O%G@KQ;8QZMX?U[2IUFM+VUE!#!L$O%<6TWF6]Y:3*L]K=0RP3(CJP'QM\
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M%/I9@2ZM9]0>WC6V1(I(D21UST]W\;^/?C+^T+^T7\2?V<_@M\0[SX-?#_X
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MT3XG:YH^B?$+]GWXI_$#3_@[K7@V^T:?Q5IUMXA^'!L_&^O76LVUGJ7A75/
M]OK(T9] U&&TN+H^)KIIHE;3Y O+Z5_P4"_9EU?Q;8^'K3Q7XE_L+5O$I\&:
M+\5)_ GB>V^#6K>*C?/I"Z'IGQ+DL4\/W,T^JI)IUMJ)E31[J\C>*UU&7*,V
M"X:SBNH/#Y7C<6U@:>85EA<)BK8:E.MC:#]I%U*$*LX2R_%.-7"SKJI"%:&&
MHUIT*]NJMQSPK04H9EGN59;2Q&95LLP7U[,\!3692HX7)L6Z^&C&%:K2H.CG
M> E*EF-'!RHNO0^LUL*\7A8R^UO+9/+W%R[D@D.Q))'4R9)7(.,@J6X&0!BE
MB@5%41QF,1,!LP HVRJSD!,+ERF7P%+Y&[UJ\'1P#M!PQ&X$ ;^<'KRIXQDG
MKD=0:M1'<N2!GH0.W7C/0Y_7J<Y%>-&*LW&*6VCNHZ)QBN3GMRQA=15K)N4K
MN4JA]CR1FU*3O..BDW&52,91BK0J3A.24FHRE)2CS-4_=;A":\[^&?PZ\'?#
M#1+WP[X,TJ33-/O_ !'XJ\9ZF;J^O-4U#4?%'COQ+J_BOQ3J^H:EJ4UQ>W5Q
MJ.MZM>RH)9VM[&S^RZ9IT5II=A9VL/HZXYQQ@X/KGG))]\_SI,;<8'4D ]US
MP/J/3VP*< .2._7K_6MZE2=6I*K4G.=2HTY3J2<YSDHQBW*4G*4G:,5JW:,8
MQ7NQ266%PM#!8>CA<-1HX?#T(<E&AAZ-.A1I14IRY:5*E&%.G!2J3ERQCK.I
M4FW*52<Y+1114'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !110> 3Z4 %?G!_P5H_Y1]?M(?\ 8JVWZZMIWL?QXXK]'SP"?3TZ
MU^<'_!6G'_#OK]I 'MX5MB?H=7T\CI6V&=L3A[]:]-)>?.G^-C&O_!J]O95+
MOM[K/YW_ /@A)_R?-<C/!^#?C($'WNM)YZYR,=L>]?V;@9')(P(B,''W@ <X
MZC().<\$]N*_C'_X(1D-^W-<D9R/@UXQ/(Z?Z5I/!&>ISQZX(S7]G*L0H.#@
M[ .><JP7&.,\ '/ SQWKKSB_US5._L863:V<YIO7YW[K0Y,L5\+>.O[UZZ+:
M,4K=_+SOV/Y=O^#B?GQ7^R>3SG2/BH">OW9_"7/UY^F3],?7O_! ,%OV._&8
M;D'XY>+,\<?\@3P^"1Z<]_7FOD/_ (.)\_\ "4_LH=LZ/\5\'(Q_Q\>$,]>#
M@$'Z'/3)KZ\_X(![O^&//&9P2?\ A>?BO@<'G1?#P(YQP,\D@<#.*VJ.2R&B
M]5>-.[U5W[22\E=/2_ROT(IM?VG43MS\K<=5?EY(?JMKIWNVC]RVQN4 #A^O
M.1SMX/4$[LGUQ[\?Y_W_  5 ./VZ?VN,8!/Q%U0DC'\&E6.P@8!!)+<C!)R2
M6P!7^@&P;*D\ ,#@D'[S 8].!GO[\8&?\_O_ (*@C_C.G]K4C)Q\1=6'!X.[
M3+'/3NNWH3SDXYP*G)M:]1:W5#HF]+IROLFN5/O;S8LU3="BTW?VR6Z6MI7L
MW:^R[ZG]DOQ(Y_X)T^*N>G['MRHP!P#\)$W$#H3P,#@<<8SQ_'[_ ,$I#_QG
M=^RUP.?$97H.,^'9F([=6&0>PZ8Z5_8#\201_P $Z?%/3+?L>W./I_PJ:,$=
MNN[CW'.:_C__ ."4@S^W=^RWC/\ R,)8D\#Y?#LXP!D9Z#DY&<D<&ML U]6S
M'71SKM)Z>[R5$MVN]DMR,8W]8P&[]VELF]>:'->R>NU]K]=F?NY_P<)$_P##
M.WP3'7/Q=N=V!C"C0Y,@GM\O7E1@9.,5Y/\ \&Z8#:/^UGT^;Q3\-<XXZ>'=
M4&..G &1V).0"37MW_!P-HFHWW[+WPNUVUMYI=/\/?&"UCU2XBCD>*T&KZ5=
M6]H]PZ +"DD\1B#2,H+'"$L5K\O/^".7[=7P5_8\\3?&3PS\<[S4O#7AOXJ2
M>&-5TCQK9:3?ZUIFEZOX;MK^QN=-UNSTR*?4;6"]M[L7%K>PVEQ$LD)MY2K.
M&545.>3NG34I6G=1A9_\O4]D^VJMT>VY4Y1IYFI5)**=/1R=M/9K36_7737O
ML?V:@# P2>!SDC/'7&>/I05!]?\ OHY^GT/?\J_,@?\ !8C_ ()VC*_\-$Z4
M=O&?^$1\='(R1][_ (1[YC@#)'4_-C! "_\ #XG_ ()V''_&1&E?^$CXZSD\
M9!_X1WCC(]>?KGRGA\0M/856_P# [?B>A[:@]JM/_P #BOS?Z?<1?\%@EC'_
M  3Y^/.-O_'EH)(+#[W]OV.#T^\3SC@\9SCBOP'_ .""C'_AN'7!R?\ BP/C
M+(V\[_\ A(O".,@\[MN0.I(P.1T^W?\ @J'_ ,%1OV4?C1^RYXM^"/P-\9W_
M ,2?%WQ"N='@N)[+P]K^E:+X=TFPU&.]OKS4=0UNQTXM<R>1'#:6L$5R)O,)
MEDC2/#?'G_! C0]0O?VS/'&O10S2:;X<^!&MV^H7:1O]FAN-9\4>'DL()'V^
M7'+.ME>/!&S@NEO*R#:M>KAJ<J.58M5(NGS*HXJ?NW3Y'%I-^J27O/II<\ZO
M)3Q^'Y7SV]FKQ]Y74I.2O%.R2M=WM:VO?^Q)@IC0N>"6';!R'XYXY'&&(XR.
M":_-?_@IS^SW^R=\6_V?/$_BW]IO7-,^&B> ;"XO?"/QBMX[=/%?AG67MYC8
MZ7H\(/VCQ6-4FW0KX0*W']I-EHH('B^TK[U^US^V1\%?V,OAE-\0/BUK6;R[
MDFLO!7@/298+CQE\0=?^SW$MMH_A[2RXD%J?*W:GKER$T?2+=@U]<^;+;VUQ
M_';\6/C+^U[_ ,%9/VBM'\-:9HUYK,[ZC,?AO\)-"FND^'?PF\.33M$/%'B3
M49(ELY-4BL;Q5\2^-]12&ZE9%L=*M[2R6TA3CP.%J3G[>,W0HTFY2JJT$XZ.
MT;]$N9;.*O:U[)]6-Q%*FO9.*JU:EU"C9.[E\+:L^6S:[/31I7/S_749-+N-
M9M=$UO48=/U0WNC27$+W.BR^)-#2Z8VZZIIT-R"T5] D%]/I<S7"6\C[7&8Q
M7[X?\$._@G^QW\0?'&I^,/B#XCM?%G[2O@ZYEO/!7PD\76EM9:%H&BVRN!XQ
M\)6D\DL'C;6!#NDO'D66?PV(A,FGQ ?;5_2[X#_\$4_V8/ OP#\1?#KXQ:8/
MBC\3OB!I=M_PEWQ2!?3M6\):G$J3VMK\+),,_AW3]%O6S#>$&[\0&-GUA'MY
MO[/B_G-_;&_8B^/W_!/3XJZ-JYU;7)?"46M_VI\(?V@?!\EWH\\=[;R?:+6T
MU.ZL%C7PQXQL%7R+S3YC]@U5=US;)=VKL#ZWUFCCH5L+2JNC*[49W<?;*.MW
MS6<D[---J5K-7W/,="KA)4\15HJI&RYXQE*:IN]]5+166JDKI2T:MJ_[TMB@
M[\AOEQP0%;E63G(' !''\('&%KYI_:RUW]HOPM\$?$VL?LJ^$-"\>?&FUOM!
MB\.>&_$DEG#I5S83ZS9Q:Y-+)?ZAI-JUQ8Z.]S<VZ2W]N7EA50WS;3^4G_!-
M;_@L1H/QO;0_@5^U/?:/X,^-D@M],\)?$4_9])\%?%B6.-UAL]19W2P\*>/Y
M6&3IOFQZ-XEN)9/[&:SO6&DM^^'.2F0I!P!M)SA"#DG))(+,"?FP"^,-SXU/
MGR[&4*F(H4,5["O&<J&(BWAL33C+FC2K*,HSG2J-<LXPE";YGK&6IV8^@\WR
MS&X7#YCC,NGC,+4PT,PRZ5.ECLOG.#BL3A*M2G4A3Q-'FO2G.G4IQG%<T)PN
MC\!3\;?^"\(8D?LM_!X@Y/\ R$/"'S< X./B"2#GDEB1DX!X->6?&K5O^"X?
MQU^%/C?X0^*_V:/ACIGASQ_H\OA[7;O0]4\%1ZK'IEQ+&UREC+>>-;F".6=8
MPAG:VD>%&9X=LBJU?TF^5WRG'^R/_B!S]3CI@"F?9E!#!$R@)4,B')/4_<W*
M,\G!'' YS7V%'C?#X>M2KT>"N$:5>A4A7H55@\SG.G5I2YZ<H\V9<B<9J,ES
M1E9PBU:SO^08SP:S''83$8+%>,'BK7PN,H5L'BZ$LSX=E&OAL30J8:O3J-Y)
M!J$Z5:<:G(^>49M1:Y4U^?7_  3 _9E\?_LH?LA^"/A1\5!ID?CU?$'B_P 5
M>(=,T:^&HV&BS>*M=NM2M-(74(TB@U"YL+![-+RXME-J;TS+;%XXU<U/^"J'
MP(^(G[0W[&7Q!^&/PD\&P>-OB!J6L^"=0\/:+)>Z5I\Q&E>+-*OM1N;2_P!9
MGM;*UN(-*BNB2;B)Y8PT 8B3#?HU&I"!2<^I!/' ! Q@\\D$=SGGNV9=R[1C
MJ&P>.@(!'!Y!P0>2,?3'ST,^Q\>((\2-4)YA',XYJXN,UAI8F-:%7E]G&3DJ
M3Y.1QYFW%M2;;;/NJG &2?\ $/I>&]"6+H9!_JW_ *L0J1JT:F.A@/J_U?VJ
MK5Z,Z,L1K4J<]2ER*51\L8\L)1^+OV ?A'XO^"7['OP,^&'C[PU;>$/&WA;P
MI<6WBK0;2YT^\-GJ]SK.I7TCSWFFO-97=S+!-!)-<133##!/,+)@87[;7C+]
MMGP?X=\"S?L6?#/PC\2/$%]KNHP>.[?Q5>:=#'I.BI8QMILME'JNMZ%#(;BZ
M,B7!BN)638F8U#9?[K6%@>-AP/3&6Z]AP.XP.F .*8T+<Y*D%E^]N(X'. <J
M!WPJ@$\8QTQ6;U)YW5SK%X'!8Z=?%XK'U\%BHU*V#K5<75JU9TZE)5:=:4(2
MJ^Y:HFN2%VN5(ZY\)TZ7!V%X/RO.,WR.G@LHRW)L#G655<+2SK"X?+:&'HTJ
MU/$5,-4PE/$588=1K3>%E"?M)I14IN9^ Q^-O_!>#./^&6/@Z5S@?\3+PB<C
MD?\ 0_ #(]L#.,>OS9^U/\/_ /@M+^V7\,XO@M\2?V=?AIH'A2_\2:/KMW>:
M/KW@[396N]&E>73A>:C_ ,)7J\]G807#_:+E[6S:>58Q$ R.R-_46(L ?<SC
MI@#GGD?(>N<X.?3/&:##DJ<(<;NJAN25(X*#.2!NY&0 !BOJL+QY' 8BCC,'
MP=PGA\7A9JMAL33PN:>UHUHJ7)5@O[1E:<&[Q:3LU=-:M?F>:>"-;/,NQF49
MQXK^*.995F-!X7,,OQ&:Y"J.,PLY4Y5</6]GDM*?LZJII34*L96T3NDCP']E
M[X5:O\$_V??@M\)M>O;?4];^'_@#PYX;UF]M"4M'U6RLH_[0%H"5+V\5Q)+#
M"Y56G51,5&[:OT1Y:Y/7G(ZGH1S].<_E[U$L+ @[A@,"% QPN<#..>IP3CKD
MYQS9KX:O7K8JOB,5B)1E7Q5>OB:SA%QINIB:LZ]10C)N2CSU9:-W3OJ]W^VY
M;E^&RK+\#E>"C..#R[ 8++L+&<W4DL+@L+1PM",IR]^<U2HP]I*;;E/FDGRM
M)(!C';@>YS@#K[ ?C2T45D=HUR K$@G S@=?\CJ>O'8U0EV[& #;B-N,X+;@
M.A/ .3R#P-IR:T3P"?2HW&5) 'W<@$9Z GWQU[#/I4M-[.SM9.U[/6S5]+J5
MI*[WBKV1+C>SLGJKIK?575UJDXWB[?9E*VMC\8? GAS]H;]I7]H;X^?M0? ;
MXS?#WX;^#],UB/\ 9G^'FH^*_A4/BG)KGA/X1ZA(/&&M^$]0A\6>&;;3M/UO
MXE77B#[:8XM0EO;G0--C^V>3I5JZ[/[*-AX]^"/C;]JK]A[XC:]H/B'Q!?Z#
MJ_[37P8U30=$E\(Z+XI\*_&Q?$B?%/2O#/@S^TM=3PW8>"?C']JDDTF+6=2E
MF;Q@-63RH9Y+:T_5CP_X6T'PKI]OHWAK0M#\.:):O.\&DZ!I5EHNFPM=7$UY
M>O;Z;IL%M9V_VJ\FDN;EHH$:YN))9KAI97WEUQX:T*[\06/B>;1M%G\2:9I]
M[I.G>(9=-LI==L-)U26TN-0TRRULVK:I9Z=?SVMM-?V4%Y%:7DUM:RSP.\*L
MGVU;C3V]/'X"6582.4RP.3X;*</2PV!AF& Q/#-? 8C(L37S"%.-;%NE/#8^
M&/HN<8XK#YSBE0:K4*-_Q?"^$DL'6RW-Z?$.82XC>;<38[B/%5L5FU7)<TPW
M'&'S?"\6X/+LBJXB6'RN5=8O)<5DM:?MUA<1P[A'C(2H8C$17\_>I?M#?!.R
M_P""-_P_^&\OQ$\*CXB77P8\"_# _#XZ_I">/[;QWH>KV.B>(-"O?!\MTGB;
M3KCP_=V%U/K,VIZ1:VMA9*;ZZN!&_F5]4_%0>!;;XZ^ K_PA^TQ??LK?M(P_
MLW>$Q;:YXT\.^"M5^$7Q8^'5O/#=K8/;?$#4M*L-=U;PKJ,=S+J!\-:UHVJ:
M/8W)F>64N&K]'%^!'P9_X23Q!XO7X2_"_P#X2SQ7#+:>+/$__"O/")\0^)[2
M50D]MXAUE]$:^U>"X542=;Z:<3HH6;S<5L^.?A'\,_B9IEEHGQ&^'G@/Q_HN
MESP7>F:3XV\(>'O%>F:9=6N$M[FPL];TR^MK&:%%58'MHHFB4!5^4+M].OQG
ME$JM5X;!Y[AZ&-S;BG-\PE4Q7#V,K3K\4X7 4JN'A@L7@*V4XS X:IA*L/8Y
MI&%3'T:M"O4E@L?A(2EXU#PFXHEAH0S/-.$\97R[)> LAR6GA\MXQRVG2P_
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M\./%XJ\.6EFUI++I&AZI<B>^N(FBDT]XHQYBC]-? /P@^&7PKMKG3OA?\.?
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ME6L[0FSN+ -9VA%G,(O,LSY"8LY3$[1F6V \A_+=H]R$1.Z ,=N'&. 1P/O
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M%@98W-\7P[A<TX1P[P&"XBXLIX&>;Y[B8\.*G6S2K6Q+Q.!S##0P\*U7#O\
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MRX8D(VHN/9RGAGABAQ!0C+#YOCJ&59KE>7YCA\7B\!&&.Q69<$8[B:C6A&&
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M^ 2?Q/?WJ)HV)/(YQVX&,<X]20<\XYZ=*FHHMYO[VM_1K[OUU*<4]TGZI/\
M-/\ K3;0C*$D$$< C!YZY[XSQV^@]\FPX(R.A''U!].O7]*DHHLEW^^7Y<R5
MO3_.YRK7SO?2.M[7O[NNW6]^M[))NT< ]NOUP!^7K]!3/+(Z,?O9]>.W;MZ#
M\ZEHI_-_>_OW"R_X=)VVVO%VV7]620C(/;IS]#FEHHH_084444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNK.W\8?#OQ7I/BKPZ+RS?;>V$^H:1-<16E]9X<WEG=B&XM2,3Q1DY'D'PO\
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M?!86EA<.J6-QT<)1R_#+$XREA)U:JA@^(J6(Q%3#RQ/.IX6>?TGEU%XMJ=/
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M=Z'X@\,ZII&L6,>LZ-++I&M6D=[]CU2PD:"[@E*1/'6U#]C/]E_4[O7;^_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****  _E]?4\#]:^:/BA#YGC+)X<:'I8.%RN?M&I\<@C&1@=<9X!)&/I?_/Y
M=*\ ^(]L9/%8D&/FTBR0DYQ\D]^5&>0.&8DX(_O \9"Z;M--^?Y:'F\$ PIV
M C&[G=A<D  L 1@CIS][AB N*UX8NG3!X)&YLC<I).0., 9)P7("J@&"9H;(
M@# P0,@[6^4@Y+%3R>W&">A<$!:T8K5L+\Q)/(PI '& QRH&Y<X/"X4*4VG
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MZE$!EWC90V5!QGH<''R\X)7'/)!X YSFU^!< -&!SP!QW(P,\Y/4@X &<'-
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M_P!)\01/\%;'X=Z%X8TKQ!$O@]-%U+6-5U:YUKQ%-KT5]%/-\BQ:?KG[=OP
M_P""&_PT_::\4>-/B!H_B3]J/]HKX5>/O%=QXIU;3/$GQS^&_P )_#OB[1=+
MF\7^)="ETN^U>T^(&D^%](A\72P+:Q>)K:.^6Y\L7\LIVI<,X>>*JX6IFE2A
M4P&+G@<UE]2A46'JPRS%9FZN7Q]K%8NC&&#J87V>)GA).I4A7A&=%J3PK9_.
MCAH8E8&,XXC#PQ.!IK$3<JT*F/H8&,<5"E";H5)3Q5&NZE%5XPBIPG.#A)+^
MD77_ -K6'3?VW?@U^R)I_A.QUK2_BU^S=\6/V@(OB=9^)4EBTL?#/QKX$\(P
M^'K/1K6PN+;5H-:C\9/?/JT>LP"R;3UA%K<_:%DAW/VU/VF[3]DO]E3]I;]H
MNST#3_B%K7[//P<\5_%FY^'1\10Z'>ZQ#X:TB?5X=/O[VVM=6O= M[Y8=L>J
MOI-RD$:LZ1.B[C^&O[67A7PC_P $\/VG=#7]C?X=>&/A1IG[.7_!$[_@J#\6
MO@]X%\/:8U]X=T3QUX?\9?#OXB:?<#1K^YNFU""Y\7E]7OK.ZN9EOE:XLX4(
M:.$> ?M-?\$S?V/M%_X(+^*?VI].MTN_VJ-0_8OT;]IWQ1^VS)XM\4S?&[X^
M?$KXI> =*\8?$32/B%\3;C4+CQ-\0_AY\?'\7:]\/9OAQXVN]8\+-H7C&QMK
M:RLM6TZRUZSZ<-DF45:G#N)J8C%4\)F#RG!RIQPGM\1BL5CJV/KUIXBE*O1A
M1HRPF&P5"=/#5*U1UJU5X>ZHU9*JF8X^,LSH1IT9U\++&5$Y8IT*=*A0^JTH
M4Z4G2GSU%4K8FJJU10@E"FI33E8_K4\'Z^GBKPUX>\0&)8)-:T#0-;EL8I1<
M/8/K.D6>J"SG= LFZ(7GRM+#$TT>V14PP4;SRPO#YPG18$)9YA+$L2I$2KL9
M]QC"*5(=BV%8%&;=G'\WOQ^^+Y_X)^?'OXG_ !HMY3!X0_;._P""8$.NZ;81
M>;%#K/[4W[)OA6WL?#!MIUNH5@\0^+OA+\1I+2*WL&DOM5B\!6+J=NE,X^//
M@?X5^)GAC]G;X;_\$5?'WB'Q+JWQ)N?VX?A59_$&YUIVDUO5_P!F74O".A?M
M<_$*XOH(9;FXB\-S^)+34? M[J,,?V:?[1-#?.DFHRL<WPG4J4YXJ&,A"C.K
M[>E#V$Y2>!2SF695KI<K60ULMHX2JE5U^L89U9QE4E">"XDH4JL,-/"U*E6,
M?9U)J5U+%-9=2P%#FLX\^8X?&SQ5-2C%/DK?#R)K^I_X>>-/BQXF^(GQP\,>
M.?A''X!\!^!O$_AK2?@_\0+?QIHGB67XR>'=5\(:5K6N>(Y/#>F!M2\$MH'B
M2\OO#*:;KFRXU'^SCK%N18W$+GQC]J/]KBT_9Y\0?L?:-I7AG2_B%#^U)^V;
MX._9(U"_L_%$-A%X"D\5?#+XO?$&Y\5 6ECJL>LWNES?"ZWT>;PQ<RZ4TW]M
M/>27T$MFMK=?SM?M7^)/%&F?&/\ X*'_  7\+^,/$?PP\'_M7?\ !7/_ ()D
M_L@?%_QAX&U74?"WBO0O@1\7O@3X+M/'>E>$?$VDI*WA'4_&%GHEC\/8=6-I
M/81V7B6XT_4+>:TU*:WKZ8_;/_X)Z_LA_LA?M/\ _!'SQ]^RU\,M#^ %[K/_
M  44^%GPF\6_#;X;7EYX>\#?%#1;#X*_'?Q1H'Q+^('@F.\>P\8_%3X;3Z/J
M/A[1_BQJ<%QXT31?BSXNT?Q'KVL6^LV,%I+R3+J6,P2QV)J1^NX7$U\+A,/@
M*]2A)X+(5CI_7)SQ"K4I5<5B:,J<Z5*M17LZN(K>RPCI(VCF.*J4L1"C2C.5
M"M3]M7JXBG"KRU\SJ8:,*"C2]G*,*%&:FI5%4E[M)1]LY-_TG7&L:9IDEA;Z
MEJ&GV%QJMR+338KR^M+*;4[H@D6]C'=SPRWERJ%"8+>.6<!ERI)-:\+JS/'A
MBX3)1EP1EB!G))!.<_, <9..#7\;?@3X;>+OVZ_C9_P4*^+WQN_X)>3_ /!2
MC5M._;-_:-_9.\&?$'Q3^U1\)?AMH_[-_P )/@+XG3P9X+^%GP8^'WCWQ&NK
M?"SQ5!82+\3=<\>^$;3P]JOB;Q'XVEUZ'66EF:>\_H6_X)6Z'^T5X3_8T^'7
M@G]IV.Z'Q%\"ZOXY\'Z3-JWQ1\*_&?Q)+\-=#\5ZA;?#6V\8?$OP=J&J:+XI
M\8:)X3-CX<\1:E'<1W-SJ.C33W=K;23"(>=F.24LNPM.K_:-/$8F$L)3Q.&?
MU9M2Q6'5?FPWLJU2O&G0YHTL2L=2PU6K-QJ82$Z/-%=6!S9XW$RI1PM2G1FJ
M]6G6]G7A%*C5]DE4E4IPHRG5LZE*.$J8BFXJ7MJD)J+?Z,! <$XSC@@#TX_Q
M[<GZ4I12<X'7)X'/3K^5*/T[>XP*6O$WL_+3O9_Y]3VK)]-.W3[MM]?Q&[%]
M,>XX]OITXZ=*"BGM[=NE.HHLOZ;T].WRZ:;!9=M]_/U&!  !@<8[#M^'<\_I
MTI2@.>F2,= >_P#/K3J*?6_7^O\ (=EMTVMT(_+7OCIC@ >N3]2, ^PI511V
M!/K@#MT/\_K3Z*5EKYZOY[_?U[W=]Q679:;:;>GW(:$4=L_7_/N?S-(J >Y[
M9 XYSQZ=ORI]%%E_3_K3RVOK:X]Q-H_4'L#D'.<C'T^F?6D*#.>GJ !R>.OY
M?K3J*=OZ6GY -"@'/^''T]/\XI-@YSC!'3 Z\<Y[GBGT4K+M_7]-_)M;-@-V
M+G.![\#D@Y!I-@QCWR.!^ I]%%OZ_P"#_6FFPK+LNOX[_?U[C-B^@[]AUR3G
M\,G_ "*/+& #S@YS@9__ %]?SI]%%E>_7?YZV?RN[=ME9#\^JZ]>^_GU[C"@
M//3\!C\N*78OH,XQGC/4'KZDC)/K3J*++UZZZ_F F!Z#\A1@>@_*EHHLELK>
MFGY!9?U]_P"8F.<\=NWI[_E^5&T8Q@8/4>OUI:*8K+LAGEKZ=L=!Q[_4]_7F
ME"@#CKCK@>F,]/\ /TIU%*VW6VUVW;[_ .NFP[?G=^?KW^8W:..G&2>.N>OY
MY/YT;1V YQGCT_\ K<4ZBG_7Z_F'_#_/;\M!FS!/(Y/H.F2=OTY^O I=HSG
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M<U^.?[?G_!15_P!GN2\^#_P6@L/%/Q[N+4OKVHWL/VWPW\'K2YMEN+:75K3
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M:_XW@@6/Q_J'@'5]$;Q9EKFXBM=3DEU"7Z0?]@C]GVVD_8]@\+Z%JG@+P_\
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M6M[:M62YKO91OHI.QYZ9R<=Q[>WZT=?48/<>G]#ZU")HB?E8')YP"V2&VXP
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M3#P_XGLI+'6])&JR7)-KJ-E+%!(C_*)+=Y+>UFN;.:WN9+6V:4PQ_6W[*/\
MQ,?A/\,&89$+II<L;#Y?^);KILFC?)!(#9#H5SM)7H,CP;XEV!MOA#?Z?-.;
MN?2X]$W22S">>=K:YBMVEFE^]-(P!::9MSR.))'')8]]^R5XHDM="T[PZF67
M2_%FHR6[$*R>7J6IC4H2,@@QK)/N<*"S!?E.XJ:[*?*J$H1M:,U&-)MQ;@XR
MC-02BW.?++6/NMQ3?-LC>F^6<7.44D_>ES6O'6_+&SE*<?<E!QBU3DO:3M%(
M_B:^*'B;QCHWQP^.\VD?$+5[%Y/C5\59F746>Y@=CXYU_P"64:C#J>FSK&P
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MDGB!XM<%5,--*EEF)SKB7$X>$5_#IQX?XWRW,L&Z$O>A)0QCPLHMQYI))O\
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MDY^SKRIKFKSC!3FXQ:ES+\DO^"AT'[/GQ$_:V^&7PZ^*?AC]L3]MSQ5H_P
M8];\-_L$?LP::]AX'\!?V[K\5HG[1?QO\:CX@?"[PQI<NMO9CP=X+C\=>,KT
M:>;/4]2\.:)YS7%[)\??#?\ :?\ VC/@/_P2]_;L\-:'<?$SX0^,/A%^V<W[
M+?PDC^)7C?1/BG\3/V9/A_\ %?QAX T"*RU#XA:=JGB'0_$FH?"[2O&FJ77A
MW5;/6=8MM'E?3TBU&XETXR#]I?C=_P $^]:\=?M!W'[3GP%_:R^.7[(GQ5\7
M_#?PS\&OC#J/PP\,_ [X@:7\4/AMX1U.]U3P[OT;XV_#'XAV'@[X@Z ^IZC;
MZ'XZ\.P1FUMKMX=4T'68XX%7F_@__P $F/V=/A1\ ?VI?V9-5\5_&+XR_![]
MK;Q/J/C'XC:?\8?&&F^(?%FG>)/$&BZ=9>(=<T'QSIOAW0O$4NN:KXDTV+Q_
M'JVM7.IW.C^*RIT,V.B6UEHMIVT,^R&& PM#$?6,9"E7R:NL-4PTY5*53#YC
MB:^9NE3J4Z.7T(2H5J=.E9XO$9A&$Y9C6I*;HOBJY-F<\7B*]*-+#59T,RPZ
MKTZL5&=.MAZ4,%SU8.ICG4]I"4JBM"AA&XQP=.7)"LO+_#O_  2Y^"?[,OB[
M]G;XT_L^_M >//@#\1O"WQ-\%6OQ=\<?$'XH^+?B-I'[7'@[Q>KZ;XO^$OQ%
MT7XA^/8M!U+Q?\2=9O[+4?!'B>QMKG7?"WBBWM9?#NDWS&.R'Y):,NJ_MN_'
MC]NWXL_M ?L4?MN?MF2^ /VU/VB_V5?@GJOP"^/'PZ^&7PT_9L^&'[.GB*R\
M!:)H/A'PK?\ [0_PR\3Z'\:-8U>RU+XD^./&.J>&VFN;G7]!_P"$9U62P&HF
M[_9/P%_P2TUN;QU\$M9_:A_;>_:7_;+^&G[*_CCP_P#$?]FKX-?%[0_@7X7\
M/^&/'_@C3I[#X??$7XM>)_A;\-O!_C3X^?$?X>))]K\'>)/&FLV.G:?K'_%0
M7_A[4M=FN=4ET_'G_!,_Q1:?&#XN_%K]DG]MS]HK]B:R_:<\50^-/VF?AE\+
M?#/P0^(7@'Q[XX_L2/PWJOQ6^'>F_&?X<>,I_@?\9O%^CVFFV?CKQ]X*GGLO
M%O\ 8GA[5M4\+MXBTFVUH887/L+3K5Y8K,Y8_&U\/&GALSJ8?'8>EAX1S:&,
MJ895<+@89G+ZQ@J3HR]KAH4<-4I_4Z$Y8"I3JSNOD\IX6%+#8.&#P\:RJ5<)
M2JX6M*O)X*>$56I3Q6)G@9.EB)QK*:KQJ58Q=6K_ +:W3C^7/A]_VO?CG-_P
M2R_X)Q_MS:E\8/AGIWQ0NOVR?%W[0%KK7CS0=(^-?[0'PH_9>U""Y_9_\'?$
M3QG\)M?U&P#>-/!WBGPMJ7Q:3PMXCCU37;_PEJ=X=0A34'FKZ"^$_P"RM\/_
M -DS_@MO\(?"?PCUKQC%\,/$_P"P=\7=>\-?#'Q)XU\0^,]%^%]_:?$KPU9:
MY!X(/B?4]6U71-%\63_9]5O-*CO'T]-2MII+&WMD9T/V_P",?^"4?P%O?V>?
MV=?@=\)?&?Q@^ /BK]D7Q#<^.OV<_P!HKP)XFTO7?C=X-^(FL3:S>>.?%GBO
M5_B#H_BOPY\3K?XN:IXCU_4/B]X6\8^'+[P_XPDUN_%M9:&\.DS:8S]G3_@F
M?+\(?VHK#]M3XN_M<_M&?M0_M*3_  HUGX1>)/$/Q)T_X/>$/AQJ'AS4=2T_
M4-/B\*?"_P"&'PW\+:7\/H-$^P%8+/0=2D.KW%[?:GXFN=9OW@N+9OB#"5*.
M8*CC'@Z&-RSB##/*:.5NG2Q..QV,ABL+C8>[66%IRIQB[5<5/%865-83^!5J
M1IIY+B(5\'4E1IXJMA\?EF(CCZF(C[7#9=AJ$J-7".+JQ]H^9RY7"DJ<XU/:
M+FJ4X2EX_P#%OQ'XAB_X+#>,= AU_6X- 3_@COXIUZ/0H=3O(M(371^T'XRM
MDUV/34F6S36DM8DM5U,0?;%MTCA641J%K\:]!_9'\,^$_P#@@=X0_P""DT/Q
M+^.FH?MP?#[]C[P'^TE\-OC[>_&3XBR:SX)N/ =I:ZU\/_A?HGAQO$(\))\-
M-'\(6UEX)UGP[=Z-<6WB>)KOQ/K@O?$MR=2B_I_\4_L<^"/%O[56K_M:WGB[
MQU:>,M6_92U3]DB?PE8R>&%\&V_@S5?'6K>/9_%L"WGAVX\0GQE#J&KSV%NT
MNO2^&UT^*#SM!:[,UV_E\_\ P3G^&-S_ ,$VE_X)CR>/?B1_PJ%?V<[7]FUO
MB%'+X5'Q//A&TTF+2$UL3-X:?PF=?FLXDC:0>&VL/F9C:"3##GP7$5+ X7+*
M>'JSIRCB.'GF,:="$5B,'@*><PS&E5E*E*<Z-1XS#1JTN>$:]TJG,J*<.V>3
MNO6QM3%4E5<JN9SP3J5I2]F\2\LEAW!0K4E&K%X:K[*7,I4E=QE%SN_H7XF_
M%36_ _[,7CKXV:?IR:CXD\,? O6OB;9Z7'"'MKS6]/\  EQXBM[>.!G&Z ZC
M'AX2R[H?D#>G\]VG_L%^&O%'_!,,?\%$Y_CE\:_^'@FJ?L[7/[8EM^U7:_&;
MQT+K2?B&WAJ?XDVOA"R\'CQ%+\/E^%ND6A/@:/X?W'A^?05T6)XI;4W*AH_Z
M=+'PCH]MX/M/!%W -<T2W\,6_A*YM]72WE;5-&ATB/1IX-0BA@AMI!J%FKB\
MC2&*%S/*B11(1&GXWS_\$98)?!]_^S1#^W1^UO:?\$^-3OKNZO/V)(8O@D^C
M+HNH>))?$M[\(['X_3?"^7X\Z=\!+B9_['3X;VOB^/4[;PZTNAVWC*WT^;R8
M^/*LTP^"I5J<<1+ SGFV'QLJL:+JT\3E5#ZU;+)4XX>M+]Y4KJHZ=2K2PM9-
MTZK@J5,TS' 5L7.G*5&.*@LOJX>$)UW3EA\=55&/URFW*G&T84G%SA[2O!P4
MJ2DJE22XWX)_&;Q1X<_:Z_8M_:<\9W.JZ'\/_P#@J9^QUX>\(^/='O[K4)/#
MW@S]IWX#> KGXP>&-3B@F3^Q/"<'CSX07_Q(BG>W>UBO_P#A6:MJ1+6UCO\
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M1KPE^SU\0?VW_P!JCXI?L$?#OQ#X8\0^#/V*_%=A\$[?PY<6O@K7[;Q+X/\
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MN>&&\57=U80Z]:6=Q'>PZEJ]S';W6O1V>JZU>,Z37!_<?X1_L8K\/OVAM/\
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MM:E^T#J6M>+-=D\)GQEI$O[0VK>(]8\2Q:.VF>%].\/[/#\_B6ZB\.'4=!U
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MSQ6VI.!G>OG,.&!(^=)]*LBSNVFZ9/*S%Y9)=/LVD=\L':4R0,[2,<$N[%B
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M.?<#TX4LV\8/\3K@ Y/R'&3@XYWGCC# 9SC'\T7Q2_:J_:]\,?L=?M=?L?\
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MQ9#:7\!+@KE?D^,GB*#=M.&96F^&><9R,;6Q]T,P&6^3O#_@K]N6W\5://\
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MLO7 <_Y_G14 FC![ 'GT(4<;R#@!2,8'!R2N"^Y0OGIN(PQZ#(VE<\D\ALC
M'.< X^3=@U,7S;1E\XR2_%?UYEW75K[_ //4FHJMYRD$[RO4,-IX(!)&>2&"
MKDA2,'T))I@EA5]IQWXVY.,%LM@DKT^52NXY 4$JP1-O;12O:S;6G7[+5UJ[
M7MIN%^R;OU5K+UUNON+E(V0"1UJ+SXR-PW,.3E5." .QX#9R %!+%CC;E6VX
M^JZUIVB:5JNM:I+]FTS2-/O=5U&Z\F25;;3].MIKV]G$-JEQ=2B&T@>7RK>&
M::0J%B1Y7"%W?-&*7-)K2$4Y3D[QBE"*5VW*48VWNUU8I244VW%)7UDTEHFW
M=MI623;UV3>R9O4'ZXKR+X*_&CX9_M"_"OP7\:O@YXC7QA\,_B%I3ZUX.\3C
M1M=T(:QI:W=Q8&Z_L?Q/IFB:]IY%Y97$/DZGI-G<?NMYA$+([^F2NH!#*=V6
M;@(,C:H(W-A.%.6"EL#"L0Y4,JJG1E.%:+HSIRG2JTZJG"I2J4^;VD*E-Q3A
M.#C*,HR<9*2Y79W00E&K&,Z<HSA-1E"49)QG&=G"<6FU*,E*+35TT]+Z-WLG
M/7CT^7!'J#D=N?:GU^8_Q!_X*\?\$]OAA\5O&GP7\8?'378_&WPY\?>'?A5X
M\NO#_P !OVB/''P\\(_$SQ3J.@Z1HO@'7OC#X(^$WB'X1:=XNDU?Q+HNCWWA
MZ?QRFI:/K%W)I6M6MA?VE[;VWZ5^:N6CX<H2"Q7&P [<[B?E.20I(!^4D;@R
MYUJX;%891E7P]>A&K=TI8BE5I*K"/(Y3HJ7/S17M(:VBO?CNFF\Z5>C6YG1K
M4JG+:_LYJ25^=:NRL^:G-6;NG"2T::5VC/;OZ=ZK'*KE6)X)*8;TY !()P2>
M#R?0M@%$//#*. <A0>IP.H!Q@<\Y!;D!LUASJS?-#E[\TM[VL_<T[7OO?0V^
M:_R^6_SU+.3Z>OXXQCZ9]*"1QR.N/Y_U'?WKC/''C;PU\.?!GBWXA>,[]=&\
M'^!?#6N>,/%6KBRU#4O[,\.>&].N=7UO4/L&DVU]J=\;/3[.XN?LFG65WJ%Q
MY?DVMK/</#%-1^&'Q*\%_%_X<> /BU\-]8'B'X>_%+P7X9^(7@?Q"NGZKI*Z
MWX1\9:'9^(?#>L#2==L=,UK3#J.D7UI=G3]7TVPU.S\W[/?V5M=)+ EVJ<GM
M?9R=)U(4?:)2]G[64'4=-3LH\RHKVMK\SCJE;4S=2"J>R<H<_)*JX*<7/V<9
MJGS\N_+[1\E]KZ;NR]"!!Y%%-3[JXYX!R>O/-.IFGKOU"BBB@ HHHH ****
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MB_:HTGQ%^U7\-M7UC5_AGXP^&OAC3?!^KQ?L\_#G3O[&U6U\=>)-"N9]1O\
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MDEO&OW7_ ,%'/VD/C+\#O _P"^&O[.\GA?3OC]^V'^TYX#_95^&OC+QIIO\
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MX%TOQ-+&U[J7AB^UW7K'P=#JFI1Z7J+7-C/XBM[F*-HAZU^U)XF_:G^!VE_
MSX;_ !<_X*?_  V_9E^&7A[X>WMS\0?VL]=^'7P?/[0W[1GQ976;I+/POX9^
M#>N0:MX$\%>&='\.E+[7]7T+P_K]QJ-]':V=DFG_ &EVC[;]GK_@GK\:?ACK
MO_!(W5_%7B+X>-!^P#^S-\4_@7\2K/0)-9E7Q'?>)/AGX4^'7A'4/!C74:'[
M%'#X7CO=6&I;)4\\I "4%2_M-?L;?M*P?MTVW[;?P \)_LX_'BZU_P"!&@_
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M_"CP7I,\OGR6G@[P)X:T[PKH5G/.%1IYDT?3;5;BX9%DGE\R=B&F:OQB\/\
M[&__  4F_9C\,?%K]DK]DKQ/^S/JO[*WQ1\6?%SQ-\-OBM\6+[QK9?%K]FG1
M_C+?ZEKOB;P59^!]#M)O#_Q'L_#NNZSK5QX(U&74M'DM8+VW764NC;LM>/E>
M+P,L7F=>@LNP5:6895/+EF=.A4P]'*,/CFL=1C*MAZT'C52P^"JU:D:4,17B
ML9*E4C6JSB>IF&'QD</A*-26-Q5-8',:>*G@YRA7JYA6P?\ LM1JG6I<M"4Z
MU>$(J;H4INA&<)TH19\<^!?VY?%G[)/_  2)_P""4_PZ\%^-_!_P-^(G[5L5
MU\.[CX[^._#=UXR\'_L^>$O#;^)O%7Q,\??\(G;%1XN\2:9;FUT/P/X?OYX-
M+U+7=2MIM5G73[6Y>O;/V2?VY_'FI?M:>$_V0-$_X*&6G[=G@[]ICX.?&VZ\
M"?&V3X">'? OQ-_9C^./PN\.:?X@L5\4Z7X4T'P[\//&'@#QKX:U/7]>\%0Z
MQI^G:E;^(/ 5YX>O;[5+>]%T?<H_^"7?QC\/?L1_L!>!?!'Q)\!:9^V+_P $
M\=:B\8_#'QMKNG:IK'PH\:ZCJ$.N:#X^\%^,[ $:LGAKXC>$=7-G>:I;(^IZ
M'J\%MJ5FK&'!^IOV;? 7_!0'Q7\=+/XP_M6:K\$?@I\-O!W@/7O"7AG]FW]G
M>\O/&6E^._%_B2^LI;[XI?$[X@^)?#^E:HK>'--TTZ7X%\)^'XK6VLQJVMWN
MM75]<30Q1^GF>-R:MA,YK4OJ.(Q.(Q7$U6<ZU3#0KXC%XC,*M3**]"G/+:V.
MKTG1E3G26%Q6$PM_;PQ]*SBY>?@<+FU&MEM&?UBC1HX7(Z4*=.CB94X4:."C
M#&TIS_M".&IRC7C.-:57#UJRA[!T)SDFU^ G[/?BG]K#]E#]B[_@H!\:M"_:
MB;QK=P_\%@O$/P/U+P]X@^!WPOL+75?B+KW_  43^"?P_P#B_P#'2YN$AU0?
MVK\5_"%]KNGKX%%F=!\ 7&O_ &SPC?07.AZ5=I^IOB7Q'_P4 _:>_P""AW[:
M/[,GP@_;!@_9@^!'P#\)?LW>*K/Q)X<^#'PY^)'Q-A\2_$;P_P",)I?"6A/X
MXMY-"MO#&O2:5+KOB/6-;T_Q!JT,NBV.B:#'I,&IWFHPUM=_X)??&_5_V-_V
MI_V>8O&?P\C\7_'#_@J=J_[;_AK59)-8;0],^&5_^V-\.?VA+;P]K#K;BY/B
MY?"?@^]TV5+9&L#K,]N@F^S,TM??7P-_9C\:?#/]MO\ ;<_:5UO6?#]YX,_:
M4T']F[2O!FDZ=]L.O:1+\'?#_C?2O$,FNB5?LHBU"X\26<NFFT9BT4<OG!6*
M@SFV;9;7_MC&499;7QU:ECU@ZGU"BX.=^&:6#E3PKHT\/3JQHX;,5"IR+FA&
MM*:YJB1U8#+<51IY?AI+%T*%.6'>(IT\55T3CFDZT'7=25>5)U*U"4H*:Y9M
M<ME=O\=/%O\ P5<_:.^%W['.A^$/B#\1OA;H?[3FH?MV?$/]@_5/VH=>\$7D
M?PZ\/>%OAG,=3\7_ +1VJ?#71[FZM9O&-IX,FL)=(\ 6FH#PWJ'C"[ABN+^'
M2K:XCDZ?]E3_ (*)>(? '[7OPP^!>L_\% --_P""BOP5^-_PX^-VMZOXRN/@
M=HGPL^)W[/\ \0?@IX#;XG":^G\":+H7@W6_AE\0_!VC>,+31[;5M.7Q!I/B
MC1[.U_MG4+.Y8U[3K'_!*OXS77PV\=ZKX5^)W@'PE^T7X+_X*(_$7]NG]FGQ
M;=:/J/B'P;#:^+TM]-O?AI\2M)F:.=M(\;>%WOM \2W6FQ376ER?8-0TQM\$
MB2?3_P "/A=_P4!^)WQET_Q]^U]-\ /@S\&?"?@'QKX-7]F_]GF\U+QK8_&?
MQ-XWM+/2KKQQ\3_'7BC0=*U#3-!\-Z0NIV?A#P=X>2*=;O5;O4-<U.["PVJZ
MXG%<,_4L4Z-' 585*V9RQ%*E4PF%KRJ8F.7RP$\#2K9?7QL:5&^)="E@\9A\
M/3K0Q-/%0M.G-\T,-GJQM!2Q&)A&$<''#SE3KXA*E2558I8NK#%T<'*=62BJ
MM2OA*U>5-T98=IQF?F'?ZU_P4X_;!_X)S?%7_@H5IW[4OAKP)X;^-_[/7QF^
M*_@']@BX^!W@SQ#\*A^SSJ7AGQD_@OP/K'QADOM)^*US\8O&'PYCTW7Y_B);
MWVG>$[/Q/J$-BOP^M=(CN)%_:C_@FPT(_P""=W[!KP.\EL?V-_V:FMY'&&:)
MO@]X0\DL,Y/[HKGN?O$ L17Y7:/^PK_P5(^$O[,'C3_@F=\&/B%^S3-^RI-X
M)^(GPM^$_P"U-XTO_' _:!^'/P-\87?B%=,^&FH?#G3[0^%]>\;>%/#>KKX*
M\._$.WU;3]+M=-BMM4DT(7NF6\<_[3_LD?"37?@-^RS^S9\#?$]UI=_XB^#7
MP'^$GPLUZ]T4SG1[O5_ ?@30_#%_<:2UR%N6TR2ZTR5K+SU$WV<Q^8-V:\S/
M\31J97/"X;$9/.G_ *Q5L9@,-E]&G2Q%+*WE%/#8>6*E3P]*;E%VH<N+K5\7
M&NL4ZDI1G&I+MRO#U5F/UFI0S"+_ +'AAL15QU3VD98M9C.M4A2:JRI7E#]Y
MS8:G2P\H.FX1BTXQ^BTP0N>#CCD]  #_ )__ %U)35&%4>@ _P ?UIU?)+9>
M73RZ+Y'U#_K\_P"O,****8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R>IP7TM^9(+
M226,VT 9U\L#?F9C'EY$^Z"/X" 2,G)%=910!QRV=Z0NZUGP 1M_<G@$C!/F
MKC(')"],$8S2FRNC_P N,P^C1#_VI7844 <E]EO>UG,N01D-%QGOCS.W4?CZ
MFHVL+UL9MYVP<](N!@],R]^AYZ<]0*[&B@#AI[/4D3$-G.[9(',2[2<$$CS>
M0OL>_7(IJ6VI''F:=<@J "?]'(8YR=H\W/<YS@YSU'-=W10!Q!M+Y<L+*<D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "@ &L# 2(  A$! Q$!_\0
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M3M*&-6VNJIM!( <8"JY8A2O]LP*7C$Y5XR"Z H0FS:NU]SMM;;L#R\LQ!V#
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MYA<;XS%=JTMON!$MG-;S*Q60&N:\/7J:IIWV8NK2;/.MCNR"P!\R(9R,,OS
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M>L9*UMCB/^"UO@WX1?&?]AS]@7XZ_!3PS?\ @&W^&'A3Q?\ !35?">H7XO\
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MAIXJ%W#+Y41UF^.J^&;F>XC4^3%<W9O]/5Y/W:W#V\>Y7E3=_,/\'/'7CO\
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M6'3?!GQ$\/PKIWBGPT+2P5!:Z7::PBZAID=K&C2>'=3TRY@3_2$)^E/AK?\
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M<L;2]B565B2/T(N]#T72M(C:SC)FMK5BTSOYMS/*%.9+B0GS'F=ADL>Y ^5
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M<[B,F.XN[6_:+/\ RS52,;AG]"JY+P'X/TGX?>#?#'@?0HA#I'A71-/T2Q7
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MLT>M:4DN+2ZFAC6S?_/=T;Q&VI6EM<--:ZA;RHC*6/S(&0$,0!AE!Y&Y2<$
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M%.4*C?- _N+^T0"V\ZXF6&.'<1)(ZHA1@68MN/)7'RJ!GT!) K\_/VTOVN?
M?P'\+Q6UQX[TSPEXJU#5M'@T.:<QS:G;:B^H6SZ;<R6+*[6%HTZ1&5[U5GFM
MBVR&*!_M _(_XU?\%L;W4([BR^!GAN^F!E-I!XJ\2V=P]TVXE)+BQT\16NGZ
M?"H8>7#:P/>N3E]1D52&_G8_:=_:P\1>*?BU<:1\0-3FU^>YMO[3UB*]G9[E
M)KN43?,"S""6-?N*H'EAE)!?+5^.8'.,OJYI0P>'E];@^>>(K-2CAXT:*YJL
M82MS5I3CS4U))4X-\SG*UC[FIPSC:& J8W&6P\I)4\-A4XRQ%6K4]VFYRO[.
MDHR]YI2E.3TBH_$?Z=?P/^+WA3XY?#3PY\1?!^IQ:EIVKVHAO=H2.XT_6[-5
MAU?3+VV5Y/LMU:788F+<5>"2"XB9X9HY']:K^9O_ ((\_M'6WA>T\ ^'[G5Y
M)? WQITG1(;2WNY=SZ7XF%M]CT#5VW84-J;0_P#"/ZC/QYTG]F3RDM#FOZ8Q
M@]/?\\\_KUHXHR*>09K/"KFE@\31I8[+ZK5_:8/%156FG)*TI4G*=&=M;TXR
MEK,\K*,P6883GE95Z%2IA<5!:.&(H2=.=XW;BI\O/%/HVE=*[_SD_B9X.73O
M%&JM#&1%=*TZ@K@?=R>0!@@' XR>AYZ?+^O^%_/03^63('.X;2>,\>G3U'7'
M(YK]'_B_HS&:*]$11L/$<C!PR-DGIT.&'RD\%>&S7QR;1Y8'E5&9%NI(Y  2
M5PV"<GH3MR2#M / ).:_J_.,%#%0HS2DJL*<U>.Z]FE[NE].5Z-Z.SLK(_&<
MJQ?U9SA)KV<Y*5FGI)[V>Z3V25K=+['E/P\\4_$KX2>+=.\:?#+QKXD\#>*]
M)E2>QUWPSJEWI=_ T;9V-+;N@FA8C$EO<+)!)]V2,J2*_I"_8U_X+Y?$#P\N
ME^#/VOO"P\<:1']GM!\4O!5E#8>++6+Y8_M7B#PR&BTS75507FNM*DT^]<[G
M:WN7.#_/[?Z IC,T2@J0<F,GY<]"R@D@GJ3QGW[\_&ODR?=4[#@=3N'&0V1D
M \=?Y5^;YKD>"S*'LL?0IUK)QC72C'$4K[*G6@U)<M_AGS1O>\3ZW!9G+#S<
ML-6=-Z.5)MN,M=7*G)M-.^\;-=UJC^[W]J#XI_";]LO_ ()V?M8#X$_%#P[X
MELO$_P"SS\3;'[?INH+#J.B7$WA'4)OLNLZ7<>3J>CW;;6MC%?6T):1BL;2+
MAC_DI_#WQ_K?A6^N_"NL7,\5YX>U"ZTF0RE@S+:3/#^\24;@Q W9(R01C@#/
M]'7@CQ[<^$[N:*SU;4]+M-9A73M8MK"_NK2WU2QE8;[+4(;>2..\M'."8+H2
MQ$D'8<U^,_\ P42_9NU3PEXTO/V@_AK ]QX(\0W:P>-M,LX7,GAC76^2/4)T
MB7":5J*J!]H8;(KC;N8*Y(^#SC@"K0R#'8S+*]7%_4<;'$-<L57P^%J8>,9\
M[A>->,)04I-134.:3BFFSZK)^*Z=+.L-A\8H8>.-PWL8MRDZ=2LJDI124HV@
MVFXI-N\K)=$:GAOQ\-4N[2TNTAN(I=@\R!MDK!B<%PH!D"@DL,GC)QTS];>%
MK'0[?6/"-Y:Z>)4FG$;3,?*F<R@+L:1ADQECTQA>,$5^''AGX@ZQIE]8SFZ=
M&BN(W1LEHV7@,.2<97(*D<<\U^H_A7XA:HMCX*U:29(]-N-1L(YF)RD$LNW8
MQ*@E8I22H&5*X[@FOPK,Z=1J%VN9N5[-J\H-O6]O>?6W1JR:/V[)L70J<W+>
M7)9:J[2DM(O1O1W7SM965_TXUC5=%LM4L!-H]L9(XH1O@M55HBJ[E9+A%21I
M8F4 2JX;>H((P,]$EQ(=0@O8+*P@MKR-(FNKR"">ZC4IQ*KRB64#J'4L23DD
M=:X#5K;^UK.RU""_ANRUO;ATMY"/*R5. 0<#&<GG)/'O7M7A[P[;ZIHEM)?2
MEX41=H4@2;D &U7!RI Z@_,!SC'(\*;G"CR*4M9J4X\\^5RUU<5-1;UM=IZ:
M;'O0A"KB>96NE.S<(M\MD^5-Q;2;MHK*]O*W66/AS0K#P[J/BBZ,-[=V%K+<
M6KR1I%;1,D;-B&V15&[(+*V-WRYP5XK^8;QWXM\0>.?VG_&%M;0S:IJ7B'7O
M[*T:SAWRS7M[<W"6EG;6R#!>1IF1 B@X&3C;FOZ6/BAK]CIGPXN?#?AC3M3U
MCQ/JL+Z;I.C:7#-J.J:AJ-T/)AM+2TA#W$TLK$;0B\ ;BP4,PN_\$Q_^"3-]
M\)_&5]^U%^U/H.F7'Q+N;N?4?AI\-KAH]13P+'<R&4>(?$TBEK5_$<B./L]H
MID73!D;VN#(R_I/A?D.)S?,,1B9*M2P5"'+7QLH2E2BFU&>'BVOWN(JTKJ-&
ME>:BU.IR4TI/X7Q.SNAE6!P&'@X5,5.K[6GA8R7M9SBO=JU%#6G0A.4>:I+E
MBM(0C.4FE]!?#RU\3_L[0?LR?#B2=].\8>&OA;I<FN1I,S+;>)9[V'7-,0N<
M$26>I6\*]!M!9!C)K^XCX0>/['XJ?"WX?_$;3G1[;QGX2T/7R(\;8;J_L(9;
M^U.. ]I?&YM9!_"\+ X(Q7\+W[47C1I/VBII+.2*:ZT:VTA7;<6=9HYOM&Q@
M!D+C 7& %QV&:_5SX,?\%(?%?P5^&7A7X:6.B7=Y9>'+:_DM)DFMD1;?7=7U
M#Q)#;JL\JRJMFFKK9@,  (,)\FVOZ+\4.'UC\CX4KX2E&&)PE*>$DYM*3PTZ
M,*E*G.5[3=+V4-;WO*=UK=_SYPAFLJ69YW"O-SAB)K$6A&T56A4E3G-1>L>=
+3DFF]HPM\+9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "2 &T# 2(  A$! Q$!_\0
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MP?7G QTU(0"@*!=BAB00.0/N@#&0>.V><=<50F3.94W+N)S@XQSR2ISC/?C
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D?S8Y;:V7[MO O^[%&.G3HM2"-!T1!]% _D***!CZ*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "6 .$# 2(  A$! Q$!_\0
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M?V-1F9<9+  CVZ9QV[].G./:HS=1K_&,#ONQV'\ACZ=Z )6C X('/H<_S_\
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M_P R>;RC]R/IRQT]E9-L;*0%S@'[P4!E 4E<,5Y4?>#'DC@=;9V3K][=E?F
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MI%.#:RP2'6,DTGW^?G_2Z=2XRYO7MKI\^I]'A,C("_E_]:H'B!!X.?< ]_\
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M'Z4RBFX[_GR!_P#7S]/2JDB<<<C/3C^?Y]NV*ON1SC &#CH.U4W'0_A_G]:
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M4++48+FPO;&YM(;ZUN[*='6.YMKZUEBN;::%ECE@8HA\N0[OO#]AK]JR&_\
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M3WZ9^F/U[4 5F7'0<=>GKVS_ "^M0OC_ &NG;IWQFK3=,^A!_456;[I_#^=
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M>0 ].F!QP.?_ -=%% %62X(Q@8SD<<=L^OM[TV-RY.>,#IV_S^OO110!="@
M<#C^?K3&7 SGIUS]?\]:** (7.!]>/T-5V;!QBBB@"-FW>V*B<< ^^/S_P#U
L445,FTKKN!"PX)Y^Z1CM_P#KJJ_3\_T!/\L_CBBBLW)OK]V@$5%%%2!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= ),# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^U--)'\2
MY/(('W2000!@YS@XY'//(P%_LA-WW=PZC=D-P<@%B&(Z=",=#7:_8_8?-A<C
M(. ,D<<\9.?7MBE%G[<'(Y!SU([CT'(]">ISD XE=''4J"IS@87/)W'CD$9
M]LYR!4J:2JY(7KD L""N1S@8/! &.IS@,3P*[46@^7Y.1G!QQG@<_P"[Z< >
M^:D6R'89YP<CWSU'N ?0_G@ XY=)1L,%'!SC;@'@@G SV#8RO!'&<\*-(0[3
MM&%]L#H01QU[\ ],9]!V7V3KD#(Y)]\^V.O'!]_>E^R@@<<CI@GM[<CH<=?R
M- ''#2EV@;4&,8)S@8XYYY;/KQ[<'+#I*?W<E2<]\9R.6ZG!Y4GCL?;M39AN
M=HZC(/?T/3 P._3ITH^R8.0HYZ\9SW'(X'4XX_+/(!Q;:2I&=B8!'  X(.>0
M.#W!Y('('>HO[+"]$7&!D <$K\V>, #ID'/(R.IKN/L@ X4CCZ#.>?S/7G\<
MTC6>=ORY^I.#D>F,D?TSP: .&&D@9^3@'"@<$@@Y/ R5W'CUYQUR86TA3RL8
M#8P,=@/O$8'&?XL9Q@ +R17??8QU([<$Y)QW[^PZ9/(QZ!IM">"JCH,<YZ@]
M_49'&.O?!H X!](#'<R\$*#T(:09P/FQPN<J<8'&>O#3HR$GY2S$=6"D87/O
M@''  '094@GGOC9@9X&![-C_  R.YP..E1-: =0<9R#@YZ<\< >F#QSSTH X
M;^QXB-C( =Q4*1E2"1DM\I&[&#QP>5QC@-.D1\[DP5( .W(5L\$X_A]3TQDX
MP>.Y:S'4\DD8&WN 3R<9) '!)]>XJ,6@&>.>_4CG'(#-C )! Q^'!% '%?V4
MB\A1N('\*@'));<00",Y [8.!W%,_LE<<1H%)( PO09(##C&>ZXSDX+$5W!L
MEXPN3CD]< @D8'WNF.GKSDT?8L_P\ \YR,@]?3(&,8'8\8XH X@Z/&Q)$9(/
M0[B.G'(/0]C[]A17;"Q'=8\\_>//7O\ YYHH Z<1Y!QCH !@>@[]<XP/PZ^B
MB(8R ,GL0>/S_P /QQBK(7D9Y!'H<=">O';G]*?L'/X#Z#KQGWY)Y]* *HC7
M_'@8/0\>G/MDXIPB';KP.W'7CH.V3^7>K(7'X9^OOG],<#T%/V\XR,C/Z#)]
M_IQSSZ4 5!$!D8Y./Y'Z#@?7&?I1Y:], _4XS[]AS^O7%7 O3G.?3MZ'G!(^
M@]>>*-AYZ^@XZ_X?4G'TYH JB/T4<<<CT]/7ZG%+Y7LOY?\ UJMJN.3U'Y?_
M %_\^E&P=<G(Z9]NE %3RO9?\_A1Y0QT'&>V>GUYY[>WY5;V#W[^G?\ "F[<
M$YZ#N?\ ]8H JF+K]T<?EUYZ?YZ=*881CH.F1G:>^21[^_I5XIR.2<YR?3TS
M_GFEV#']?_K<B@"AY(ZXZC/;H,<GC\?KVIA@'!('/(R/P(]@1CMS6CL''//7
M_P#5Z=: G7/& /?/\L?K0!EF 'G ]^F![\C_ #QQ4;6_MTY) XQ^'3GCZ=,5
MJLA((.?UYY[<8_K3"HZ=_?GIQR#QP#CD=Z ,PP$9.!QCK_3J...G3.*=Y(],
M<<G'Z\_RK0*#MG^?I^G^?JA3!P,_IP<\YZ=OUH SS$,GDCVY&/U%%7_+!Y..
M_4>G%% %:*<,0,\^F>OX=?QZ<]"*U%4%>F>,GZ _7^7XUS]G&QF7G&.<9_'_
M #UY_7IT7 P0/;ITZ_CS_P#6H A*_@1QGTYX'OTZ>V?4TNPGC#>G<=?\]^!Z
M"I\#T'Y4I'3(^F1_*@" (<XZ' ZGC _/_/ZN"'/(X^H_S^E3E3_GCW[^@]<=
MQVI",?7&>.>,GOF@"'8?\G]/K^G3WH*8!.>G\O\ 'VJ?;T]R/UZ'^>?I3&Q@
MYZ<_7_/I[T <%XS^(O@;X<:+/XE^(?C'PGX!\,VT]M;77B3QKXCT?PIH%M<7
MLR6UG!<:SK]]I^FPS7=S(EO:Q272R7$S+'"KN0M:,?C'PK+-I5LGB7P\UUKM
MK%?:%9KKVDF\UVPN(A/!?:)9B\^TZQ93P$307>G17-O+$3)'*R!F'\XW_!S;
MJ^HZQ^R-\%/@5I8U*>Z_:&_:O^#/P^MM/LM,L;U-2-I)XDUB2!9)I?MLMRNH
MKH3VUE;0Q))=I:Q7%TL-Y(C<IXH\+Z;X[_X.4_V6_AA;Q67_  C'[%O[!R:E
M:POH+6-EH=[-X=\2V&D3V\UI(+:WCCB\9:%<Z<]R5L--,-WHT*NPB8YRDU+2
MS24--4[RJ*"\K6;?GREJ*<4V[>])?*,'-O\ )?,_J"6X1F5%^=W("(A#NQ)"
M@!!\V<D#! .>.I ,V3YC1%)!*HRT;1N)%!P02A&X @@@D8(.1VK^'?\ 9\^.
M/C*Q_8+_ .#B;]MVW\5>-+'5?B1\=_%OPZ^&FOQ:[_;$FD+?>(-1T#3KGP]J
M\5Y#)9-IMK\4](M7U72C:16=C%I6K:4LEY:*Z>@?M(?$S]HKX4?\$X?^"#_P
M ^'GQM^+O@SXK_M2_$[X?WGQ%\9Z)XW\;Z;XN\4Z%XODTO5;_2_%FOIJK^/K
MFW,WQ6TTWD4%U]CN(=)F>-8X[;2X8USM7NMO:NU[7C3=KK3KVZ*SOJTCDVL]
M^16LM'--]]4DD_F^Q_:4"AQ\V[U [>H/(Y_PZ4X)GG@@YQUZ^O3UKR+X1:QJ
M7B+1_$FIWT[RV<?Q)^)&C^'(Y$D6:V\,^&/%VH^&-+MYO-DEEEE1M&NV:>25
MS,CQRABC!1[$ .@P!]0/Q]_?O6B=TGWO^#:_1DM6=M_/^O4B*@8YYQGG)Y'T
M' '7-,VYXQGG]2"?Y9-62O?M^6?PZD=<?G3<#IV].W_UOPQ3$5RHX[_F1].>
M...!WQZ4;1SP.?\ )_SVJQC'3 ']>,']/Z\TS8/?J<X(&/3C'Y_I0!"5&3\I
M/OG_ .N**FVD=L^_R_U!/'2B@#(TZ+YRYZ\8!QV/\_ZXK?5<CGO[<_G^ Q[$
M_6J-C%MC!Z9Z\>_I[^_\N*TJ (PG.?;H>>?0]B/R_"G;!V]\]SSD?AU]/2GX
M/''7IV_G001U!'UH CQC@ GCUXR>,GGTST'?Z4J],YXZ ?3C/KS^GOUIU% "
M$9_S_+D8/H>U5IR%1N!T/XY!.1V^@]:L-T/./QZ_3W_G^59MX^V(C.,XZ=>_
M3D?U^E '\Q'_  5WL;;XR_\ !4O_ ((S_L[/;07,%S\>/$'QD\0VEYH^JCS=
M'\#ZAX/DMYI-0M9MESILL7@_Q! 'A2+[%="VN;R9;,+YOG'[,_CB#4_^"L/_
M  7R_:\:=+NQ_9Y^!E]\.M!U#2YKFZE6Y\'^&7:[$.DZF([2\F2^^#UPEY;2
M2P6%MJ\4D5G"UI?O(?6KF2P^+7_!ROX(GN;S3IM"_9/_ &(/$7BV^$6K:@]G
MI^N>,X]8NII+E;HK;6,PTSXJ6%UJ-NC+9S6 BNIV,EJL<?YA_ 'QW=Z3_P $
M?/\ @NS^UAJ-Q?37_P"T_P#M)>,O!NAZAJ,C:TFHQ>)=;TG18A;ZK8+#=3W*
M1?$_4+7^U+ATTOS;33+L1^1),DV+NYW6EII/TA&;U6UDY+=;];HTC\-GUC+[
MY3C%6^4;];H^=]>TNY\ ?\&R/PV\/2+80>+?VT?VY_MJM<:9J%A<:U;VGBK5
M5MYHKJ'%I- C?#;3V@O)XQ8OHEU/9V5O-=VJ.OZT?MA>';*7_@L__P $6/V=
MHTCC\/\ [)7[/<GQ5UF%WNC)81?#WP[KVJ126^M!)9]>BM[?X+:9)'9I;1SW
M1AN+=W634P(OFK]H[X9R6_PH_P"#9[]ABU$_G^(O&7PZ^,GC'2K#4&6\DCNI
M_!'B:_OKC0]35XL13>*/&,UO>W8:.UGMM9T^RMA'.5KZ-U/69_BO_P %_?\
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M;Z&!)O,DNH0O]=$@R.O&"/S]/\]J_@._X/$OB3<ZG\?_ -C;X/P74DMKX/\
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MG:_^0+1/LTU]]ONO;3YG]'ZKT'H!V[9 Z>PJ49P,DCGID\^Q_$?T],-'/!(
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MH*0#<5P'8,[NXP#'M1MPWXHY7V=_5?ENQ\[^7E;\F_0_1/\ X)(?"N3XN_\
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MXXZ8]>GY=:3CG.<]O_K_ $IP4YXV\9'7DCZ G'I_]?!H(/3Y>.>/PZCWXYX
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MESP!G@9Q]>?U_P ^M1@'N./^^3^GU[FG $$CMU')SGOG/K[?UH <#C_]>/\
M/Z4$Y_S[?Y/XTE ^G/'7&/QSQ_GO0 X. ,;@/8D#_P!E/\_\**;10!8H/^?\
MX/\ *BB@!A!SGID8/3CD9Y&.@[]?YAC') !R!^'^ _+ J4C(Q_3/Z&F8!/N?
M<GCH<-G!ZYQST(Q0!$1D$?YX]ZK21@@DX'!'/)(Q_+\,]*ND#!V\X/)[X^F.
M![]>O:HR >M &2UNK$C (&&)(SD=QSC'X?UJN;)"20 /?&,G''OWSG/![UNE
M%/M]*:8@>Y_S^7Y&@#E[W2;7487M=2M+75+9U97M-2MH-0MG5A\RM;WD<T+*
MV>04(QP<C@Y.B^ O!^A3S7&B^%]$T::Y.ZX_LK3[?3HY6P 6:VLDAM@Q"C<4
MB4D!=Q(Z][Y*#U)SW/O_ (4Y4"G([GT_SS[_ %XYJ7"#:?)"ZV?+&Z^=F^_7
MJQW=K7=NUW;[KV_ @BM88U 2-4QV"C&?5?3\.,]JLJD77 ZX^7!Z?IU[4FT]
M.H.<YYX'IC ^OI3BF5],_3 &0..0>W?U]!5"#:GI_P".C_&G!4P/4=O7)!P!
M^'!'?DXXI0!D@8X'&>1Z'/<_YQQ4@ '0?Y_G0 S9_G/09^G/'<_E2A2#D'].
MV1QUST__ %BGT4 19 )..<GD>O?&>GX@]>U&T'OC..,=R!TYSW_SBI>E% $9
MVY.0,]^6_H**<0V>,?FP_D<44 .HHHH /\_G[_A2$ _AZ'V/'Z_K[FEI,#GT
M/7_'ZT -..".<')QR>P('7VXR,<4W9UQSZ8/O[_X\8J3'Y?K^G3M0,<@=OZT
M ,VXSU;\."?S(R#G)/Y4FWUZ8X/;.>/7@]<\5)C.<\\]!T_^N?7/0]*.@XR3
MCKUY[?YZ?2@",!>>O;'.".>2>GX8R/6E'0G@\\ G/&/0?Q'OZG/%+SGW(ST'
M ]SWZ8_7TIV/4>I(///MV]?3\.: &8P <' SD'MGKU'(]/UI<#!V@@^ASV[8
MY!]NO6EQC).,8YP,#C/U]:=^'_U_>@!H&,9Z\GC&/P'';J<>V:=1]** "BBB
M@ HHHH 0J,__ %A_4$_YXXHI:* "BBB@ HHHH **** "BD()Z''X9I: $.3P
M,CU..@YZ>_\ 3FE^M-W?/LQ_ 6SGN&P>,=\COVIU "=>YQCI@CGUSP:6BF[O
IFVX_'\,T .HHI <Y]O\ $C^E "YSTHHI!R ?4?SH 6BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
